

**Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Office of the President</u></b>				
<b><u>WUKY</u></b>				
Yelton, Stacy L	3048105177	\$6,000.	\$0.	\$6,000.
Lexarts Tonic: Arts and Music Magazine				
<b>WUKY</b>	<b>Totals:</b>	<b>\$6,000.</b>	<b>\$0.</b>	<b>\$6,000.</b>
<b>Office of the President Totals:</b>		<b>\$6,000.</b>	<b>\$0.</b>	<b>\$6,000.</b>
<b><u>Commercialization &amp; Economic Development</u></b>				
<b><u>Business Development</u></b>				
Harvey, Dean E	3048104677	\$165,700.	\$0.	\$165,700.
Economic Development Administration University of Kentucky Technology Development Center				
Harvey, Dean E	3048104881	\$170,000.	\$0.	\$170,000.
KY Science and Technology Co Inc KSTC ICC Project				
Harvey, Dean E	3048104881	\$0.	\$5,000.	\$5,000.
KY Science and Technology Co Inc KSTC ICC Project				
<b>Business Development</b>	<b>Totals:</b>	<b>\$335,700.</b>	<b>\$5,000.</b>	<b>\$340,700.</b>
<b><u>Small Business Development Center</u></b>				
Naugle, Lottie Becky		\$1,239,664.	\$0.	\$1,239,664.
Small Business Administration Kentucky Small Business Development Center				
Naugle, Lottie Becky	3048105317	\$100,000.	\$0.	\$100,000.
Small Business Administration Veterans Assistance and Services Program				
<b>Small Business Development Center</b>	<b>Totals:</b>	<b>\$1,339,664.</b>	<b>\$0.</b>	<b>\$1,339,664.</b>
<b>Commercialization &amp; Economic Development Totals:</b>		<b>\$1,675,364.</b>	<b>\$5,000.</b>	<b>\$1,680,364.</b>
<b><u>Fiscal Affairs and Information Technology</u></b>				
<b><u>Fiscal Affairs and Information Technology</u></b>				
Friskney, Doyle N	3048105199	\$6,000.	\$0.	\$6,000.
Southeastern Universities Research Association Inc A Demonstration Microsoft Cluster Compute Server Environment for Bioinformatics				
<b>Fiscal Affairs and Information Technology</b>	<b>Totals:</b>	<b>\$6,000.</b>	<b>\$0.</b>	<b>\$6,000.</b>
<b>Fiscal Affairs and Information Technology Totals:</b>		<b>\$6,000.</b>	<b>\$0.</b>	<b>\$6,000.</b>
<b><u>Research</u></b>				
<b><u>VP for Research</u></b>				
Tracy, James W	3048103738	\$0.	\$63,135.	\$63,135.
KY Department of Environmental Protection Supplemental Environmental Project Compliance Assistance Tools and Services				

**Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Research</u></b>				
<b><u>VP for Research</u></b>				
<b>Tracy, James W</b>	3048104799	\$1,422,094.	\$0.	\$1,422,094.
Health Resources and Services Administration High Bandwidth Network Connection to Support Health Care Delivery and Critical Clinical and Biomedical Research				
<b>VP for Research</b>	<b>Totals:</b>	<b>\$1,422,094.</b>	<b>\$63,135.</b>	<b>\$1,485,229.</b>
<b><u>KY Geological Survey</u></b>				
<b>Andrews, William M</b>	3048104778	\$215,005.	\$0.	\$215,005.
US Geological Survey Quaternary and Surficial Geologic Mapping for Geotechnical and Geophysical Applications in Kentucky				
<b>Cobb, James C</b>	3048105152	\$59,000.	\$0.	\$59,000.
KY Energy and Environment Cabinet CAER and KGS Advisory Support of State Energy Related Issues				
<b>Greb, Stephen F</b>	3046917300	\$0.	\$15,000.	\$15,000.
US Geological Survey Kentucky Coal Data for the National Coal Resource Data System				
<b>Greb, Stephen F</b>	3046957200	\$0.	\$12,574.	\$12,574.
Virginia Polytechnic Institute and State University Southeast Kentucky: Coals as CO2 Sequestration Reservoirs (part of Southeast Regional Carbon Sequestration Partnership Phase 2 Project)				
<b>Hickman, John B</b>	3048104896	\$62,862.	\$0.	\$62,862.
KY Office of Energy Policy Rough Creek Graben Year Two				
<b>Lynch, Michael J</b>	3048104792	\$15,000.	\$0.	\$15,000.
KY Board of Registration for Professional Geologists Communication Specilist Liaison				
<b>Nuttall, Brandon C</b>	3048105184	\$115,890.	\$0.	\$115,890.
University of Illinois Assessment of Geological Carbon Sequestration Options in the Illinois Basin-Phase II & III				
<b>Wang, Zhenming N</b>	3048091700	\$0.	\$55,800.	\$55,800.
US Geological Survey Operation of the Mid-American Integrated Seismic Network-UKY				
<b>Wang, Zhenming N</b>	3048091700	\$0.	\$4.	\$4.
US Geological Survey Operation of the Mid-American Integrated Seismic Network-UKY				
<b>Weisenfluh, Gerald A</b>	3048019600	\$0.	\$125,000.	\$125,000.
KY Transportation Cabinet Integrating Geotechnical Drill Hole Data with Geologic Information				
<b>Weisenfluh, Gerald A</b>	3048105091	\$24,647.	\$0.	\$24,647.
US Geological Survey National Catalog Metadata Submissions for Kentucky Sites				
<b>KY Geological Survey</b>	<b>Totals:</b>	<b>\$492,404.</b>	<b>\$208,378.</b>	<b>\$700,782.</b>

**Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Research</u></b>				
<b><u>Interdisc Human Development Institute</u></b>				
<b>Compton, Jonathan F</b>	3048105234	\$217,100.	\$0.	\$217,100.
KY Department of Education UK Post Secondary Transition				
<b>Farley, Joanne</b>	3048105186	\$10,411.	\$0.	\$10,411.
KY Cabinet for Health and Family Services Aging Disability Resources Centers				
<b>Farley, Joanne</b>	3048105379	\$45,000.	\$0.	\$45,000.
University of Tennessee Tennessee State Improvement Grant				
<b>Hall, Meada G</b>	3048104789	\$100,573.	\$0.	\$100,573.
KY Department of Education UK Community Based Work Transition (CBWT)				
<b>Hall, Meada G</b>	3048105246	\$152,943.	\$0.	\$152,943.
KY Department of Vocational Rehabilitation Community Based Work Transition Program 09-10				
<b>Harrison, Elizabeth</b>	3048105212	\$112,040.	\$0.	\$112,040.
KY Department of Education ParaEducators of Kentucky (PEK)				
<b>Harrison, Elizabeth</b>	3048105229	\$193,335.	\$0.	\$193,335.
KY Council on Developmental Disabilities KY's Postsecondary Inclusion Project (PIP)				
<b>Harrison, Ron N</b>	3048105095	\$3,100,029.	\$0.	\$3,100,029.
Department for Mental Health Mental Retardation Service Supports for Community Living				
<b>Harrison, Ron N</b>	3048105201	\$260,931.	\$0.	\$260,931.
KY Department of Vocational Rehabilitation UK Migrant Program 09-10				
<b>Kearns, Jacqueline</b>	3048104454	\$0.	\$39,995.	\$39,995.
University of Minnesota Multi-State General Supervision Enhancement Grant Consortium				
<b>Kleinert, Harold L</b>	3048104741	\$520,000.	\$0.	\$520,000.
Administration for Children and Families University Center for Excellence in Developmental Disabilities				
<b>Lewis, Preston O</b>	3048084500	\$0.	\$42,262.	\$42,262.
University of Oregon National Center for the Study for the Study of Supported Text in Electronic Learning Environments				
<b>Lewis, Preston O</b>	3048103717	\$0.	\$200,000.	\$200,000.
Department of Education Supported Math Accessibility Reading Tool (SMART)				

**Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Research</u></b>				
<b><u>Interdisc Human Development Institute</u></b>				
<b>Lewis, Richard J</b>	3046824700	\$0.	\$1,300,000.	\$1,300,000.
Department of Education Mid-South Regional Resource Center				
<b>Rous, Beth</b>	3048104410	\$0.	\$40,000.	\$40,000.
University of North Carolina Early Childhood Personnel Center				
<b>Rous, Beth</b>	3048104682	\$2,670,570.	\$0.	\$2,670,570.
KY Families and Children Cabinet IHDI Child Care Quality Enhancement Initiative				
<b>Rous, Beth</b>	3048104785	\$375,000.	\$0.	\$375,000.
KY Health Services Cabinet Training Into Practice Project Services FY09/Z915				
<b>Rous, Beth</b>	3048104786	\$80,000.	\$0.	\$80,000.
KY Department of Education Kentucky Early Childhood Transition Project Part B				
<b>Rous, Beth</b>	3048104787	\$220,000.	\$0.	\$220,000.
KY Department of Education Early Childhood Data Platform				
<b>Rous, Beth</b>	3048104805	\$150,059.	\$0.	\$150,059.
KY Health Services Cabinet Kentucky Early Childhood Data System (KEDS) First Steps				
<b>Rous, Beth</b>	3048105008	\$58,014.	\$0.	\$58,014.
KY Department for Public Health UK First Steps Transition Activities				
<b>Rous, Beth</b>	3048105058	\$264,038.	\$0.	\$264,038.
Rutgers University Kentucky Teacher Qualifications Comparison Study				
<b>Rous, Beth</b>	3048105085	\$5,705,020.	\$0.	\$5,705,020.
KY Cabinet for Health and Family Services Child Care CCR&R Services SFY 09-10				
<b>Sheppard-Jones, Kathleen A</b>	3046935400	\$0.	\$83,961.	\$83,961.
Department of Education Ky. Resident Training Program in Rehabilitation Technology				
<b>Sheppard-Jones, Kathleen A</b>	3048104788	\$402,916.	\$0.	\$402,916.
KY Department of Vocational Rehabilitation Consumer Satisfaction Survey 09-10				
<b>Sheppard-Jones, Kathleen A</b>	3048105119	\$28,988.	\$0.	\$28,988.
KY Department for the Blind UK Client Satisfaction Survey				

**Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Research</u></b>				
<b><u>Interdisc Human Development Institute</u></b>				
<b>Sheppard-Jones, Kathleen A</b>	3048105228	\$1,132,759.	\$0.	\$1,132,759.
KY Cabinet for Health and Family Services Human Development Services - Home Modifications				
<b>Taub, Deborah A.</b>	3048105218	\$81,985.	\$0.	\$81,985.
Edcount LLC ILSSA EdCount				
<b>Tyree, Milton S</b>	3048104783	\$411,952.	\$0.	\$411,952.
KY Department of Vocational Rehabilitation Kentucky Support Employment 09-10				
<b>Tyree, Milton S</b>	3048104846	\$19,231.	\$0.	\$19,231.
Lifeskills Inc The ROLES Initiative (Real Opportunities for Lifestyles Enriched through valued Social roles)				
<b>Wickham, Donna R</b>	3046846000	\$0.	\$250,000.	\$250,000.
Pearson Educational Measurement ILSSA NJ				
<b>Wickham, Donna R</b>	3046846000	\$0.	\$567,257.	\$567,257.
Pearson Educational Measurement ILSSA NJ				
<b>Wickham, Donna R</b>	3046846000	\$0.	\$707,164.	\$707,164.
Pearson Educational Measurement ILSSA NJ				
<b>Wickham, Donna R</b>	3048104780	\$257,500.	\$0.	\$257,500.
KY Department of Education Kentucky Alternate Portfolio				
<b>Wickham, Donna R</b>	3048104990	\$50,136.	\$0.	\$50,136.
KY Department of Education ILSSA Georgia Enhanced Assessment Grant				
<b>Wickham, Donna R</b>	3048105028	\$14,971.	\$0.	\$14,971.
Edcount LLC edCount Assessment				
<b>Wickham, Donna R</b>	3048105155	\$513,022.	\$0.	\$513,022.
University of Guam Pacific Rim ILSSA				
<b>Wickham, Donna R</b>	3048105217	\$330,148.	\$0.	\$330,148.
Pearson Educational Measurement Inclusive Large Scale Standards and Assessment-Puerto Rico Alternative Assessment				
<b>Interdisc Human Development Institute</b>	<b>Totals:</b>	<b>\$17,478,671.</b>	<b>\$3,230,639.</b>	<b>\$20,709,310.</b>
<b><u>Computational Sciences</u></b>				
<b>Connolly, John W</b>	3048104850	\$0.	\$1,000,000.	\$1,000,000.
KY Council on Postsecondary Education State EPSCoR: Transforming Kentucky's New Economy				

**Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Research</u></b>				
<b><u>Computational Sciences</u></b>				
<b>Connolly, John W</b>	3048105113	\$2,434,000.	\$0.	\$2,434,000.
National Science Foundation NSF/EPSCoR: Transforming Kentucky's New Economy with EPSCoR				
<b>Connolly, John W</b>	3048105250	\$254,815.	\$0.	\$254,815.
National Science Foundation Collaborative Research: CRIF: CRF: Extensible Cyberenvironments for Empirical and Semiempirical Hamiltonian Parameter Optimization and Dissemination				
<b>Computational Sciences</b>	<b>Totals:</b>	<b>\$2,688,815.</b>	<b>\$1,000,000.</b>	<b>\$3,688,815.</b>
<b><u>KY Water Resources Institute</u></b>				
<b>Ormsbee, Lindell E</b>		\$148,189.	\$0.	\$148,189.
KY Energy and Environment Cabinet TMDLs for Critical Watersheds in the Kentucky River Basin				
<b>Ormsbee, Lindell E</b>	3048104771	\$9,828.	\$0.	\$9,828.
Stantec Consulting Services Inc Water Resources Technical Support Services				
<b>Ormsbee, Lindell E</b>	3048104771	\$0.	\$-548.	\$-548.
Stantec Consulting Services Inc Water Resources Technical Support Services				
<b>Ormsbee, Lindell E</b>	3048104837	\$95,795.	\$0.	\$95,795.
KY River Authority Watershed Management Service				
<b>Ormsbee, Lindell E</b>	3048104942	\$94,201.	\$0.	\$94,201.
KY Department for Public Health UK Maxey Flats				
<b>Ormsbee, Lindell E</b>	3048104943	\$453,983.	\$0.	\$453,983.
KY Department for Public Health UK Paducah Gaseous Diffusion Plant-AIP				
<b>Ormsbee, Lindell E</b>	3048104981	\$14,020.	\$0.	\$14,020.
KY Natural Resources Environmental Protection Cabinet Environmental Protection Scholarship Program				
<b>Ormsbee, Lindell E</b>	3048104981	\$0.	\$105,980.	\$105,980.
KY Natural Resources Environmental Protection Cabinet Environmental Protection Scholarship Program				
<b>Ormsbee, Lindell E</b>	3048105293	\$3,158.	\$0.	\$3,158.
KY Department of Environmental Protection Development of Pathogen TMDLs for Four Streams in the Kentucky River Basin				
<b>KY Water Resources Institute</b>	<b>Totals:</b>	<b>\$819,174.</b>	<b>\$105,432.</b>	<b>\$924,606.</b>
<b><u>Ctr for Applied Energy Research</u></b>				
<b>Andrews, Rodney</b>	3048104562	\$0.	\$-8,503.	\$-8,503.
Materials Sciences Corp Multifunctional Polymer Composites SBIR Phase II				

**Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Research</u></b>				
<b><u>Ctr for Applied Energy Research</u></b>				
<b>Andrews, Rodney</b>	3048104562	\$0.	\$8,503.	\$8,503.
Materials Sciences Corp Multifunctional Polymer Composites SBIR Phase II				
<b>Andrews, Rodney</b>	3048104956	\$1,370,065.	\$0.	\$1,370,065.
Department of Energy Coal Fuel Alliance (CFA): Design and Construction of Early Lead Mini Fischer-Tropsch Refinery at the University of Kentucky Center for Applied Energy Research				
<b>Andrews, Rodney</b>	3048104956	\$0.	\$-50,000.	\$-50,000.
Department of Energy Coal Fuel Alliance (CFA): Design and Construction of Early Lead Mini Fischer-Tropsch Refinery at the University of Kentucky Center for Applied Energy Research				
<b>Andrews, Rodney</b>	3048104964	\$123,000.	\$0.	\$123,000.
KY Office of Energy Policy GOEP Matching: Establishment of a Laboratory for Biofuels Research at the University of Kentucky				
<b>Andrews, Rodney</b>	3048105043	\$492,000.	\$0.	\$492,000.
Department of Energy Establishment of a Laboratory for Biofuels at the University of Kentucky				
<b>Andrews, Rodney</b>	3048105144	\$120,000.	\$0.	\$120,000.
KY Energy and Environment Cabinet CAER and KGS Advisory Support of State Energy Related Issues				
<b>Andrews, Rodney</b>	3048105144	\$0.	\$-59,000.	\$-59,000.
KY Energy and Environment Cabinet CAER and KGS Advisory Support of State Energy Related Issues				
<b>Andrews, Rodney</b>	3048105200	\$567,021.	\$0.	\$567,021.
KY Office of Energy Policy Development of an Algae-Based System for CO2 Mitigation from Coal-Fired Power Plants				
<b>Andrews, Rodney</b>	3048105359	\$836,964.	\$0.	\$836,964.
National Institute for Hometown Security Carbon Foam-Based Protection Systems				
<b>Crocker, Mark</b>	3046947300	\$0.	\$30,000.	\$30,000.
Department of Energy Investigation of Aging Mechanisms in Lean NOx Traps				
<b>Crocker, Mark</b>	3046947300	\$0.	\$21,058.	\$21,058.
Department of Energy Investigation of Aging Mechanisms in Lean NOx Traps				
<b>Crocker, Mark</b>	3046947300	\$0.	\$44,078.	\$44,078.
Department of Energy Investigation of Aging Mechanisms in Lean NOx Traps				
<b>Davis, Burtron H</b>		\$240,000.	\$0.	\$240,000.
Integrated Concepts and Research Corporation Production of High Hydrogen Content Coal Derived Liquids				

**Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009**

		New Accounts	Adjustments to Existing Accounts	Total
<b>Research</b>				
<b><u>Ctr for Applied Energy Research</u></b>				
<b>Davis, Burtron H</b>	3048105170	\$1,088,066.	\$0.	\$1,088,066.
Department of Energy Sensitivity of Fischer-Tropsch Synthesis and Water-Gas Shift Catalysts to Poisons from High-Temperature High-Pressure Entrained-Flow (EF) Oxygen-Blown Gasifier Gasification of Coal/Biomass Mixtures				
<b>Hiett, John K</b>	3048104790	\$220,687.	\$0.	\$220,687.
KY Department for Natural Resources Mine Mapping Program				
<b>Hower, James C</b>	3048099600	\$0.	\$17,500.	\$17,500.
US Geological Survey Vitrinite maximum reflectance and maceral studeis in support of USGS coal research.				
<b>Lipka, Steve</b>	3048104401	\$0.	\$81,000.	\$81,000.
US Office of Naval Research High Energy Density Carbons for Electrochemical Capacitors				
<b>Robl, Thomas L</b>	3046735300	\$0.	\$-4,040.	\$-4,040.
Department of Energy Advanced Multi-Product Coal Utilization By-product Processing Plant				
<b>Robl, Thomas L</b>	3048105360	\$991,408.	\$0.	\$991,408.
National Institute for Hometown Security Rapidly Deployable System for the Structural Stabilization of Shock Damaged Structures				
<b>Taulbee, Darrell N</b>	3048105267	\$14,969.	\$0.	\$14,969.
KY Office of Energy Policy Project Revision: Demonstration of the Combustion Characteristics of Fuel Briquettes made from Fine Coal and Biomass				
<b>Ctr for Applied Energy Research</b>	<b>Totals:</b>	<b>\$6,064,180.</b>	<b>\$80,596.</b>	<b>\$6,144,776.</b>
<b><u>Div of Laboratory Animal Research</u></b>				
<b>Smiley, Jeffrey R</b>	3048104678	\$0.	\$54,540.	\$54,540.
National Center for Research Resources Enhancement of BBSRB Vivarium				
<b>Div of Laboratory Animal Research</b>	<b>Totals:</b>	<b>\$0.</b>	<b>\$54,540.</b>	<b>\$54,540.</b>
	<b>Research Totals:</b>	<b>\$28,965,338.</b>	<b>\$4,742,720.</b>	<b>\$33,708,058.</b>
<b>Dentistry</b>				
<b><u>Dentistry Research &amp; Graduate Studies</u></b>				
<b>Ebersole, Jeffrey L</b>	3048105103	\$350,500.	\$0.	\$350,500.
KY Cabinet for Health and Family Services Support for Dental Public Health Activities				
<b>Ebersole, Jeffrey L</b>	3048105147	\$2,031,636.	\$0.	\$2,031,636.
National Center for Research Resources Center for the Biological Basis of Oral/Systemic Disease: AEC				
<b>Ebersole, Jeffrey L</b>	3048105208	\$2.	\$0.	\$2.
Center for Disease Control and Prevention Obtain Specimens and Supporting Clinical Information to Establish A Standardized National Repository of Control Serum Samples for the Study of Lyme Borreliosis (Periodontitis)				

**Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Dentistry</u></b>				
<b><u>Dentistry Research &amp; Graduate Studies</u></b>				
<b>Novak, Michael J</b>	3048104411	\$0.	\$28,541.	\$28,541.
University of Minnesota Effects of Periodontal Therapy on Preterm Birth				
<b>Dentistry Research &amp; Graduate Studies</b>	<b>Totals:</b>	<b>\$2,382,138.</b>	<b>\$28,541.</b>	<b>\$2,410,679.</b>
<b><u>Oral Health Science</u></b>				
<b>Raybould, Ted P</b>	3048105056	\$278,880.	\$0.	\$278,880.
Health Resources and Services Administration Residency Training in General and Pediatric Dentistry: Advocacy and Care Disparities				
<b>Oral Health Science</b>	<b>Totals:</b>	<b>\$278,880.</b>	<b>\$0.</b>	<b>\$278,880.</b>
<b><u>Oral Health Practice</u></b>				
<b>Kovarik, Robert E</b>	3048105138	\$473,707.	\$0.	\$473,707.
Health Resources and Services Administration Designated Health Projects: Kentucky Oral Health Network				
<b>Miller, Craig S</b>	3048103659	\$0.	\$181,111.	\$181,111.
National Institute of Dental Research Effects of ART on Oral Epithelial Cell Biology				
<b>Yepes, Juan F</b>	3048104388	\$0.	\$5,748.	\$5,748.
Amarillo Biosciences Inc Eval of Natural Human Interferon Alpha in the Treatment of Oral Warts in HIV				
<b>Oral Health Practice</b>	<b>Totals:</b>	<b>\$473,707.</b>	<b>\$186,859.</b>	<b>\$660,566.</b>
	<b>Dentistry Totals:</b>	<b>\$3,134,725.</b>	<b>\$215,400.</b>	<b>\$3,350,125.</b>
<b><u>Nursing</u></b>				
<b><u>Nursing</u></b>				
<b>Chung, Misook L</b>	3048032000	\$0.	\$97,939.	\$97,939.
National Institute for Nursing Research Impact of Family Distress and Burden on Patients Outcomes in Heart Failure				
<b>Hahn, Ellen J</b>	3048104094	\$0.	\$50,000.	\$50,000.
Foundation for a Healthy KY UK Tobacco Policy Research Program - Kentucky Center for Smoke-Free Policy				
<b>Hahn, Ellen J</b>	3048104804	\$225,000.	\$0.	\$225,000.
Robert Wood Johnson Foundation Tobacco Policy Change: A Collaborative for Healthier Communities and States				
<b>Hahn, Ellen J</b>	3048104849	\$25,500.	\$0.	\$25,500.
KY Department for Public Health Indoor Radon Project				
<b>Hahn, Ellen J</b>	3048104878	\$189,850.	\$0.	\$189,850.
KY Health Services Cabinet Community Partnerships for Tobacco Cessation and Prevention				
<b>Hahn, Ellen J</b>	3048104878	\$0.	\$16,024.	\$16,024.
KY Health Services Cabinet Community Partnerships for Tobacco Cessation and Prevention				

**Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Nursing</u></b>				
<b><u>Nursing</u></b>				
<b>Hahn, Ellen J</b>	3048105291	\$16,500.	\$0.	\$16,500.
Foundation for a Healthy KY Clean Indoor Air Partnership - UK Tobacco Policy Research Program - Kentucky Center for Smoke-Free Policy - RWJF Match				
<b>Howard, Patricia B</b>	3048104724	\$63,553.	\$0.	\$63,553.
Health Resources and Services Administration Advanced Education Nursing Traineeships				
<b>Moser, Debra K</b>	3046987000	\$0.	\$600.	\$600.
Patient Centered Education and Research Pain Assessment, Incidence, and Nature in Heart Failure (PAIN-HF)				
<b>Moser, Debra K</b>	3048060900	\$0.	\$207,934.	\$207,934.
University of California San Francisco Improving Self Care Behaviors and Outcomes in Rural Patients with Heart Failure				
<b>Moser, Debra K</b>	3048104417	\$0.	\$7,498.	\$7,498.
University of California San Francisco Post Discharge Nausea and Vomiting: Incidence and Management Strategies				
<b>Moser, Debra K</b>	3048104719	\$43,000.	\$0.	\$43,000.
American Heart Association Great Rivers Affiliate Fellowship/Jia-Rong Wu: Effect of a Medication Taking Behavior Feedback, Theory-Based Intervention on Outcomes in Patients with Heart Failure				
<b>Moser, Debra K</b>	3048105083	\$227,064.	\$0.	\$227,064.
National Institute for Nursing Research Center for Biobehavioral Research in Self-Management of Cardiopulmonary Disease				
<b>Reed, Deborah B</b>	3048104034	\$0.	\$348,050.	\$348,050.
National Institute of Occupational Safety and Health Refinement and Enhancement of Agricultural Safety Curricula for Children (REACCH)				
<b>Nursing</b>	<b>Totals:</b>	<b>\$790,467.</b>	<b>\$728,045.</b>	<b>\$1,518,512.</b>
	<b>Nursing Totals:</b>	<b>\$790,467.</b>	<b>\$728,045.</b>	<b>\$1,518,512.</b>
<b><u>Medicine</u></b>				
<b><u>Area Health Educ Ctr</u></b>				
<b>Norton, James C</b>	3048104768	\$918,737.	\$0.	\$918,737.
KY Health Services Cabinet FY09 SAAA UK Area Health Education Centers				
<b>Norton, James C</b>	3048104975	\$25,000.	\$0.	\$25,000.
KY Department for Public Health AHEC Hispanic Health Education				
<b>Norton, James C</b>	3048105055	\$262,900.	\$0.	\$262,900.
University of Louisville Model State Supported AHEC project				
<b>Area Health Educ Ctr</b>	<b>Totals:</b>	<b>\$1,206,637.</b>	<b>\$0.</b>	<b>\$1,206,637.</b>

## Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b><u>Spinal Cord &amp; Brain Injury Res Ctr</u></b>				
<b>Geddes, James W</b>	3048103705	\$0.	\$44,000.	\$44,000.
American Heart Association Great Rivers Affiliate Fellowship for Naga: Role of cyclophilin D in the vulnerability of neuronal and synaptic mitochondria to undergo permeability transition.				
<b>Hall, Edward D</b>		\$42,676.	\$0.	\$42,676.
Stallion Therapeutics Inc Novel Neuroprotectants for TBI				
<b>Hall, Edward D</b>	3048105191	\$269,131.	\$0.	\$269,131.
National Institute on Drug Abuse Therapeutic Strategies for Neurodegeneration Training Grant				
<b>Hall, Edward D</b>	3048105247	\$46,826.	\$0.	\$46,826.
National Institute of Neurological Disorders & Stroke Fellowship Radhika Vaishnav: Therapeutic Strategies for Spinal Cord Injury				
<b>Hall, Edward D</b>	3048105270	\$26,000.	\$0.	\$26,000.
National Institute of Neurological Disorders & Stroke 26th National Neurotrauma Symposium 2008				
<b>Snow, Diane M</b>	3048104905	\$326,000.	\$0.	\$326,000.
National Institute of Neurological Disorders & Stroke Designer PGs for CNS Injury				
<b>Sullivan, Patrick G</b>	3048104842	\$7,000.	\$0.	\$7,000.
National Institute of Neurological Disorders & Stroke 14th Annual KSCHIRT Symposium 2008				
<b>Spinal Cord &amp; Brain Injury Res Ctr</b>	<b>Totals:</b>	<b>\$717,633.</b>	<b>\$44,000.</b>	<b>\$761,633.</b>
<b><u>Graduate Center for Toxicology</u></b>				
<b>Mellon, Isabel</b>		\$150,000.	\$0.	\$150,000.
KY Lung Cancer Research Fund Inhibition of Nucleotide Excision Repair by Cigarette Smoke				
<b>Orren, David K</b>	3048104927	\$240,260.	\$0.	\$240,260.
National Cancer Institute Telomeric Dysfunction and the Premature Aging and Cancer-Prone Disease Werner Syndrome				
<b>Shi, Xianglin</b>	3048083200	\$0.	\$250,515.	\$250,515.
National Cancer Institute Oxidative Stress in Cr(VI)-Induced Carcinogenesis				
<b>Shi, Xianglin</b>	3048089500	\$0.	\$331,091.	\$331,091.
National Institute of Environmental Health Sciences Apple Peel Extract Protects UV-induced Carcinogenesis				
<b>SHI, XIANGLIN</b>	3048054000	\$0.	\$204,522.	\$204,522.
National Cancer Institute Mechanisms of As-induced Carcinogenesis				

## Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b><u>Graduate Center for Toxicology</u></b>				
<b>St Clair, Daret K</b>	3048105006	\$368,990.	\$0.	\$368,990.
National Cancer Institute Redox Regulation of Tumor Suppression by MnSOD				
<b>St Clair, Daret K</b>	3048105006	\$0.	\$15,000.	\$15,000.
National Cancer Institute Redox Regulation of Tumor Suppression by MnSOD				
<b>St Clair, Daret K</b>	3048105194	\$270,000.	\$0.	\$270,000.
National Cancer Institute MnSOD in Chemotherapeutic-Induced Cardiac Injury				
<b>VORE, MARY</b>	3048104815	\$149,844.	\$0.	\$149,844.
National Institute of Environmental Health Sciences NRSA T32: Molecular Mechanisms of Toxicity Training Grant				
<b>VORE, MARY</b>	3048105232	\$270,000.	\$0.	\$270,000.
National Cancer Institute The Role of MRP1 in Protection of Cardiac Injury				
<b>Wang, Zhigang</b>	3048103777	\$0.	\$72,043.	\$72,043.
KY Lung Cancer Research Fund A Transgenic Mouse Model for Understanding Rev1 and Lung Cancer				
<b>Graduate Center for Toxicology</b>	<b>Totals:</b>	<b>\$1,449,094.</b>	<b>\$873,171.</b>	<b>\$2,322,265.</b>
<b><u>McDowell Cancer Network</u></b>				
<b>Armstrong, Debra K</b>	3048104882	\$2,500.	\$0.	\$2,500.
East Tennessee State University Kentucky Appalachian Regional Roundtable Discussions				
<b>Armstrong, Debra K</b>	3048104883	\$5,000.	\$0.	\$5,000.
East Tennessee State University Comprehensive Cancer Control Plan for Appalachian Communities: Kentucky Appalachian Cancer Forum				
<b>Armstrong, Debra K</b>	3048104936	\$28,144.	\$0.	\$28,144.
KY Department for Public Health Kentucky Cancer Program Demonstration Project				
<b>Armstrong, Debra K</b>	3048105179	\$10,500.	\$0.	\$10,500.
KY Breast Cancer Trust and Research Fund Horses and Hope				
<b>D'Orazio, John A</b>	3048103790	\$0.	\$73,250.	\$73,250.
National Cancer Institute Defining the role of MC1R in UV-induced oxidative damage and DNA repair				
<b>D'Orazio, John A</b>	3048104922	\$164,813.	\$0.	\$164,813.
National Cancer Institute Coleus forskohlii extract: melanization and UV protection by a natural product				
<b>Durbin, Eric B</b>	3048105190	\$4,500.	\$0.	\$4,500.
KY Department for Public Health KCR Data Matching Project				

**Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Medicine</u></b>				
<b><u>McDowell Cancer Network</u></b>				
<b>Means, Robert T</b>	3046572100	\$0.	\$1,929,816.	\$1,929,816.
KY Lung Cancer Research Fund Kentucky Lung Cancer Research Program				
<b>Mullett, Timothy</b>	3048104949	\$0.	\$1,900.	\$1,900.
Eli Lilly and Company Non-Small Cell Lung Cancer: The Impact of Ethnic Origin on Patients being Treated Second Line with Pemetrexed - an Observational Study				
<b>Mullett, Timothy</b>	3048104949	\$2.	\$0.	\$2.
Eli Lilly and Company Non-Small Cell Lung Cancer: The Impact of Ethnic Origin on Patients being Treated Second Line with Pemetrexed - an Observational Study				
<b>Mullett, Timothy</b>	3048104949	\$0.	\$940.	\$940.
Eli Lilly and Company Non-Small Cell Lung Cancer: The Impact of Ethnic Origin on Patients being Treated Second Line with Pemetrexed - an Observational Study				
<b>Tucker, Thomas C</b>	3046921300	\$0.	\$900,200.	\$900,200.
National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) Program Expansion				
<b>Tucker, Thomas C</b>	3046921300	\$0.	\$110,267.	\$110,267.
National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) Program Expansion				
<b>Tucker, Thomas C</b>	3048104870	\$1,177,491.	\$0.	\$1,177,491.
Center for Disease Control and Prevention National Program of Cancer Registries				
<b>Tucker, Thomas C</b>	3048105016	\$111,320.	\$0.	\$111,320.
Macro International Co Surveillance Pilot Project for Precancerous Lesions Among Cancer Registries in Monitoring the Impact of HPV				
<b>Wyatt, Stephen W</b>	3046859900	\$0.	\$345,555.	\$345,555.
National Cancer Institute Cancer Information Services				
<b>McDowell Cancer Network</b>	<b>Totals:</b>	<b>\$1,504,270.</b>	<b>\$3,361,928.</b>	<b>\$4,866,198.</b>
<b><u>Sanders-Brown Center on Aging</u></b>				
<b>Blonder, Lee X</b>	3048011400	\$0.	\$355,629.	\$355,629.
National Institute of Mental Health Neuroimaging Studies of Depression in Parkinson's Disease				
<b>Jicha, Gregory A</b>	3048089900	\$0.	\$10,625.	\$10,625.
University of California San Diego Effects of DHA in Slowing the Progression of Alzheimer's Disease				
<b>Jicha, Gregory A</b>	3048089900	\$0.	\$12,750.	\$12,750.
University of California San Diego Effects of DHA in Slowing the Progression of Alzheimer's Disease				

**Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Medicine</u></b>				
<b><u>Sanders-Brown Center on Aging</u></b>				
<b>Jicha, Gregory A</b>	3048089900	\$0.	\$-3,000.	\$-3,000.
University of California San Diego Effects of DHA in Slowing the Progression of Alzheimer's Disease				
<b>Jicha, Gregory A</b>	3048089900	\$0.	\$10,875.	\$10,875.
University of California San Diego Effects of DHA in Slowing the Progression of Alzheimer's Disease				
<b>Jicha, Gregory A</b>	3048103730	\$0.	\$28,213.	\$28,213.
Alzheimers Association Telemedicine Assessment of Cognition in Rural Kentucky: the TACK Study				
<b>Jicha, Gregory A</b>	3048103788	\$0.	\$15,481.	\$15,481.
University of California San Diego MultiCenter Trial to Evaluate Home-Based Assessment Methods for Alzheimer's Disease Prevention Research in People over 75 Years Old				
<b>Jicha, Gregory A</b>	3048103788	\$0.	\$29,156.	\$29,156.
University of California San Diego MultiCenter Trial to Evaluate Home-Based Assessment Methods for Alzheimer's Disease Prevention Research in People over 75 Years Old				
<b>Jicha, Gregory A</b>	3048104560	\$0.	\$4,967.	\$4,967.
University of California San Diego A Double-Blind, Placebo-Controlled, Randomized, Multi-Center Study Evaluating the Efficacy and Safety of 18 Months Treatment with PF-04494700 in Participants with Mild-to-Moderate AD (RAGE)				
<b>Jicha, Gregory A</b>	3048104818	\$0.	\$19,623.	\$19,623.
Elan Pharmaceuticals PLC A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) in patients with mild to moderate Alzheimer's Disease who are Apolipoprotien E4 epsilon4 NON-Carriers				
<b>Jicha, Gregory A</b>	3048104818	\$2.	\$0.	\$2.
Elan Pharmaceuticals PLC A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) in patients with mild to moderate Alzheimer's Disease who are Apolipoprotien E4 epsilon4 NON-Carriers				
<b>Jicha, Gregory A</b>	3048104819	\$2.	\$0.	\$2.
Elan Pharmaceuticals PLC A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) in patients with mild to moderate Alzheimer's Disease who are Apolipoprotien E4 epsilon4 Carriers				
<b>Jicha, Gregory A</b>	3048104819	\$0.	\$19,623.	\$19,623.
Elan Pharmaceuticals PLC A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) in patients with mild to moderate Alzheimer's Disease who are Apolipoprotien E4 epsilon4 Carriers				
<b>LeVine, Harry</b>	3048058200	\$0.	\$46,958.	\$46,958.
Alzheimers Association Chaperone-Mediated Protein Refolding Dysfunction in Alzheimer's Disease				

**Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Medicine</u></b>				
<b><u>Sanders-Brown Center on Aging</u></b>				
<b>Lovell, Mark</b>	3048105024	\$155,656.	\$0.	\$155,656.
National Institute on Aging Aberrant Protein Complexes as Biomarkers of Alzheimer's Disease				
<b>Markesbery, William</b>	3046969700	\$0.	\$-1,220.	\$-1,220.
Oregon Health and Sciences University Genetic Associations with Alzheimer-Free Survival				
<b>Markesbery, William</b>	3048104692	\$1,267,485.	\$0.	\$1,267,485.
National Institute on Aging Alzheimer's Disease Core Center				
<b>Markesbery, William</b>	3048104773	\$0.	\$13,320.	\$13,320.
University of Washington National Alzheimer's Coordinating Center (NACC) - Year 10				
<b>Markesbery, William</b>	3048104773	\$28,900.	\$0.	\$28,900.
University of Washington National Alzheimer's Coordinating Center (NACC) - Year 10				
<b>Nelson, Peter</b>	3048105044	\$50,000.	\$0.	\$50,000.
Alzheimers Association New Investigators Research Grant Program: Mechanism and therapeutic significance of an AD-relevant microRNA pathway				
<b>Nelson, Peter</b>	3048105195	\$320,469.	\$0.	\$320,469.
National Institute of Neurological Disorders & Stroke A Specific microRNA (MIR-107) is a Potential Therapeutic Target in Alzheimer's Disease				
<b>NORRIS, CHRISTOPHER</b>	3046825900	\$0.	\$91,166.	\$91,166.
National Institute on Aging Calcineurin and Biobehavioral Markers of Brain Aging				
<b>Scheff, Stephen W</b>	3048105031	\$73,836.	\$0.	\$73,836.
University of Pittsburgh Neurobiology of Mild Cognitive Impairment in the Elderly				
<b>Scheff, Stephen W</b>	3048105377	\$99,402.	\$0.	\$99,402.
KY Spinal Cord and Head Injury Research Trust Hyperglycemia and Traumatic Brain Injury				
<b>Schmitt, Frederick A</b>	3046648500	\$0.	\$7,125.	\$7,125.
University of California San Diego A multi-centered, randomized, double-blind, placebo-controlled trial of Simvastatin to slow the progression of Alzheimer's disease				
<b>Telling, Glenn</b>	3048105286	\$440,060.	\$0.	\$440,060.
University of Texas Medical Branch at Galveston Pathogenesis, Transmission and Detection of Zoonotic Prion Diseases				
<b>Sanders-Brown Center on Aging</b>	<b>Totals:</b>	<b>\$2,435,812.</b>	<b>\$661,291.</b>	<b>\$3,097,103.</b>

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b><u>Mag Resonance Imag Sys Ctr</u></b>				
<b>Smith, Charles D</b>	3046940800	\$0.	\$17,975.	\$17,975.
University of California San Diego Alzheimer's Disease Neuroimaging Initiative				
<b>Smith, Charles D</b>	3046940800	\$0.	\$2,500.	\$2,500.
University of California San Diego Alzheimer's Disease Neuroimaging Initiative				
<b>Smith, Charles D</b>	3046940800	\$0.	\$33,093.	\$33,093.
University of California San Diego Alzheimer's Disease Neuroimaging Initiative				
<b>Smith, Charles D</b>	3046940800	\$0.	\$15,500.	\$15,500.
University of California San Diego Alzheimer's Disease Neuroimaging Initiative				
<b>Mag Resonance Imag Sys Ctr</b>	<b>Totals:</b>	<b>\$0.</b>	<b>\$69,068.</b>	<b>\$69,068.</b>
<b><u>Rural Ky Healthcare</u></b>				
<b>Allen, Larry</b>	3048104699	\$30,000.	\$0.	\$30,000.
KY Department for Public Health Rural Cooperative Agreement				
<b>Allen, Larry</b>	3048104702	\$147,700.	\$0.	\$147,700.
Health Resources and Services Administration State Offices of Rural Health Grant Program				
<b>Allen, Larry</b>	3048105036	\$493,000.	\$0.	\$493,000.
Health Resources and Services Administration Medicare Rural Hospital Flexibility Grant Program				
<b>Allen, Larry</b>	3048105129	\$340,013.	\$0.	\$340,013.
Health Resources and Services Administration Small Rural Hospital Improvement Grant Program (SHIP)				
<b>Allen, Larry</b>	3048105261	\$270,000.	\$0.	\$270,000.
Health Resources and Services Administration Kentucky State Loan Repayment Program				
<b>Casey, Baretta R</b>	3048105140	\$173,263.	\$0.	\$173,263.
National Institute of General Medical Sciences Appalachian Kentucky Bridges to Success				
<b>Feltner, Frances J</b>	3048104700	\$0.	\$80,000.	\$80,000.
KY Department for Public Health Kentucky Homeplace				
<b>Feltner, Frances J</b>	3048104700	\$1,919,900.	\$0.	\$1,919,900.
KY Department for Public Health Kentucky Homeplace				
<b>Rural Ky Healthcare</b>	<b>Totals:</b>	<b>\$3,373,876.</b>	<b>\$80,000.</b>	<b>\$3,453,876.</b>

**Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Medicine</u></b>				
<b><u>Center on Drug and Alcohol Research</u></b>				
<b>Leukefeld, Carl G</b>	3048104959	\$5,759,193.	\$0.	\$5,759,193.
KY Health Services Cabinet TAP and Substance Abuse and Domestic Violence Project				
<b>Leukefeld, Carl G</b>	3048105294	\$715,539.	\$0.	\$715,539.
National Institute on Drug Abuse Central States Criminal Justice Drug Abuse Center (CJDATS)				
<b>Shannon, Lisa</b>		\$120,000.	\$0.	\$120,000.
KY Administrative Office of the Courts Treatment Drug Court Service Enhancement Project - Perry and Floyd Counties				
<b>Stoops, William W</b>	3048103671	\$0.	\$149,225.	\$149,225.
National Cancer Institute Internet Based Voucher Reinforcement for Smoking Cessation				
<b>Tindall, Michele Staton</b>	3048104810	\$140,000.	\$0.	\$140,000.
KY Department of Corrections Treatment Outcome Study for Prison-Based Substance Abuse Treatment Program 08-09 (CJ-KTOS)				
<b>Walker, James R</b>	3048104615	\$0.	\$60,000.	\$60,000.
KY River Community Care Inc Program Evaluation, Clinical Training, and Consultative Services for KRCC Staff				
<b>Walker, James R</b>	3048104906	\$1,290,744.	\$0.	\$1,290,744.
Department for Mental Health Mental Retardation Service FS/OP (TAA6, TAA7, TAAU) -- Kentucky Treatment Outcome Study				
<b>Walsh, Sharon L</b>	3046966600	\$0.	\$458,590.	\$458,590.
National Institute on Drug Abuse Licit & Illicit Opioids: Comparative Studies in Humans				
<b>Walsh, Sharon L</b>	3048048600	\$0.	\$617,144.	\$617,144.
National Institute on Drug Abuse Evaluation of Novel Treatments for Stimulant Dependence				
<b>Walsh, Sharon L</b>	3048092200	\$0.	\$348,516.	\$348,516.
National Institute on Drug Abuse Evaluation of Atomoxetine for Cocaine Dependence: A Pilot Trial				
<b>Walsh, Sharon L</b>	3048105221	\$0.	\$27,088.	\$27,088.
Catalyst Pharmaceutical Partners Inc Vigabatrin For Treatment of Methamphetamine Dependence: A Phase II Study				
<b>Walsh, Sharon L</b>	3048105221	\$2.	\$0.	\$2.
Catalyst Pharmaceutical Partners Inc Vigabatrin For Treatment of Methamphetamine Dependence: A Phase II Study				
<b>Webster, John Matthew</b>	3048104821	\$73,250.	\$0.	\$73,250.
National Institute on Alcohol Abuse and Alcoholism Drugged Driving in Alcohol-restricted Rural Appalachia				

**Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Medicine</u></b>				
<b><u>Center on Drug and Alcohol Research</u></b>				
<b>Webster, John Matthew</b>	3048105295	\$219,750.	\$0.	\$219,750.
National Institute on Drug Abuse A Web-based Employment Intervention for Drug Court Participants				
<b>Wunsch, Martha J</b>	3048105326	\$2,808.	\$0.	\$2,808.
Carilion Medical Center The Treatment of Neonatal Opioid Withdrawal: A Comparison of Methadone Loading and Tapering Regimens				
<b>Wunsch, Martha J</b>	3048105327	\$2,808.	\$0.	\$2,808.
Carilion Medical Center Prescription Medication Misuse in an Outpatient Clinic: A Study of Prevalance and Screening				
<b>Center on Drug and Alcohol Research</b>	<b>Totals:</b>	<b>\$8,324,094.</b>	<b>\$1,660,563.</b>	<b>\$9,984,657.</b>
<b><u>Anatomy &amp; Neurobiology</u></b>				
<b>Bueler, Hans Rudolf</b>	3048105092	\$50,000.	\$0.	\$50,000.
American Parkinsons Disease Association Identification of PINK1 Substrates Using Conditional PINK1 Knockout Cells and Quantitative Phosphoproteomics				
<b>Bueler, Hans Rudolf</b>	3048105258	\$29,507.	\$0.	\$29,507.
Parkinson Schweiz Identification of Novel PINK1 Substrates Using Proteomics and Conditional PINK1 Knockout Cells				
<b>Cass, Wayne A</b>	3048103646	\$0.	\$179,463.	\$179,463.
National Institute on Drug Abuse Calcitriol and Methamphetamine Neurotoxicity				
<b>Duncan, Marilyn J</b>	3048103522	\$0.	\$294,319.	\$294,319.
National Institute on Aging Neural Mechanisms Resetting the Aged Circadian Pacemaker				
<b>Duncan, Marilyn J</b>	3048104274	\$0.	\$264,619.	\$264,619.
National Institute of Neurological Disorders & Stroke Multiple Circadian oscillators: Regulation of a neuroendocrine rhythm				
<b>Gash, Don M</b>	3048091000	\$0.	\$63,445.	\$63,445.
Medtronics Inc RNA-Mediated SIRNA Master Research Agreement				
<b>Gash, Don M</b>	3048091000	\$0.	\$32,583.	\$32,583.
Medtronics Inc RNA-Mediated SIRNA Master Research Agreement				
<b>Gash, Don M</b>	3048091000	\$0.	\$110,779.	\$110,779.
Medtronics Inc RNA-Mediated SIRNA Master Research Agreement				
<b>Gash, Don M</b>	3048091000	\$0.	\$298,980.	\$298,980.
Medtronics Inc RNA-Mediated SIRNA Master Research Agreement				
<b>Gash, Don M</b>	3048100000	\$0.	\$-38,459.	\$-38,459.
Johnson and Johnson Screening Dopaminergic Trophic Factors in Rat Model Systems				

**Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Medicine</u></b>				
<b><u>Anatomy &amp; Neurobiology</u></b>				
<b>Gash, Don M</b>	3048103727	\$0.	\$33,783.	\$33,783.
Johnson and Johnson Screening Dopaminergic Trophic Factors in Rat Model Systems				
<b>Gash, Don M</b>	3048103727	\$0.	\$137,372.	\$137,372.
Johnson and Johnson Screening Dopaminergic Trophic Factors in Rat Model Systems				
<b>Gerhardt, Greg A</b>	3046967500	\$0.	\$27,316.	\$27,316.
Medical University of South Carolina Dual Hit Hypothesis of Aging Related DA Dysfunction				
<b>Gerhardt, Greg A</b>	3048078800	\$0.	\$81,913.	\$81,913.
Ohio State University High-Speed detection of Stimulant-induced Cortical ACh Release				
<b>Gerhardt, Greg A</b>	3048105018	\$1,120,083.	\$0.	\$1,120,083.
National Institute of Neurological Disorders & Stroke Project 1 Morris K. Udall Parkinson's Center of Excellence: Restoration of Dopaminergic Function in Parkinson's Disease				
<b>Gold, Brian T</b>	3048105251	\$125,313.	\$0.	\$125,313.
National Science Foundation The Cognitive Neuroscience of Bilingual Advantages in Executive Control				
<b>Grondin, Richard C</b>	3046956000	\$0.	\$94,031.	\$94,031.
Medtronics Inc New Neural Therapy Studies: 2005-1				
<b>Joseph, Jane E</b>	3048103764	\$0.	\$59,294.	\$59,294.
Autism Speaks Exploring Functional Brain Connectivity for Visual Cognition in Autism Spectrum Disorder				
<b>Stein, Pamela Ann</b>		\$2,400.	\$0.	\$2,400.
American Dental Education Association Muscles of Mastication Tutorial CD ROM				
<b>Zhang, Zhiming</b>	3048092900	\$0.	\$288,422.	\$288,422.
National Institute of Neurological Disorders & Stroke Relationship between BOLD Effects and DA Degeneration				
<b>Anatomy &amp; Neurobiology</b>	<b>Totals:</b>	<b>\$1,327,303.</b>	<b>\$1,927,860.</b>	<b>\$3,255,163.</b>
<b><u>Anesthesiology</u></b>				
<b>Holtman, Joseph R</b>	3048104940	\$77,529.	\$0.	\$77,529.
Insys Therapeutics Inc Cannabinoid and Opioid Combination Therapy				
<b>Holtman, Joseph R</b>	3048104941	\$73,369.	\$0.	\$73,369.
Insys Therapeutics Inc Morphine-6-O-sulfate for Treatment of Pain				
<b>Anesthesiology</b>	<b>Totals:</b>	<b>\$150,898.</b>	<b>\$0.</b>	<b>\$150,898.</b>

**Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009**

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Emergency Medicine</b>				
<b>Humphries, Roger L</b>	3048087100	\$0.	\$1,998.	\$1,998.
MedImmune Inc An Epidemiological Study to Evaluate the Seasonality of Respiratory Syncytial Virus-Associated Lower Respiratory TRact Infections (LRI) or Apnea in Infants in the Emergency Department				
<b>Humphries, Roger L</b>	3048100900	\$0.	\$194,118.	\$194,118.
National Institute of Neurological Disorders & Stroke UK NETT Clinical Site hub				
<b>Humphries, Roger L</b>	3048104000	\$0.	\$352,330.	\$352,330.
University of Michigan UK NETT Clinical Hub Site				
<b>Emergency Medicine</b>	<b>Totals:</b>	<b>\$0.</b>	<b>\$548,446.</b>	<b>\$548,446.</b>
<b>Behavioral Science</b>				
<b>Andrykowski, Michael A</b>		\$149,516.	\$0.	\$149,516.
KY Lung Cancer Research Fund Disparities in Mental Health Outcomes Between Rural and Nonrural Lung Cancer Survivors				
<b>Andrykowski, Michael A</b>	3046794500	\$0.	\$128,411.	\$128,411.
National Cancer Institute Psychological and Behavioral Impact of Cancer Screening				
<b>Andrykowski, Michael A</b>	3046847000	\$0.	\$159,950.	\$159,950.
H Lee Moffitt Cancer Center and Research I Cognitive Behavioral Aspects of Cancer-Related Fatigue				
<b>Cole, Cynthia M</b>	3048021500	\$0.	\$-9,631.	\$-9,631.
People Encouraging People Inc Evaluation of the Lee County People Encouraging People (PEP) Coalition				
<b>Garrity, Thomas F</b>	3048104974	\$275,539.	\$0.	\$275,539.
National Institute on Drug Abuse Research Training in Drug Abuse Behavior				
<b>Kelly, Thomas H</b>	3048103866	\$0.	\$52,763.	\$52,763.
National Institute on Drug Abuse Separate and Combined Effects of Progesterone and Triazolam in Healthy Women				
<b>Knudsen, Hannah K</b>	3048104382	\$0.	\$28,293.	\$28,293.
University of Georgia CTN Membership and Adoption of Innovative TX Practices				
<b>Knudsen, Hannah K</b>	3048105288	\$115,584.	\$0.	\$115,584.
Robert Wood Johnson Foundation Barriers to the Adoption of Pharmacotherapies in Publicly Funded Substance Abuse Treatment: Policy Barriers and Access to Physicians				
<b>Knudsen, Hannah K</b>	3048105325	\$25,843.	\$0.	\$25,843.
University of Georgia Use of Evidence-Based Practices in Alcoholism Treatment				

**Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009**

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b><u>Behavioral Science</u></b>				
<b>Leukefeld, Carl G</b>	3048077800	\$0.	\$251,656.	\$251,656.
National Center for Research Resources TRY-IT Translating Reserach to Youth through Information Technology				
<b>Lile, Joshua</b>	3046902300	\$0.	\$148,209.	\$148,209.
National Institute on Drug Abuse A Pharmacological Analysis of Delta 9-THC in Humans				
<b>Lile, Joshua</b>	3048105287	\$366,250.	\$0.	\$366,250.
National Institute on Drug Abuse GABA Drugs for Cannabis-Use Disorders: Initial Mechanistic Studies in Humans				
<b>Rush, Craig R</b>	3046956200	\$0.	\$340,325.	\$340,325.
National Institute on Drug Abuse Preventing Cocaine Relapse: Developing Pharmacotherapies				
<b>Rush, Craig R</b>	3048105279	\$329,625.	\$0.	\$329,625.
National Institute on Drug Abuse GABAA Modulation as a Target for Developing Medications for Methamphetamine Abuse				
<b>Schoenberg, Nancy E</b>	3048104977	\$579,454.	\$0.	\$579,454.
National Center on Minority Health and Health Disparities Faith Moves Mountains: A CBPR Appalachian Wellness & Cancer Prevention Program				
<b>SCHOENBERG, NANCY</b>	3048105145	\$577,274.	\$0.	\$577,274.
National Institute Diabetes & Digestive & Kidney An Intergenerational CBPR Intervention to Reduce Appalachian Health Disparities				
<b>Behavioral Science</b>	<b>Totals:</b>	<b>\$2,419,085.</b>	<b>\$1,099,976.</b>	<b>\$3,519,061.</b>
<b><u>Graduate Center for Nutritional Sciences</u></b>				
<b>Cassis, Lisa A</b>	3048104794	\$21,000.	\$0.	\$21,000.
American Heart Association Great Rivers Affiliate Fellowship for Xuan Zhang: Androgen Regulation of the AT1a Receptor (AT1aR) in Angiotensin II-Induced Abdominal Aortic Aneurysms				
<b>Cassis, Lisa A</b>	3048104798	\$21,000.	\$0.	\$21,000.
American Heart Association Great Rivers Affiliate Fellowship for Manisha Gupte: ACE2 Expression in Adipocytes and Regulation in Obesity-Related Hypertension				
<b>Glauert, Howard P</b>	3048103660	\$0.	\$73,250.	\$73,250.
National Cancer Institute Prevention of Cigarette Smoke-Induced Lung Cancer by Dietary Selenium				
<b>Shao, Jianhua</b>	3048103750	\$0.	\$197,500.	\$197,500.
American Diabetes Association Inc Transcriptional Regulation of Adiponectin Gene Expression				
<b>St Clair, Daret K</b>	3048104989	\$78,659.	\$0.	\$78,659.
National Institute Diabetes & Digestive & Kidney NRSA T32: Training Program in Oxidative Stress and Nutrition				

## Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b><u>Graduate Center for Nutritional Sciences</u></b>				
<b>Wang, Shuxia</b>	3048104980	\$110,000.	\$0.	\$110,000.
Juvenile Diabetes Research Foundation Increased PKG Activity Prevents the Development of Diabetic Nephropathy				
<b>Graduate Center for Nutritional Sciences</b>	<b>Totals:</b>	<b>\$230,659.</b>	<b>\$270,750.</b>	<b>\$501,409.</b>
<b><u>Molecular &amp; Cellular Biochemistry</u></b>				
<b>Chi, Young-In</b>	3048104812	\$197,500.	\$0.	\$197,500.
American Diabetes Association Inc Structural Studies of HNF 1alpha and HNF 4alpha				
<b>Chi, Young-In</b>	3048104911	\$25,000.	\$0.	\$25,000.
KY Diabetes Research Trust Fund Identification of HNF and HNF4 Mediated Regulators of Insulin Secretion in Beta-Cells				
<b>Creamer, Trevor P</b>	3048105151	\$69,999.	\$0.	\$69,999.
KY Science and Technology Co Inc R&D Excellence: Using Calmodulin to Probe the Role of Intrinsic Disorder in Biomolecular Recognition				
<b>Dickson, Robert C</b>	3048105149	\$366,250.	\$0.	\$366,250.
National Institute on Aging Characterization of the Sch9-Longevity Pathway in Yeast				
<b>Dutch, Rebecca</b>	3048103832	\$0.	\$215,575.	\$215,575.
National Institute of Allergy and Infectious Diseases HMPV Fusion Protein-host Cell Interactions				
<b>Fried, Michael Gregory</b>	3046889200	\$0.	\$247,257.	\$247,257.
National Institute of General Medical Sciences Cooperative Interactions in DNA Repair				
<b>Gentry, Matthew Shawn</b>	3048105237	\$232,725.	\$0.	\$232,725.
National Institute of Neurological Disorders & Stroke Novel Model Systems Link Floridean Starch Metabolism to Lafora Disease				
<b>Hersh, Louis B</b>	3048104542	\$0.	\$50,000.	\$50,000.
Institute of the Study of Aging Inc Nepriylsin and Peripheral Clearance of Amyloid Peptides				
<b>Hersh, Louis B</b>	3048104910	\$157,252.	\$0.	\$157,252.
National Institute on Drug Abuse NRSA T32: Training in Drug Abuse Related Research				
<b>Hersh, Louis B</b>	3048104925	\$77,442.	\$0.	\$77,442.
Alzheimers Association A Modified Nepriylsin for Gene Therapy				
<b>Hersh, Louis B</b>	3048105053	\$2,003,172.	\$0.	\$2,003,172.
National Center for Research Resources Center of Biomedical Research Excellence in the Molecular Basis of Human Disease - Administrative Core				
<b>Moncman, Carole</b>	3048105265	\$219,750.	\$0.	\$219,750.
National Eye Institute Temporal and Spatial Patterns of Structural Proteins in Extraocular Muscles				

## Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b><u>Molecular &amp; Cellular Biochemistry</u></b>				
<b>Murphy, Michael Paul</b>	3048096300	\$0.	\$7,348.	\$7,348.
University of Southern California Progesterone in Brain Aging and Alzheimer's Disease				
<b>Ozcan, Sabire</b>		\$43,000.	\$0.	\$43,000.
American Heart Association Great Rivers Affiliate Fellowship/Prahalathan Chidambaram: Role of Histone Deacetylase HDAC7 in Pancreatic Beta Cell Function				
<b>Ozcan, Sabire</b>	3048103415	\$0.	\$21,000.	\$21,000.
American Heart Association Ohio Valley Affiliate Fellowship for Megan Sampley: PDX-1 Regulates Insulin Biosynthesis by Interaction with Transcription and Translation				
<b>Ozcan, Sabire</b>	3048104718	\$47,000.	\$0.	\$47,000.
American Heart Association Great Rivers Affiliate Fellowship/Muniappan: Identification for miRNAs Regulated by Beta-Cell Transcription Factors				
<b>Rodgers, David W</b>	3046504700	\$0.	\$-329,625.	\$-329,625.
National Institute of Neurological Disorders & Stroke Neuropeptidase Function				
<b>Rodgers, David W</b>	3048105045	\$329,625.	\$0.	\$329,625.
National Institute of Neurological Disorders & Stroke Neuropeptidase Function				
<b>Spielmann, H Peter</b>	3048104852	\$289,574.	\$0.	\$289,574.
National Institute of General Medical Sciences Synthetic Probes of Protein Prenylation				
<b>Stamm, Stefan</b>	3048104302	\$0.	\$32,713.	\$32,713.
University of Massachusetts Tau Missplicing Caused by RNA Processing Proteins Located on the Chromosome 21NIH				
<b>Tang, Xiaoqing</b>	3048103834	\$0.	\$101,505.	\$101,505.
National Institute Diabetes & Digestive & Kidney Role of microRNAs in insulin production and secretion in pancreatic beta-cells				
<b>Turco, Salvatore J</b>	3048105277	\$0.	\$12,911.	\$12,911.
Washington University Glycosylation Mutants of Leishmania				
<b>Turco, Salvatore J</b>	3048105277	\$280,707.	\$0.	\$280,707.
Washington University Glycosylation Mutants of Leishmania				
<b>Waechter, Charles J</b>	3046925500	\$0.	\$312,545.	\$312,545.
National Institute of General Medical Sciences Regulation of Protein N-Glycosylation in the CNS				
<b>Zhu, Haining</b>	3046809700	\$0.	\$253,622.	\$253,622.
National Institute of Neurological Disorders & Stroke Proteomic and Functional Studies of Mitochondria in ALS				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b><u>Molecular &amp; Cellular Biochemistry</u></b>				
<b>Zhu, Haining</b>	3046809700	\$0.	\$73,250.	\$73,250.
National Institute of Neurological Disorders & Stroke Proteomic and Functional Studies of Mitochondria in ALS				
<b>Zhu, Haining</b>	3048105148	\$658,905.	\$0.	\$658,905.
US Army Medical Research and Materiel Command Biomarker Discovery and Mechanistic Studies of Prostate Cancer using Targeted Proteomic Approaches				
<b>Zhu, Haining</b>	3048105150	\$231,250.	\$0.	\$231,250.
National Institute on Aging Role of P62 in Protein Aggregation and Neurodegeneration in ALS				
<b>Molecular &amp; Cellular Biochemistry</b>	<b>Totals:</b>	<b>\$5,229,151.</b>	<b>\$998,101.</b>	<b>\$6,227,252.</b>
<b><u>Internal Medicine</u></b>				
<b>Ain, Kenneth B</b>	3048093400	\$0.	\$1,886.	\$1,886.
AstraZeneca Pharmaceuticals An international Phase II randomized double-blinded, placebo-controlled, multi-center study to assess the efficacy of ZD6474(Zactima TM) versus placebo in patients with unresectable locally advanced or metastatic medullary thyroid cancer				
<b>Ain, Kenneth B</b>	3048093400	\$0.	\$1,834.	\$1,834.
AstraZeneca Pharmaceuticals An international Phase II randomized double-blinded, placebo-controlled, multi-center study to assess the efficacy of ZD6474(Zactima TM) versus placebo in patients with unresectable locally advanced or metastatic medullary thyroid cancer				
<b>Ain, Kenneth B</b>	3048104863	\$126,000.	\$0.	\$126,000.
National Cancer Institute Transcriptional Repression of Sodium-Iodide Symporter in Thyroid Carcinoma				
<b>Arnold, Susanne M</b>	3046259800	\$0.	\$50.	\$50.
Southwest Oncology Group Southwest Oncology Group Studies				
<b>Arnold, Susanne M</b>	3046259800	\$0.	\$-250.	\$-250.
Southwest Oncology Group Southwest Oncology Group Studies				
<b>Arnold, Susanne M</b>	3046259800	\$0.	\$150.	\$150.
Southwest Oncology Group Southwest Oncology Group Studies				
<b>Arnold, Susanne M</b>	3046259800	\$0.	\$4,000.	\$4,000.
Southwest Oncology Group Southwest Oncology Group Studies				
<b>Arnold, Susanne M</b>	3046259800	\$0.	\$6,000.	\$6,000.
Southwest Oncology Group Southwest Oncology Group Studies				
<b>Arnold, Susanne M</b>	3046259800	\$0.	\$150.	\$150.
Southwest Oncology Group Southwest Oncology Group Studies				

**Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009**

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Internal Medicine</b>				
<b>Arnold, Susanne M</b>	3046259800	\$0.	\$2,000.	\$2,000.
Southwest Oncology Group Southwest Oncology Group Studies				
<b>Arnold, Susanne M</b>	3046828600	\$0.	\$1,800.	\$1,800.
Eli Lilly and Company A Randomized Phase 3 Trial of ALIMTA and Cisplatin versus GEMZAR and Cisplatin in Patients with Locally Advanced or Metastatic Non-Small Lung Cancer				
<b>Arnold, Susanne M</b>	3046828600	\$0.	\$-1,355.	\$-1,355.
Eli Lilly and Company A Randomized Phase 3 Trial of ALIMTA and Cisplatin versus GEMZAR and Cisplatin in Patients with Locally Advanced or Metastatic Non-Small Lung Cancer				
<b>Arnold, Susanne M</b>	3048062300	\$0.	\$-1,800.	\$-1,800.
Eli Lilly and Company A Randomized Phase 3 Trail of Alimta (Pemetrexed) and Carboplatin vs Etoposide and Carboplatin in Extensive-stage Small Cell Lung Cancer				
<b>Arnold, Susanne M</b>	3048065800	\$0.	\$82,260.	\$82,260.
Arno Therapeutics Inc A Phase 1 Study of DB-67 (7-t-butylidimethylsilyl-10-hydroxycamptothecin) in Adult Patients with Refractory or Metastatic Solid Malignancies				
<b>Arnold, Susanne M</b>	3048065800	\$0.	\$68,850.	\$68,850.
Arno Therapeutics Inc A Phase 1 Study of DB-67 (7-t-butylidimethylsilyl-10-hydroxycamptothecin) in Adult Patients with Refractory or Metastatic Solid Malignancies				
<b>Arnold, Susanne M</b>	3048076600	\$0.	\$7,352.	\$7,352.
AstraZeneca Pharmaceuticals A Phase III, International, RANdomized, Double-BLind, Parallel-Group, Multi-Center, Study to Assess the Efficacy of ZD6474 Versus Erlotinib (TARCEVA) in Patients with Locally Advanced or Metastatic (Stage IIIB-IV) Non-Small Cell Lung Cancer (NSCLC)				
<b>Arnold, Susanne M</b>	3048076600	\$0.	\$2,682.	\$2,682.
AstraZeneca Pharmaceuticals A Phase III, International, RANdomized, Double-BLind, Parallel-Group, Multi-Center, Study to Assess the Efficacy of ZD6474 Versus Erlotinib (TARCEVA) in Patients with Locally Advanced or Metastatic (Stage IIIB-IV) Non-Small Cell Lung Cancer (NSCLC)				
<b>Arnold, Susanne M</b>	3048104325	\$0.	\$6,248.	\$6,248.
AMGen A Randomized, Open Label, Controlled, Phase II Trial of Combination Chemotherapy with or without Panitumumab as First Line Treatment of Subjects with Metastatic or Recurrent Head and Neck Cancer and Cross				
<b>Arnold, Susanne M</b>	3048104326	\$0.	\$15,819.	\$15,819.
AMGen A Phase 2, Single-Arm, Open Label, Multi-Center Trial of Panitumumab Monotherapy in Patients with Platinum Refractory Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck				
<b>Arsenescu, Razvan I</b>	3046847900	\$0.	\$15,933.	\$15,933.
Otsuka America Pharmaceutical Inc A Randomized, Prospective, Double-Blinded, Placebo-Contolled Study to Evaluate the Safety and Effectiveness of the Adacolumn Apheresis System for the Treatment of Moderate to Severe Ulcerative Colitis				

## Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Internal Medicine</b>				
<b>Arsenescu, Razvan I</b>	3046964400	\$0.	\$6,474.	\$6,474.
Robarts Research Institute				
A Randomized, Prospective, Double-Blinded, Placebo-Controlled (Sham-Controlled) Study to Evaluate the Safety and Effectiveness of the Adacolumn Apheresis System for the Treatment of Moderate to Severe Crohn's Disease				
<b>Arsenescu, Razvan I</b>	3048061500	\$0.	\$3,497.	\$3,497.
Robarts Research Institute				
A Prospective, Open-Label Study to Evaluate the Adacolumn Apheresis System for the Treatment of Moderate to Severe Crohn's Disease				
<b>Arsenescu, Razvan I</b>	3048061500	\$0.	\$11,277.	\$11,277.
Robarts Research Institute				
A Prospective, Open-Label Study to Evaluate the Adacolumn Apheresis System for the Treatment of Moderate to Severe Crohn's Disease				
<b>Arsenescu, Razvan I</b>	3048103221	\$0.	\$20,415.	\$20,415.
AstraZeneca Pharmaceuticals				
Role of Polymeric Immunoglobulin Receptor (pIgR) in the Pathogenesis of Crohn's Disease				
<b>Arsenescu, Razvan I</b>	3048104014	\$0.	\$4,855.	\$4,855.
Alba Therapeutics Corp				
A Phase IIb, randomized, double-blind, placebo controlled, dose ranging multicenter study to determine the safety, tolerance, and efficacy of AT-001 in celiac disease subjects during a gluten challenge				
<b>Arsenescu, Razvan I</b>	3048104014	\$0.	\$13,500.	\$13,500.
Alba Therapeutics Corp				
A Phase IIb, randomized, double-blind, placebo controlled, dose ranging multicenter study to determine the safety, tolerance, and efficacy of AT-001 in celiac disease subjects during a gluten challenge				
<b>Arsenescu, Razvan I</b>	3048104014	\$0.	\$3,077.	\$3,077.
Alba Therapeutics Corp				
A Phase IIb, randomized, double-blind, placebo controlled, dose ranging multicenter study to determine the safety, tolerance, and efficacy of AT-001 in celiac disease subjects during a gluten challenge				
<b>Arsenescu, Razvan I</b>	3048104625	\$0.	\$4,676.	\$4,676.
Alba Therapeutics Corp				
A Phase IIb, Randomized, Double-Blind, Placebo Controlled Study for the Treatment of Active Celiac Disease with AT-1001				
<b>Arsenescu, Razvan I</b>	3048104894	\$80,600.	\$0.	\$80,600.
UCB Pharma				
Role of Adiponectin in the Pathogenesis of Inflammatory Bowel Disease				
<b>Booth, David C</b>	3046763700	\$0.	\$171.	\$171.
ENCYSIVE LP				
FPH02-X An Open-Label Study to Evaluate the Long-Term Safety of Sitaxsentan Sodium Treatment with a Bosentan Arm in Patients with Pulmonary Arterial Hypertension (STRIDE II-X)				
<b>Booth, David C</b>	3046763800	\$0.	\$-171.	\$-171.
ENCYSIVE LP admin by ResearchPoint				
A Long-Term, Open-Label Study to Evaluate the Safety of Sitaxsentan Sodium Treatment in Patients with Pulmonary Arterial Hypertension (STRIDE-III)				
<b>Booth, David C</b>	3046763800	\$0.	\$1,108.	\$1,108.
ENCYSIVE LP admin by ResearchPoint				
A Long-Term, Open-Label Study to Evaluate the Safety of Sitaxsentan Sodium Treatment in Patients with Pulmonary Arterial Hypertension (STRIDE-III)				

## Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Internal Medicine</b>				
<b>Booth, David C</b>	3048012300	\$0.	\$1,890.	\$1,890.
Actelion Pharmaceuticals Ltd COMPASS 2: Effects of Combination of Bosentan and Sildenafil Versus Sildenafil Monotherapy on Morbidity and Mortality in Symptomatic Pts. with Pulmonary Arterial Hypertension-A Multicenter, Double-Blind, RANdomized, Placebo-Controlled,.....Phase IV Study				
<b>Booth, David C</b>	3048012300	\$0.	\$4,725.	\$4,725.
Actelion Pharmaceuticals Ltd COMPASS 2: Effects of Combination of Bosentan and Sildenafil Versus Sildenafil Monotherapy on Morbidity and Mortality in Symptomatic Pts. with Pulmonary Arterial Hypertension-A Multicenter, Double-Blind, RANdomized, Placebo-Controlled,.....Phase IV Study				
<b>Booth, David C</b>	3048012300	\$0.	\$1,890.	\$1,890.
Actelion Pharmaceuticals Ltd COMPASS 2: Effects of Combination of Bosentan and Sildenafil Versus Sildenafil Monotherapy on Morbidity and Mortality in Symptomatic Pts. with Pulmonary Arterial Hypertension-A Multicenter, Double-Blind, RANdomized, Placebo-Controlled,.....Phase IV Study				
<b>Booth, David C</b>	3048012300	\$0.	\$3,780.	\$3,780.
Actelion Pharmaceuticals Ltd COMPASS 2: Effects of Combination of Bosentan and Sildenafil Versus Sildenafil Monotherapy on Morbidity and Mortality in Symptomatic Pts. with Pulmonary Arterial Hypertension-A Multicenter, Double-Blind, RANdomized, Placebo-Controlled,.....Phase IV Study				
<b>Bruemmer, Dennis C</b>	3048103420	\$0.	\$44,000.	\$44,000.
American Heart Association Ohio Valley Affiliate Gizard Post-Doc Fellowship: Role of Telomerase in Macrophage Inflammation and Atherosclerosis				
<b>Bruemmer, Dennis C</b>	3048104987	\$21,000.	\$0.	\$21,000.
American Heart Association Great Rivers Affiliate Fellowship for Yue Zhao: The Regulation of Function of NOR1 in Endothelial Cells				
<b>Bruemmer, Dennis C</b>	3048105001	\$25,000.	\$0.	\$25,000.
KY Diabetes Research Trust Fund Telomeres in Obesity and Diabetes				
<b>Bruemmer, Dennis C</b>	3048105383	\$177,750.	\$0.	\$177,750.
American Diabetes Association Inc Telomere Attrition in Adipose Tissue Senescence and Insulin Resistance				
<b>Bryson, James S</b>	3048105378	\$150,000.	\$0.	\$150,000.
KY Lung Cancer Research Fund Allogeneic Immunotherapy of Lung Cancer				
<b>Campbell, Charles L.</b>	3046979000	\$0.	\$800.	\$800.
Schering Plough Co IMPROVE-IT: Improved Reduction of Outcomes: Vytarin Efficacy International Trail				
<b>Campbell, Charles L.</b>	3046979000	\$0.	\$750.	\$750.
Schering Plough Co IMPROVE-IT: Improved Reduction of Outcomes: Vytarin Efficacy International Trail				
<b>Campbell, Charles L.</b>	3046979000	\$0.	\$2,300.	\$2,300.
Schering Plough Co IMPROVE-IT: Improved Reduction of Outcomes: Vytarin Efficacy International Trail				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Internal Medicine</b>				
<b>Campbell, Charles L.</b>	3046979000	\$0.	\$900.	\$900.
Schering Plough Co IMPROVE-IT: Improved Reduction of Outcomes: Vytorin Efficacy International Trail				
<b>Campbell, Charles L.</b>	3046979000	\$0.	\$2,100.	\$2,100.
Schering Plough Co IMPROVE-IT: Improved Reduction of Outcomes: Vytorin Efficacy International Trail				
<b>Campbell, Charles L.</b>	3046979000	\$0.	\$1,900.	\$1,900.
Schering Plough Co IMPROVE-IT: Improved Reduction of Outcomes: Vytorin Efficacy International Trail				
<b>Campbell, Charles L.</b>	3048103622	\$0.	\$2,000.	\$2,000.
AstraZeneca Pharmaceuticals Plato: A Randomized, Double-Blind, Parallel Group, Phase 3, Efficacy and Safety Study of AZD6140 Compared with Clpoidogrel for Prevention of Vascular Events in Patients with Non-ST or ST Elevation Acute Coronary Syndromes				
<b>Campbell, Charles L.</b>	3048104421	\$0.	\$2,000.	\$2,000.
Scios Inc Double-Blind, Placebo-Controlled, Multicenter Acute Study of Clinical Effectiveness of Nesiritide in Subjects with Decompensated Heart Failure (ASCEND-HF)				
<b>Campbell, Charles L.</b>	3048104421	\$0.	\$6,500.	\$6,500.
Scios Inc Double-Blind, Placebo-Controlled, Multicenter Acute Study of Clinical Effectiveness of Nesiritide in Subjects with Decompensated Heart Failure (ASCEND-HF)				
<b>Campbell, Charles L.</b>	3048104421	\$0.	\$2,250.	\$2,250.
Scios Inc Double-Blind, Placebo-Controlled, Multicenter Acute Study of Clinical Effectiveness of Nesiritide in Subjects with Decompensated Heart Failure (ASCEND-HF)				
<b>Campbell, Charles L.</b>	3048104547	\$0.	\$7,748.	\$7,748.
Portola Pharmaceuticals Inc ERASE-MI: Early Rapid Reversal of Platelet Thrombosis with Intravenous PRT060128 before PCI to optimize Reperfusion in Acute MI				
<b>Cassis, Lisa A</b>	3048105204	\$2,082,003.	\$0.	\$2,082,003.
National Center for Research Resources COBRE: Center of Research in Obesity and Cardiovascular Disease				
<b>Caudill, Timothy S</b>	3046875600	\$0.	\$3,420.	\$3,420.
AstraZeneca Pharmaceuticals A Randomized, Double-Blind, Placebo-Controlled, Mutilcenter, Phase III Study of Rosuvastatin (CRESTOR) 20 mg in the Primary Prevention of Cardiovascular Events Among Subjects with Low Levels of LDL-Cholesterol and Eevated Levels of C-Reactive Protein				
<b>Caudill, Timothy S</b>	3046875600	\$0.	\$2,925.	\$2,925.
AstraZeneca Pharmaceuticals A Randomized, Double-Blind, Placebo-Controlled, Mutilcenter, Phase III Study of Rosuvastatin (CRESTOR) 20 mg in the Primary Prevention of Cardiovascular Events Among Subjects with Low Levels of LDL-Cholesterol and Eevated Levels of C-Reactive Protein				

**Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009**

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Internal Medicine</b>				
<b>Chasen, Craig A</b>	3046783200	\$0.	\$45.	\$45.
Novartis ACCOMPLISH (Avoiding Cardiovascular Events Through Combination Therapy in Patients Living with Systolic Hypertension):				
<b>Chasen, Craig A</b>	3046783200	\$0.	\$2,344.	\$2,344.
Novartis ACCOMPLISH (Avoiding Cardiovascular Events Through Combination Therapy in Patients Living with Systolic Hypertension):				
<b>Crofford, Leslie J</b>	3046988500	\$0.	\$34,419.	\$34,419.
University of Pittsburgh Rituximab in the Treatment of Refractory Adult and Juvenile Dermatomyositis and				
<b>Crofford, Leslie J</b>	3048103683	\$0.	\$70,653.	\$70,653.
University of Cincinnati Development of a Fibromyalgia Responder Index				
<b>Crofford, Leslie J</b>	3048104953	\$2.	\$0.	\$2.
Psychiatric Professional Services Inc Development and Testing of a Fibromyalgia Diagnostic Screening Instrument for Primary Care				
<b>Crofford, Leslie J</b>	3048105027	\$2.	\$0.	\$2.
Boehringer Ingelheim A Randomized, Double-Blind, Placebo-Controlled, Dose Titration, Efficacy & Safety Study of Pramipexole ER (0.75 mg to 4.5 mg) Administered Orally Once Daily Versus Placebo Over a 16-week Maintenance Phase in Patients				
<b>Daugherty, Alan</b>	3046989400	\$0.	\$1.	\$1.
National Heart Lung and Blood Institute Mechanisms of Abdominal Aortic Aneurysm Formation				
<b>Daugherty, Alan</b>	3048012400	\$0.	\$83,733.	\$83,733.
James Cook University Osteoprotegerin and osteopontin in aortic aneurysm				
<b>Daugherty, Alan</b>	3048104843	\$232,701.	\$0.	\$232,701.
Novartis Comparative Efficacy of Selected Modes of Inhibiting the Renin Angiotensin System on the Development of Hypercholesterolemia-Induced Atherosclerosis				
<b>Daugherty, Alan</b>	3048104844	\$166,419.	\$0.	\$166,419.
Novartis The Efficacy of Renin Inhibition on Progression and Regression of Hypercholesterolemia-Induced Atherosclerosis				
<b>Daugherty, Alan</b>	3048104960	\$43,000.	\$0.	\$43,000.
American Heart Association Great Rivers Affiliate Fellowship for Venkateswaran Subramanian: Role of peroxisome proliferator activated receptor gamma in angiotensin II induced abdominal aortic aneurysm				
<b>Daugherty, Alan</b>	3048105369	\$366,250.	\$0.	\$366,250.
National Heart Lung and Blood Institute Sources and Effects of Angiotensin Peptides in Atherosclerosis				

**Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009**

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Internal Medicine</b>				
<b>De Villiers, Willem</b>	3046569500	\$0.	\$3,226.	\$3,226.
Centocor Inc A Randomized, Placebo-Controlled, Double-Blind Trial to Evaluate and Efficacy of Infliximab in Patients with Active Ulcerative Colitis				
<b>De Villiers, Willem</b>	3046864500	\$0.	\$672.	\$672.
Abbott Laboratories Multi-Center Open Labeled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate the Long-Term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects with Crohn's Disease				
<b>De Villiers, Willem</b>	3046978300	\$0.	\$3,660.	\$3,660.
PDL BioPharma Inc Visilizumab				
<b>De Villiers, Willem</b>	3046978300	\$0.	\$2,700.	\$2,700.
PDL BioPharma Inc Visilizumab				
<b>De Villiers, Willem</b>	3048054200	\$0.	\$5,445.	\$5,445.
Ocera Therapeutics Inc A Double-Blind, Randomized, Placebo-Controlled Multicenter Study to Assess the Safety and Efficacy of AST-120 in Mild to Moderately Active Crohn's Patients with Fistulas				
<b>De Villiers, Willem</b>	3048066700	\$0.	\$1,170.	\$1,170.
Procter & Gamble Company A Double-Blind, Randomized, 6-week, Parallel-Group Clinical Trial to Assess the Safety and Efficacy of Asacol 4.8 g/day (800 mg Mesalamine Tablet) Versus Asacol 2.4 g/day (400 mg Mesalamine Tablet) for the Treatment of Moderately Active Ulcerative Colitis				
<b>De Villiers, Willem</b>	3048073100	\$0.	\$-13,500.	\$-13,500.
Salix Pharmaceuticals Inc A Multicenter, Randomized, Double-Blind, Actively Controlled Trial to Evaluate the Safety and Efficacy of a New Tablet Formulation and Dosing Regimen of Balsalazide Disodium 3.3g Bid vs. Mesalamine (5-ASA) As Asacol 0.8 G Tid ub Mildly to				
<b>De Villiers, Willem</b>	3048103743	\$0.	\$9,047.	\$9,047.
Bristol Myers Squibb Company Abatacept in Subject with Active Ulcerative Colitis				
<b>De Villiers, Willem</b>	3048103743	\$0.	\$12,854.	\$12,854.
Bristol Myers Squibb Company Abatacept in Subject with Active Ulcerative Colitis				
<b>De Villiers, Willem</b>	3048103743	\$0.	\$556.	\$556.
Bristol Myers Squibb Company Abatacept in Subject with Active Ulcerative Colitis				
<b>De Villiers, Willem</b>	3048103743	\$0.	\$3,613.	\$3,613.
Bristol Myers Squibb Company Abatacept in Subject with Active Ulcerative Colitis				
<b>De Villiers, Willem</b>	3048103744	\$0.	\$1,856.	\$1,856.
Bristol Myers Squibb Company Abatacept in Subject with Active Crohn's Disease				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Internal Medicine</b>				
<b>De Villiers, Willem</b>	3048103744	\$0.	\$5,391.	\$5,391.
Bristol Myers Squibb Company Abatacept in Subject with Active Crohn's Disease				
<b>De Villiers, Willem</b>	3048103744	\$0.	\$3,737.	\$3,737.
Bristol Myers Squibb Company Abatacept in Subject with Active Crohn's Disease				
<b>De Villiers, Willem</b>	3048103744	\$0.	\$1,955.	\$1,955.
Bristol Myers Squibb Company Abatacept in Subject with Active Crohn's Disease				
<b>De Villiers, Willem</b>	3048103744	\$0.	\$1,980.	\$1,980.
Bristol Myers Squibb Company Abatacept in Subject with Active Crohn's Disease				
<b>De Villiers, Willem</b>	3048103744	\$0.	\$-3,737.	\$-3,737.
Bristol Myers Squibb Company Abatacept in Subject with Active Crohn's Disease				
<b>De Villiers, Willem</b>	3048104103	\$0.	\$6,905.	\$6,905.
Duke University A Phase III, Multi-Center, Placebo-Controlled, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of PROCHYMAL TM IV Infusion for the Induction of Remission in Subjects Experiencing Treatment-Refractory Moderate-to-Sever Crohn's Disease				
<b>De Villiers, Willem</b>	3048104103	\$0.	\$1,903.	\$1,903.
Duke University A Phase III, Multi-Center, Placebo-Controlled, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of PROCHYMAL TM IV Infusion for the Induction of Remission in Subjects Experiencing Treatment-Refractory Moderate-to-Sever Crohn's Disease				
<b>De Villiers, Willem</b>	3048104103	\$0.	\$13,906.	\$13,906.
Duke University A Phase III, Multi-Center, Placebo-Controlled, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of PROCHYMAL TM IV Infusion for the Induction of Remission in Subjects Experiencing Treatment-Refractory Moderate-to-Sever Crohn's Disease				
<b>De Villiers, Willem</b>	3048104255	\$0.	\$1,257.	\$1,257.
Quintiles Inc A Phase 3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety & Efficacy of Golimumab Maintenance Therapy, Administered Subcutaneously, in Subjects with Moderately to Severely Active Ulcerative Colitis				
<b>De Villiers, Willem</b>	3048104557	\$0.	\$32,497.	\$32,497.
Genentech Inc Observational Study of Biomarkers in Subjects with Inflammatory Bowel Disease (IBD) Compared with Non-IBD Control Subjects				
<b>De Villiers, Willem</b>	3048104557	\$0.	\$5,646.	\$5,646.
Genentech Inc Observational Study of Biomarkers in Subjects with Inflammatory Bowel Disease (IBD) Compared with Non-IBD Control Subjects				

## Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Internal Medicine</b>				
<b>De Villiers, Willem</b>	3048104557	\$0.	\$25,250.	\$25,250.
Genentech Inc Observational Study of Biomarkers in Subjects with Inflammatory Bowel Disease (IBD) Compared with Non-IBD Control Subjects				
<b>De Villiers, Willem</b>	3048105249	\$2.	\$0.	\$2.
Genentech Inc A Phase I, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Intravenous and Subcutaneous rhuMAb Beta 7				
<b>De Villiers, Willem</b>	3048105249	\$0.	\$9,998.	\$9,998.
Genentech Inc A Phase I, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Intravenous and Subcutaneous rhuMAb Beta 7				
<b>Desimone, Philip A</b>	3046777200	\$0.	\$1,349.	\$1,349.
Hoffmann La Roche Inc A 2x2 Factorial Randomized Phase III Study of Intermittent Oral Capecitabine in Combination With Intravenous Oxaliplatin (Q3W) ("XELOX") with/without Intravenous Bevacizumab (Q3W) versus Bolus and Continuous Infusion				
<b>Desimone, Philip A</b>	3048004400	\$0.	\$496.	\$496.
Roche Laboratories A Randomized Study of Intermittent Capcitabine in Combination with Oxaliplatin (XELOOX Q3W) and Bevacizumab vs Intermittent Capcitabine in Combinations with Oxaliplatin (XELOX Q2W) and Bevacizumab as First-Line Treatment for Patients				
<b>Dignan, Mark B</b>	3048104633	\$0.	\$80,421.	\$80,421.
National Cancer Institute Appalachia Community Cancer Network				
<b>Dignan, Mark B</b>	3048104633	\$0.	\$82,500.	\$82,500.
National Cancer Institute Appalachia Community Cancer Network				
<b>Dignan, Mark B</b>	3048105070	\$395,643.	\$0.	\$395,643.
National Cancer Institute Kentucky Cancer Prevention and Control Training Program				
<b>Dignan, Mark B</b>	3048105196	\$857,342.	\$0.	\$857,342.
Center for Disease Control and Prevention Kentucky Prevention Research Center				
<b>Doherty, Dennis E</b>	3048024400	\$0.	\$5,116.	\$5,116.
InterMune Pharmaceuticals A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Safety and Efficacy of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis				
<b>Doherty, Dennis E</b>	3048024400	\$0.	\$2,495.	\$2,495.
InterMune Pharmaceuticals A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Safety and Efficacy of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis				
<b>Doherty, Dennis E</b>	3048024400	\$0.	\$2,708.	\$2,708.
InterMune Pharmaceuticals A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Safety and Efficacy of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis				

## Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Internal Medicine</b>				
<b>Doherty, Dennis E</b>	3048024400	\$0.	\$2,993.	\$2,993.
InterMune Pharmaceuticals A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Safety and Efficacy of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis				
<b>Doherty, Dennis E</b>	3048024400	\$0.	\$1,355.	\$1,355.
InterMune Pharmaceuticals A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Safety and Efficacy of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis				
<b>Doherty, Dennis E</b>	3048103685	\$0.	\$1,310.	\$1,310.
Pfizer Inc A 24 Week, randomized, Double-Blind, Placebo Controlled, Multicenter Study to Evaluate the Efficacy and Safety of 18 MCG of Tiotropium Inhalation Capsules Administered by Handihaler Once-Daily Plus PRN Albuterol (Salbutamol) VS Placebo Plus PRN Albuterol				
<b>Doherty, Dennis E</b>	3048104260	\$0.	\$9,290.	\$9,290.
Novartis A 26-week treatment, multicenter, randomized, double-blind, placebo-controlled, adaptive, seamless, parallel-group study to access the efficacy, safety and tolerability of two doses of indacaterol (selected from				
<b>Doherty, Dennis E</b>	3048104260	\$0.	\$1,915.	\$1,915.
Novartis A 26-week treatment, multicenter, randomized, double-blind, placebo-controlled, adaptive, seamless, parallel-group study to access the efficacy, safety and tolerability of two doses of indacaterol (selected from				
<b>Doherty, Dennis E</b>	3048104260	\$0.	\$7,943.	\$7,943.
Novartis A 26-week treatment, multicenter, randomized, double-blind, placebo-controlled, adaptive, seamless, parallel-group study to access the efficacy, safety and tolerability of two doses of indacaterol (selected from				
<b>Doherty, Dennis E</b>	3048104260	\$0.	\$428.	\$428.
Novartis A 26-week treatment, multicenter, randomized, double-blind, placebo-controlled, adaptive, seamless, parallel-group study to access the efficacy, safety and tolerability of two doses of indacaterol (selected from				
<b>Doherty, Dennis E</b>	3048104260	\$0.	\$1,850.	\$1,850.
Novartis A 26-week treatment, multicenter, randomized, double-blind, placebo-controlled, adaptive, seamless, parallel-group study to access the efficacy, safety and tolerability of two doses of indacaterol (selected from				
<b>Doherty, Dennis E</b>	3048104892	\$0.	\$630.	\$630.
InterMune Pharmaceuticals An Open-Label Extension Study of the Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (IPF) Who Complete the CAPACITY Studies				
<b>Doherty, Dennis E</b>	3048104892	\$2.	\$0.	\$2.
InterMune Pharmaceuticals An Open-Label Extension Study of the Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (IPF) Who Complete the CAPACITY Studies				
<b>Doherty, Dennis E</b>	3048104892	\$0.	\$2,524.	\$2,524.
InterMune Pharmaceuticals An Open-Label Extension Study of the Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (IPF) Who Complete the CAPACITY Studies				

## Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Internal Medicine</b>				
<b>Doherty, Dennis E</b>	3048104892	\$0.	\$9,511.	\$9,511.
InterMune Pharmaceuticals An Open-Label Extension Study of the Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (IPF) Who Complete the CAPACITY Studies				
<b>Doherty, Dennis E</b>	3048105290	\$2.	\$0.	\$2.
Merck and Company Inc A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study, Conducted Under In-House Blinding Conditions of MK-0633 in Patients with COPD				
<b>Doherty, Dennis E</b>	3048105290	\$0.	\$6,293.	\$6,293.
Merck and Company Inc A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study, Conducted Under In-House Blinding Conditions of MK-0633 in Patients with COPD				
<b>Fleischman, Roger A</b>	3048095800	\$0.	\$200.	\$200.
Eli Lilly and Company PRELUDE: A Phase 3 Clinical Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin				
<b>Fleischman, Roger A</b>	3048095800	\$0.	\$200.	\$200.
Eli Lilly and Company PRELUDE: A Phase 3 Clinical Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin				
<b>Fleischman, Roger A</b>	3048095800	\$0.	\$23,774.	\$23,774.
Eli Lilly and Company PRELUDE: A Phase 3 Clinical Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin				
<b>Fleischman, Roger A</b>	3048095800	\$0.	\$8,534.	\$8,534.
Eli Lilly and Company PRELUDE: A Phase 3 Clinical Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin				
<b>Fleischman, Roger A</b>	3048103811	\$0.	\$13,558.	\$13,558.
Celgene A Phase II, Multicenter, Single-Arm, Open-Label Study to Evaluate the Safety and Efficacy of Lenalidomide (Revlimid) in Combination with Dexamethasone in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma				
<b>Greenberg, Richard N</b>	3046535000	\$0.	\$590.	\$590.
Bristol Myers Squibb Company Study of the Antiviral Efficacy and Safety of Atazanavir in Combination with Ritonavir or Saquinavir and the Combination of Lopinavir/Ritonavir Each With Tenofovir and Nucleoside in Subjects who Have Experienced Virologic Failure				
<b>Greenberg, Richard N</b>	3046665500	\$0.	\$1,280.	\$1,280.
Boehringer Ingelheim Randomized, Open-Label, Comparative Safety and Efficacy Study of Tipranavir Boosted with Low-dose Ritonavir (TPV/RTV) Versus Genotypically-defined Protease Inhibitor/Ritonavir (PI/RTV) in Multiple Antiretroviral Drug-Experienced Patients (Resist 1:)				
<b>Greenberg, Richard N</b>	3046665500	\$0.	\$444.	\$444.
Boehringer Ingelheim Randomized, Open-Label, Comparative Safety and Efficacy Study of Tipranavir Boosted with Low-dose Ritonavir (TPV/RTV) Versus Genotypically-defined Protease Inhibitor/Ritonavir (PI/RTV) in Multiple Antiretroviral Drug-Experienced Patients (Resist 1:)				

**Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009**

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Internal Medicine</b>				
<b>Greenberg, Richard N</b>	3046811300	\$0.	\$4,360.	\$4,360.
Tibotec Pharmaceuticals Ltd A Randomized, Controlled, Partially Blinded Phase IIb Dose-Finding Trial of TMC125M, in HIV-1 Infected Subjects with Documented Geotypic Evidence of Resistance to Currently Available NNRTIs and With at Least Three Primary PI Mutations.				
<b>Greenberg, Richard N</b>	3046811300	\$0.	\$-4,360.	\$-4,360.
Tibotec Pharmaceuticals Ltd A Randomized, Controlled, Partially Blinded Phase IIb Dose-Finding Trial of TMC125M, in HIV-1 Infected Subjects with Documented Geotypic Evidence of Resistance to Currently Available NNRTIs and With at Least Three Primary PI Mutations.				
<b>Greenberg, Richard N</b>	3046865800	\$0.	\$687.	\$687.
Bristol Myers Squibb Company Phase IV, Multicenter Cross-Sectional Study to Evaluate the I50L Substitution among subjects Experiencing Virologic Failure on a HART regimen containing Atazanavir (ATV)				
<b>Greenberg, Richard N</b>	3046865800	\$0.	\$-687.	\$-687.
Bristol Myers Squibb Company Phase IV, Multicenter Cross-Sectional Study to Evaluate the I50L Substitution among subjects Experiencing Virologic Failure on a HART regimen containing Atazanavir (ATV)				
<b>Greenberg, Richard N</b>	3046865800	\$0.	\$350.	\$350.
Bristol Myers Squibb Company Phase IV, Multicenter Cross-Sectional Study to Evaluate the I50L Substitution among subjects Experiencing Virologic Failure on a HART regimen containing Atazanavir (ATV)				
<b>Greenberg, Richard N</b>	3046946700	\$0.	\$1,152.	\$1,152.
GlaxoSmithKline 96-week Phase IV, Randomized, Double-Blind, Multicenter Study of the Safety and Efficacy of EPZICOM Versus Truvada Administered in Conjunction with Kaletra in Antiretroviral-Naive HIV-1 Infected Subjects				
<b>Greenberg, Richard N</b>	3046946700	\$0.	\$1,484.	\$1,484.
GlaxoSmithKline 96-week Phase IV, Randomized, Double-Blind, Multicenter Study of the Safety and Efficacy of EPZICOM Versus Truvada Administered in Conjunction with Kaletra in Antiretroviral-Naive HIV-1 Infected Subjects				
<b>Greenberg, Richard N</b>	3046946700	\$0.	\$15,553.	\$15,553.
GlaxoSmithKline 96-week Phase IV, Randomized, Double-Blind, Multicenter Study of the Safety and Efficacy of EPZICOM Versus Truvada Administered in Conjunction with Kaletra in Antiretroviral-Naive HIV-1 Infected Subjects				
<b>Greenberg, Richard N</b>	3046975000	\$0.	\$11,265.	\$11,265.
PPD Development Inc An Open-Label Trial with TMC125 in HIV-1 Infected Subjects, who were Randomized to a TMC125 Treatment Arm in a Sponsor-Selected TMC125 Trail and were Treated for at least 48 weeks				
<b>Greenberg, Richard N</b>	3046975000	\$0.	\$-4,360.	\$-4,360.
PPD Development Inc An Open-Label Trial with TMC125 in HIV-1 Infected Subjects, who were Randomized to a TMC125 Treatment Arm in a Sponsor-Selected TMC125 Trail and were Treated for at least 48 weeks				
<b>Greenberg, Richard N</b>	3046975000	\$0.	\$4,334.	\$4,334.
PPD Development Inc An Open-Label Trial with TMC125 in HIV-1 Infected Subjects, who were Randomized to a TMC125 Treatment Arm in a Sponsor-Selected TMC125 Trail and were Treated for at least 48 weeks				

**Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Medicine</u></b>				
<b><u>Internal Medicine</u></b>				
<b>Greenberg, Richard N</b>	3046975000	\$0.	\$4,360.	\$4,360.
PPD Development Inc An Open-Label Trail with TMC125 in HIV-1 Infected Subjects, who were Randomized to a TMC125 Treatment Arm in a Sponsor-Selected TMC125 Trail and were Treated for at least 48 weeks				
<b>Greenberg, Richard N</b>	3046978600	\$0.	\$108,551.	\$108,551.
Origin Pharmaceutical Services Ltd Randomized, Double-Blind, Placebo-Controlled Phase II Trail of the Safety, Tolerability and Immunology of Lyophilized Chimerivax TM-WN02 West Nile Vaccine in Healthy Adults; Safety and Effectiveness of West Nile Vaccine in Healthy Adults				
<b>Greenberg, Richard N</b>	3048061700	\$0.	\$1,763.	\$1,763.
Tibotec Pharmaceuticals Ltd A Phase II randomized, double-blinded, placebo controlled trial to investigate the efficacy, tolerability and safety of TMC 125 as part of				
<b>Greenberg, Richard N</b>	3048061700	\$0.	\$384.	\$384.
Tibotec Pharmaceuticals Ltd A Phase II randomized, double-blinded, placebo controlled trial to investigate the efficacy, tolerability and safety of TMC 125 as part of				
<b>Greenberg, Richard N</b>	3048073000	\$0.	\$12,073.	\$12,073.
Bavarian Nordic A Multicenter, Open-Label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA-BN (IMVAMUNE) Smallpox Vaccine in 18-40 Year Old Subjects with Diagnosed Atopic Dermatitis				
<b>Greenberg, Richard N</b>	3048103306	\$0.	\$1,493.	\$1,493.
GlaxoSmithKline Safety and Efficacy of an Initial Regimen of Atazanavir + Ritonavir + the Abacavir/Lamivudine Fixed-Dose Combination Tablet for 36 weeks followed by Simplification to Atazanavir with ABC/3TC FTC or Maintenance of the Initial Regimen for an Additional 48				
<b>Greenberg, Richard N</b>	3048103306	\$0.	\$1,408.	\$1,408.
GlaxoSmithKline Safety and Efficacy of an Initial Regimen of Atazanavir + Ritonavir + the Abacavir/Lamivudine Fixed-Dose Combination Tablet for 36 weeks followed by Simplification to Atazanavir with ABC/3TC FTC or Maintenance of the Initial Regimen for an Additional 48				
<b>Greenberg, Richard N</b>	3048103306	\$0.	\$1,572.	\$1,572.
GlaxoSmithKline Safety and Efficacy of an Initial Regimen of Atazanavir + Ritonavir + the Abacavir/Lamivudine Fixed-Dose Combination Tablet for 36 weeks followed by Simplification to Atazanavir with ABC/3TC FTC or Maintenance of the Initial Regimen for an Additional 48				
<b>Greenberg, Richard N</b>	3048103306	\$0.	\$1,209.	\$1,209.
GlaxoSmithKline Safety and Efficacy of an Initial Regimen of Atazanavir + Ritonavir + the Abacavir/Lamivudine Fixed-Dose Combination Tablet for 36 weeks followed by Simplification to Atazanavir with ABC/3TC FTC or Maintenance of the Initial Regimen for an Additional 48				
<b>Greenberg, Richard N</b>	3048103306	\$0.	\$1,635.	\$1,635.
GlaxoSmithKline Safety and Efficacy of an Initial Regimen of Atazanavir + Ritonavir + the Abacavir/Lamivudine Fixed-Dose Combination Tablet for 36 weeks followed by Simplification to Atazanavir with ABC/3TC FTC or Maintenance of the Initial Regimen for an Additional 48				

## Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Internal Medicine</b>				
<b>Greenberg, Richard N</b>	3048103895	\$0.	\$11,159.	\$11,159.
University of Massachusetts A Phase II Randomized, Double-Blind, Placebo Controlled Study of the Clinical Effectiveness of a Human Monoclonal Antibody to Clostridium difficile Toxin A [GS-CDA1] and a Human Monoclonal Antibody to				
<b>Greenberg, Richard N</b>	3048104321	\$0.	\$11,529.	\$11,529.
Wyeth Pharmaceuticals Inc A Phase 3, Randomized, Active-Controlled, Modified Double-Blind Trial, Evaluating the Safety, Tolerability & Immunogenicity of a 13-Valent Pneumococcal Conjugate Vaccine Compared with a 23-Valent Pneumococcal Polysaccharide Vaccine (23vPS) in Ambulatory				
<b>Greenberg, Richard N</b>	3048104321	\$0.	\$25,024.	\$25,024.
Wyeth Pharmaceuticals Inc A Phase 3, Randomized, Active-Controlled, Modified Double-Blind Trial, Evaluating the Safety, Tolerability & Immunogenicity of a 13-Valent Pneumococcal Conjugate Vaccine Compared with a 23-Valent Pneumococcal Polysaccharide Vaccine (23vPS) in Ambulatory				
<b>Greenberg, Richard N</b>	3048104321	\$0.	\$19,108.	\$19,108.
Wyeth Pharmaceuticals Inc A Phase 3, Randomized, Active-Controlled, Modified Double-Blind Trial, Evaluating the Safety, Tolerability & Immunogenicity of a 13-Valent Pneumococcal Conjugate Vaccine Compared with a 23-Valent Pneumococcal Polysaccharide Vaccine (23vPS) in Ambulatory				
<b>Greenberg, Richard N</b>	3048104349	\$0.	\$17,798.	\$17,798.
Wyeth Pharmaceuticals Inc A Phase 3, Randomized, Active-Controlled, Modified, Double-Blind Trial to Evaluate the Safety, Tolerability and Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine When Administered Over 12 Months				
<b>Greenberg, Richard N</b>	3048104641	\$0.	\$4,998.	\$4,998.
Boehringer Ingelheim A randomized, double-blind, double dummy, parallel group, active controlled trial to evaluate the antiviral efficacy of 400 mg QD neVirapine Extended Release formulation in comparison to 200 mg BID neVirapineE with Truvada				
<b>Greenberg, Richard N</b>	3048104641	\$0.	\$-2,000.	\$-2,000.
Boehringer Ingelheim A randomized, double-blind, double dummy, parallel group, active controlled trial to evaluate the antiviral efficacy of 400 mg QD neVirapine Extended Release formulation in comparison to 200 mg BID neVirapineE with Truvada				
<b>Greenberg, Richard N</b>	3048104861	\$2.	\$0.	\$2.
Pfizer Inc An International, Multi-Center, Prospective, Observational Study of the Safety of Maraviroc Used With Optimized Background Therapy in Treatment Experienced HIV 1 Infected Patients				
<b>Greenberg, Richard N</b>	3048105117	\$2.	\$0.	\$2.
Tibotec Pharmaceuticals Ltd A Phase III, Randomized, Double-Blind Trial of TMC278 25 mg q.d. versus efavirenz 600 mg q.d. in Combination with a Background Regimen Containing 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Antiretroviral-naive HIV-1 Infected Subjects				
<b>Greenberg, Richard N</b>	3048105117	\$0.	\$2,498.	\$2,498.
Tibotec Pharmaceuticals Ltd A Phase III, Randomized, Double-Blind Trial of TMC278 25 mg q.d. versus efavirenz 600 mg q.d. in Combination with a Background Regimen Containing 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Antiretroviral-naive HIV-1 Infected Subjects				

## Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Internal Medicine</b>				
<b>Greenberg, Richard N</b>	3048105289	\$2.	\$0.	\$2.
Gilead Sciences Inc A Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Ritonavir-Boosted Elvitegravir (EVG/r) Versus Raltegravir (RAL) Each Administered with a Background Regimen in HIV-1				
<b>Guo, Zhenheng</b>	3048104909	\$25,000.	\$0.	\$25,000.
KY Diabetes Research Trust Fund A Novel Mechanism by which Type 2 Diabetes Promotes Restenosis				
<b>Gurley, John C</b>	3046640500	\$0.	\$250.	\$250.
Medtronic Inc Insync Registry: Insync Post Market Registry Cardiac Resynchronization Therapy				
<b>Gurley, John C</b>	3046640500	\$0.	\$1,035.	\$1,035.
Medtronic Inc Insync Registry: Insync Post Market Registry Cardiac Resynchronization Therapy				
<b>Gurley, John C</b>	3046857600	\$0.	\$5,618.	\$5,618.
Atritech Inc WATCHMEN Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation (Protect AF)				
<b>Gurley, John C</b>	3048034600	\$0.	\$7,993.	\$7,993.
AGA Medical Co Prospective Randomized Investigation to Evaluate Incidence of Headache Reduction in Subjects with Migraine and PFO Using the AMPLATZER PFO Occluder Compared to Medical Management				
<b>Gurley, John C</b>	3048034600	\$0.	\$7,383.	\$7,383.
AGA Medical Co Prospective Randomized Investigation to Evaluate Incidence of Headache Reduction in Subjects with Migraine and PFO Using the AMPLATZER PFO Occluder Compared to Medical Management				
<b>Gurley, John C</b>	3048034600	\$0.	\$5,065.	\$5,065.
AGA Medical Co Prospective Randomized Investigation to Evaluate Incidence of Headache Reduction in Subjects with Migraine and PFO Using the AMPLATZER PFO Occluder Compared to Medical Management				
<b>Gurley, John C</b>	3048034600	\$0.	\$21,194.	\$21,194.
AGA Medical Co Prospective Randomized Investigation to Evaluate Incidence of Headache Reduction in Subjects with Migraine and PFO Using the AMPLATZER PFO Occluder Compared to Medical Management				
<b>Gurley, John C</b>	3048034600	\$0.	\$6,041.	\$6,041.
AGA Medical Co Prospective Randomized Investigation to Evaluate Incidence of Headache Reduction in Subjects with Migraine and PFO Using the AMPLATZER PFO Occluder Compared to Medical Management				
<b>Gurley, John C</b>	3048034600	\$0.	\$2,654.	\$2,654.
AGA Medical Co Prospective Randomized Investigation to Evaluate Incidence of Headache Reduction in Subjects with Migraine and PFO Using the AMPLATZER PFO Occluder Compared to Medical Management				
<b>Hamdalla, Hussam Nader</b>	3048104582	\$0.	\$6,000.	\$6,000.
Momenta Pharmaceuticals Inc A Randomized, Multi-Center, Open-Label, Parallel Group Feasibility Study to Determine the Safety and Efficacy of the Rationally Engineered Heparin M118 vs. UFH in Subjects with Stable Coronary Artery Disease Undergoing				

## Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Internal Medicine</b>				
<b>Hamdalla, Hussam Nader</b>	3048104582	\$0.	\$5,600.	\$5,600.
Momenta Pharmaceuticals Inc A Randomized, Multi-Center, Open-Label, Parallel Group Feasability Study to Determine the Safety and Efficacy of the Rationally Engineered Heparin M118 vs. UFH in Subjects with Stable Coronary Artery Disease Undergoing				
<b>Hamdalla, Hussam Nader</b>	3048104582	\$0.	\$2,800.	\$2,800.
Momenta Pharmaceuticals Inc A Randomized, Multi-Center, Open-Label, Parallel Group Feasability Study to Determine the Safety and Efficacy of the Rationally Engineered Heparin M118 vs. UFH in Subjects with Stable Coronary Artery Disease Undergoing				
<b>Hamdalla, Hussam Nader</b>	3048104582	\$0.	\$800.	\$800.
Momenta Pharmaceuticals Inc A Randomized, Multi-Center, Open-Label, Parallel Group Feasability Study to Determine the Safety and Efficacy of the Rationally Engineered Heparin M118 vs. UFH in Subjects with Stable Coronary Artery Disease Undergoing				
<b>Hamdalla, Hussam Nader</b>	3048104582	\$0.	\$3,498.	\$3,498.
Momenta Pharmaceuticals Inc A Randomized, Multi-Center, Open-Label, Parallel Group Feasability Study to Determine the Safety and Efficacy of the Rationally Engineered Heparin M118 vs. UFH in Subjects with Stable Coronary Artery Disease Undergoing				
<b>Hayslip, John</b>	3048104985	\$0.	\$10,628.	\$10,628.
Celgene A Phase 2, Open label trial to evaluate the Efficacy and Safety of MGCD0103 Administered in Combination with Vidaza to subjects with Relapsed or Refractory Hodgkins or non-Hodgkin Lymphoma and to evaluate different formulations of MGCD0103				
<b>Hayslip, John</b>	3048104985	\$2.	\$0.	\$2.
Celgene A Phase 2, Open label trial to evaluate the Efficacy and Safety of MGCD0103 Administered in Combination with Vidaza to subjects with Relapsed or Refractory Hodgkins or non-Hodgkin Lymphoma and to evaluate different formulations of MGCD0103				
<b>Hayslip, John</b>	3048104995	\$0.	\$93,969.	\$93,969.
Cephalon Inc Frontline Treatment with Bendamustine in Combination with Rituximab in Adults Age 65 or Older with Chronic Lymphocytic Leukemia: A Phase II Study				
<b>Hayslip, John</b>	3048104995	\$2.	\$0.	\$2.
Cephalon Inc Frontline Treatment with Bendamustine in Combination with Rituximab in Adults Age 65 or Older with Chronic Lymphocytic Leukemia: A Phase II Study				
<b>Hayslip, John</b>	3048105235	\$2.	\$0.	\$2.
Celgene Azacitidine with Rituximab, Vincristine, and Cyclophosphamide in Refractory Follicular Lymphoma: A Phase I Trial				
<b>Howard, Dianna S</b>	3048037800	\$0.	\$550.	\$550.
Genzyme Corp 06-LEUK-GZ (CLO341000405): A Phase III Randomized, Double-Blind, Controlled Study Comparing Clofarabine and Cytarabine versus Cytarabine Alone in Adult Patients>60 years old with Acute Myelogenous Leukemia (AML) who Have Relapsed or are Refractory after				
<b>Howard, Dianna S</b>	3048103404	\$0.	\$-6,095.	\$-6,095.
ViroPharma Inc A Randomized, Double-Blind, Placebo-Controlled Study To Assess the Efficacy and Safety of Prophylactic use of Maribavir for the Prevention of Cytomegalovirus Disease in Recipients of Allogeneic Stem Cell Transplants				

## Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Internal Medicine</b>				
<b>Howard, Dianna S</b>	3048104472	\$0.	\$7,998.	\$7,998.
Pfizer Inc A prospective, randomized trial comparing the efficacy of anidulafungin and voriconazole in combination to that of voriconazole alone when used for primary therapy of proven or probable invasive aspergillosis				
<b>Howard, Dianna S</b>	3048104581	\$0.	\$950.	\$950.
i3 Research A Randomized, Blinded, Multicenter Study of Proteinase 3 PR1 Peptide Mixed with Montanide ISA-51 VG Adjuvant and Administered with GM-CSF in Elderly Patients with AML in First Complete Remission or Adults in Second Complete Remission: A Pivotal Study				
<b>Howard, Dianna S</b>	3048104581	\$0.	\$15,040.	\$15,040.
i3 Research A Randomized, Blinded, Multicenter Study of Proteinase 3 PR1 Peptide Mixed with Montanide ISA-51 VG Adjuvant and Administered with GM-CSF in Elderly Patients with AML in First Complete Remission or Adults in Second Complete Remission: A Pivotal Study				
<b>Karounos, Dennis G</b>	3046861000	\$0.	\$2,835.	\$2,835.
George Washington University Natural History of the Development of Type 1 Diabetes				
<b>Karounos, Dennis G</b>	3048103618	\$0.	\$98,783.	\$98,783.
American Diabetes Association Inc Mechanisms of preventing type 1 diabetes with inactive insulin				
<b>Karounos, Dennis G</b>	3048105225	\$2.	\$0.	\$2.
TKL Research Inc A Phase III, 3-Arm, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Investigate the Impact of Diamyd on the Progression of Diabetes in Patients Newly Diagnosed with Type 1 Diabetes Mellitus				
<b>Karounos, Dennis G</b>	3048105238	\$2.	\$0.	\$2.
Osiris Therapeutics Inc A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Prochymal (ex vivo cultured adult human mesenchymal stem cells) for the Treatment of Recently Diagnosed Type 1 Diabetes Mellitus (T1DM)				
<b>Karounos, Dennis G</b>	3048105358	\$2.	\$0.	\$2.
Spherix Inc The Effects of Naturlose (Tagatose) on Glycemic Control and Safety of Naturlose Over One Year in Subjects with Type 2 Diabetes Under Diet Control and Exercise				
<b>Kee, Bryan K</b>	3048104993	\$2.	\$0.	\$2.
Amplimed Corp A Phase 2 Randomized, Double-Blind, Multicenter Trial with Amplimexon plus Gemcitabine versus Gemcitabine plus Placebo in Subjects with Metastatic Chemotherapy Naive Pancreatic Adenocarcinoma (Stage IV)				
<b>Koch, Alvaro</b>	3046775800	\$0.	\$23,422.	\$23,422.
Schering Plough Co Comparison of PEG-Intron 1/5 mcg/kg/wk Plus REBETOL vs. PeG-Intron 1 mcg/kg/wk Plus REBETOL vs PEGASYS 180 mcg/wk Plus COPEGUS in Previously Untreated Adult Subjects With Chronic Hepatitis C Infected With Genotype 1				
<b>Koch, Alvaro</b>	3046775800	\$0.	\$-22.	\$-22.
Schering Plough Co Comparison of PEG-Intron 1/5 mcg/kg/wk Plus REBETOL vs. PeG-Intron 1 mcg/kg/wk Plus REBETOL vs PEGASYS 180 mcg/wk Plus COPEGUS in Previously Untreated Adult Subjects With Chronic Hepatitis C Infected With Genotype 1				

## Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Internal Medicine</b>				
<b>Koch, Alvaro</b>	3048068400	\$0.	\$6,330.	\$6,330.
Sanofi Aventis US Inc Satavaptan in the Prevention of Ascited Recurrence: A Double-Blind, Randomized, Parallel-Group Comparison of 12 Weeks Treatment with SR121463B at 5 to 10 mg Daily Versus Placebo in Patients with Recurrent Ascited due to Cirrhosis of the Liver				
<b>Koch, Alvaro</b>	3048068400	\$0.	\$8,012.	\$8,012.
Sanofi Aventis US Inc Satavaptan in the Prevention of Ascited Recurrence: A Double-Blind, Randomized, Parallel-Group Comparison of 12 Weeks Treatment with SR121463B at 5 to 10 mg Daily Versus Placebo in Patients with Recurrent Ascited due to Cirrhosis of the Liver				
<b>Koch, Alvaro</b>	3048068400	\$0.	\$1,115.	\$1,115.
Sanofi Aventis US Inc Satavaptan in the Prevention of Ascited Recurrence: A Double-Blind, Randomized, Parallel-Group Comparison of 12 Weeks Treatment with SR121463B at 5 to 10 mg Daily Versus Placebo in Patients with Recurrent Ascited due to Cirrhosis of the Liver				
<b>Koch, Alvaro</b>	3048072900	\$0.	\$1,500.	\$1,500.
Sanofi Aventis US Inc Satavaptan Cirrhotic Ascites Treatment Study: A Double-Blind, Randomized, Parallel Group Comparison of Treatment with Satavaptan at 5 to 10 mg daily Versus Placebo on top of Conventional Treatment in Patients with Ascites due to Cirrhosis of the Liver				
<b>Koch, Alvaro</b>	3048072900	\$0.	\$700.	\$700.
Sanofi Aventis US Inc Satavaptan Cirrhotic Ascites Treatment Study: A Double-Blind, Randomized, Parallel Group Comparison of Treatment with Satavaptan at 5 to 10 mg daily Versus Placebo on top of Conventional Treatment in Patients with Ascites due to Cirrhosis of the Liver				
<b>Koch, Alvaro</b>	3048104481	\$0.	\$4,015.	\$4,015.
GlaxoSmithKline Randomized, placebo-controlled, multi-center study to assess the efficacy and safety of eltrombopag in thrombocytopenic subjects with hepatitis C virus (HCV) infection who are otherwise eligible to initiate antiviral therapy ENABLE 2				
<b>Koch, Alvaro</b>	3048104481	\$0.	\$2,498.	\$2,498.
GlaxoSmithKline Randomized, placebo-controlled, multi-center study to assess the efficacy and safety of eltrombopag in thrombocytopenic subjects with hepatitis C virus (HCV) infection who are otherwise eligible to initiate antiviral therapy ENABLE 2				
<b>Koch, Alvaro</b>	3048104481	\$0.	\$1,223.	\$1,223.
GlaxoSmithKline Randomized, placebo-controlled, multi-center study to assess the efficacy and safety of eltrombopag in thrombocytopenic subjects with hepatitis C virus (HCV) infection who are otherwise eligible to initiate antiviral therapy ENABLE 2				
<b>Koch, Alvaro</b>	3048104827	\$0.	\$3,998.	\$3,998.
Sanofi Aventis US Inc A Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study of Rimonabant 20 mg Daily for the Treatment of Non-Diabetic Patients with Non-Alcoholic Steatohepatitis (NASH)				
<b>Koch, Alvaro</b>	3048104827	\$2.	\$0.	\$2.
Sanofi Aventis US Inc A Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study of Rimonabant 20 mg Daily for the Treatment of Non-Diabetic Patients with Non-Alcoholic Steatohepatitis (NASH)				

## Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Internal Medicine</b>				
<b>Koch, Alvaro</b>	3048104828	\$2.	\$0.	\$2.
Sanofi Aventis US Inc A Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study of Rimonabant 20 mg Daily for the Treatment of Type 2 Diabetic Patients with Non-Alcoholic Steatohepatitis (NASH)				
<b>Koch, Alvaro</b>	3048104828	\$0.	\$3,998.	\$3,998.
Sanofi Aventis US Inc A Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study of Rimonabant 20 mg Daily for the Treatment of Type 2 Diabetic Patients with Non-Alcoholic Steatohepatitis (NASH)				
<b>Koch, Alvaro</b>	3048104830	\$0.	\$4,498.	\$4,498.
Sanofi Aventis US Inc Long Term Safety and Tolerability of Satavaptan in Patients with Cirrhosis of the Liver That Have Been Previously Randomized and Completed Treatment in Any of the Phase III Studies: EFC4492, EFC4493 or EFC6682:				
<b>Koch, Alvaro</b>	3048104830	\$2.	\$0.	\$2.
Sanofi Aventis US Inc Long Term Safety and Tolerability of Satavaptan in Patients with Cirrhosis of the Liver That Have Been Previously Randomized and Completed Treatment in Any of the Phase III Studies: EFC4492, EFC4493 or EFC6682:				
<b>Koch, Alvaro</b>	3048104830	\$0.	\$930.	\$930.
Sanofi Aventis US Inc Long Term Safety and Tolerability of Satavaptan in Patients with Cirrhosis of the Liver That Have Been Previously Randomized and Completed Treatment in Any of the Phase III Studies: EFC4492, EFC4493 or EFC6682:				
<b>Koch, Alvaro</b>	3048105298	\$0.	\$9,998.	\$9,998.
Schering Plough Co A Phase 3, Safety and Efficacy Study of Boceprevir in Previously Untreated Subjects with Chronic Hepatitis C Genotype 1				
<b>Koch, Alvaro</b>	3048105298	\$2.	\$0.	\$2.
Schering Plough Co A Phase 3, Safety and Efficacy Study of Boceprevir in Previously Untreated Subjects with Chronic Hepatitis C Genotype 1				
<b>Li, Zhenyu</b>	3048105278	\$38,500.	\$0.	\$38,500.
American Heart Association The Role of Platelets in Sepsis				
<b>Lohr, Kristine</b>	3048104362	\$25,000.	\$0.	\$25,000.
American College of Rheumatology Rachel Chase Fellowship: Rheumatology Fellowship Training Award				
<b>Malluche, Hartmut H</b>	3048057000	\$0.	\$17,097.	\$17,097.
Emory University Pyrophosphate in Vascular Calcification of Renal Failure				
<b>Malluche, Hartmut H</b>	3048103863	\$0.	\$17,245.	\$17,245.
Childrens Hospital of Philadelphia Changes in Skeletal Microarchitecture Following Renal Transplantation				
<b>Malluche, Hartmut H</b>	3048103863	\$0.	\$-340.	\$-340.
Childrens Hospital of Philadelphia Changes in Skeletal Microarchitecture Following Renal Transplantation				

## Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Internal Medicine</b>				
<b>Mardini, Houssam Eddin</b>	3048103706	\$0.	\$1,050.	\$1,050.
PRS Clinical Inc Chemoprevention of Colorectal Adenomas				
<b>Mardini, Houssam Eddin</b>	3048103706	\$0.	\$1,750.	\$1,750.
PRS Clinical Inc Chemoprevention of Colorectal Adenomas				
<b>McDonagh, Kevin T</b>	3046946800	\$0.	\$22,057.	\$22,057.
Novartis A Randomized Open-label Study of 400 mg Versus 800 mg of Gleevac/Gilvac (imatinab mesylate) in patients with newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase (CML-CP) using Molecular Endpoints				
<b>McDonagh, Kevin T</b>	3046946800	\$0.	\$676.	\$676.
Novartis A Randomized Open-label Study of 400 mg Versus 800 mg of Gleevac/Gilvac (imatinab mesylate) in patients with newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase (CML-CP) using Molecular Endpoints				
<b>McDonagh, Kevin T</b>	3046952500	\$0.	\$1,411.	\$1,411.
Bristol Myers Squibb Company A Randomized Two Arm, Multicenter, Open-Label Phase II Study of BMS-354825 Administered Orally at a Dose of 70 mg Twice Daily or 140 mg Once Daily in Subjects with Chronic Myeloid Leukemia in Accelerated Phae or in Myeloid or Lymphoid				
<b>McDonagh, Kevin T</b>	3046959100	\$0.	\$750.	\$750.
Bristol Myers Squibb Company A Randomized Two-by-Two, Multicenter, Open-Label Phase III Study of BMS-354825 Administered Orally at a Dose of 50 mg or 70 mg Twice Daily or 100 mg or 140 mg Once Daily in Subjects with Chronic Phase Philadelphia Chromosome or BCR-ABL Positive Chronic				
<b>McDonagh, Kevin T</b>	3048050100	\$0.	\$1,080.	\$1,080.
Cephalon Inc A Multicenter Phase III Study to Investigate the Safety and Efficacy of Treanda )Bendamustine HC1) in Patients with Indolent Non-Hodgkin's Lymphoma (NHL) who are Refractory to Rituximab (SDX-105-03)				
<b>McDonagh, Kevin T</b>	3048103824	\$0.	\$9,860.	\$9,860.
Proteolix Inc An Open-Label, Single-Arm, Phase 2 Study of Carfilzomib in Patients with Relapsed Multiple Myeloma				
<b>McDonagh, Kevin T</b>	3048104375	\$0.	\$29,147.	\$29,147.
Erimos Pharmaceuticals LLC Phase I Study of Terameprocol (EM-1421), a Survivin and Cyclin-Dependent-Kinase-1 (Cdc2) Inhibitor, in Patients				
<b>Miller, Beth A</b>	3046829900	\$0.	\$100.	\$100.
Genentech Inc An Epidemiologic Study of Xolair (Omalizumab): Evaluating Clinical Effectiveness and Long-Term Safety in Patients with Moderate to Severe Asthma (EXCELS)				
<b>Miller, Beth A</b>	3046829900	\$0.	\$864.	\$864.
Genentech Inc An Epidemiologic Study of Xolair (Omalizumab): Evaluating Clinical Effectiveness and Long-Term Safety in Patients with Moderate to Severe Asthma (EXCELS)				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Internal Medicine</b>				
<b>Miller, Beth A</b>	3046829900	\$0.	\$4,167.	\$4,167.
Genentech Inc An Epidemiologic Study of Xolair (Omalizumab): Evaluating Clinical Effectiveness and Long-Term Safety in Patients with Moderate to Severe Asthma (EXCELS)				
<b>Miller, Beth A</b>	3046829900	\$0.	\$3,222.	\$3,222.
Genentech Inc An Epidemiologic Study of Xolair (Omalizumab): Evaluating Clinical Effectiveness and Long-Term Safety in Patients with Moderate to Severe Asthma (EXCELS)				
<b>Miller, Beth A</b>	3046829900	\$0.	\$5,068.	\$5,068.
Genentech Inc An Epidemiologic Study of Xolair (Omalizumab): Evaluating Clinical Effectiveness and Long-Term Safety in Patients with Moderate to Severe Asthma (EXCELS)				
<b>Miller, Beth A</b>	3046994700	\$0.	\$-600.	\$-600.
Novartis A 26 Week, Randomized, Double-Blind, Parallel-Group-Controlled, Multi-center Study To Evaluate the Effect of Xolair(Omalizumab) on Improving the Tolerability of Specific Immunotherapy In Patients With Persistent Allergic Asthma				
<b>Miller, Beth A</b>	3046994700	\$0.	\$-345.	\$-345.
Novartis A 26 Week, Randomized, Double-Blind, Parallel-Group-Controlled, Multi-center Study To Evaluate the Effect of Xolair(Omalizumab) on Improving the Tolerability of Specific Immunotherapy In Patients With Persistent Allergic Asthma				
<b>Miller, Beth A</b>	3046994700	\$0.	\$1,670.	\$1,670.
Novartis A 26 Week, Randomized, Double-Blind, Parallel-Group-Controlled, Multi-center Study To Evaluate the Effect of Xolair(Omalizumab) on Improving the Tolerability of Specific Immunotherapy In Patients With Persistent Allergic Asthma				
<b>Miller, Beth A</b>	3048041000	\$0.	\$1,260.	\$1,260.
Genentech Inc A Phase IIIb Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Xolair in Subjects with Moderate to Severe Persistent Asthma who are Inadequately Controlled with High-Dose Inhaled Corticosteroids and Long-Acting Beta-Agonists				
<b>Miller, Beth A</b>	3048041000	\$0.	\$11,975.	\$11,975.
Genentech Inc A Phase IIIb Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Xolair in Subjects with Moderate to Severe Persistent Asthma who are Inadequately Controlled with High-Dose Inhaled Corticosteroids and Long-Acting Beta-Agonists				
<b>Miller, Beth A</b>	3048041000	\$0.	\$1,357.	\$1,357.
Genentech Inc A Phase IIIb Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Xolair in Subjects with Moderate to Severe Persistent Asthma who are Inadequately Controlled with High-Dose Inhaled Corticosteroids and Long-Acting Beta-Agonists				
<b>Miller, Beth A</b>	3048041000	\$0.	\$16,931.	\$16,931.
Genentech Inc A Phase IIIb Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Xolair in Subjects with Moderate to Severe Persistent Asthma who are Inadequately Controlled with High-Dose Inhaled Corticosteroids and Long-Acting Beta-Agonists				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Internal Medicine</b>				
<b>Miller, Beth A</b>	3048104585	\$0.	\$3,324.	\$3,324.
GlaxoSmithKline A Randomized Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group, Multicenter, Dose Ranging Study to Evaluate the Efficacy and Safety of GW685698X Inhalation Powder Once Daily and Fluticasone Propionate Inhalation powder 250mcg Twice Daily				
<b>Miller, Beth A</b>	3048104585	\$0.	\$3,687.	\$3,687.
GlaxoSmithKline A Randomized Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group, Multicenter, Dose Ranging Study to Evaluate the Efficacy and Safety of GW685698X Inhalation Powder Once Daily and Fluticasone Propionate Inhalation powder 250mcg Twice Daily				
<b>Miller, Beth A</b>	3048104585	\$0.	\$863.	\$863.
GlaxoSmithKline A Randomized Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group, Multicenter, Dose Ranging Study to Evaluate the Efficacy and Safety of GW685698X Inhalation Powder Once Daily and Fluticasone Propionate Inhalation powder 250mcg Twice Daily				
<b>Miller, Beth A</b>	3048104585	\$0.	\$4,670.	\$4,670.
GlaxoSmithKline A Randomized Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group, Multicenter, Dose Ranging Study to Evaluate the Efficacy and Safety of GW685698X Inhalation Powder Once Daily and Fluticasone Propionate Inhalation powder 250mcg Twice Daily				
<b>Miller, Beth A</b>	3048104585	\$0.	\$3,238.	\$3,238.
GlaxoSmithKline A Randomized Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group, Multicenter, Dose Ranging Study to Evaluate the Efficacy and Safety of GW685698X Inhalation Powder Once Daily and Fluticasone Propionate Inhalation powder 250mcg Twice Daily				
<b>Miller, Beth A</b>	3048104585	\$0.	\$4,544.	\$4,544.
GlaxoSmithKline A Randomized Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group, Multicenter, Dose Ranging Study to Evaluate the Efficacy and Safety of GW685698X Inhalation Powder Once Daily and Fluticasone Propionate Inhalation powder 250mcg Twice Daily				
<b>Miller, Beth A</b>	3048105366	\$2.	\$0.	\$2.
Quintiles Inc A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Phase III Study of the Efficacy and Safety of 300 IR Sublingual Immunotherapy (SLIT) Administered as Allergen Based Tablets Once Daily to Adult Patients				
<b>Miller, Ralph E</b>	3046644900	\$0.	\$682.	\$682.
Eli Lilly and Company Hypopituitary Control and Complications Study				
<b>Miller, Ralph E</b>	3046644900	\$0.	\$1,104.	\$1,104.
Eli Lilly and Company Hypopituitary Control and Complications Study				
<b>Miller, Ralph E</b>	3046644900	\$0.	\$2,046.	\$2,046.
Eli Lilly and Company Hypopituitary Control and Complications Study				
<b>Miller, Ralph E</b>	3046644900	\$0.	\$6,603.	\$6,603.
Eli Lilly and Company Hypopituitary Control and Complications Study				

## Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Internal Medicine</b>				
<b>Miller, Ralph E</b>	3046644900	\$0.	\$3,720.	\$3,720.
Eli Lilly and Company Hypopituitary Control and Complications Study				
<b>Miller, Ralph E</b>	3046644900	\$0.	\$1,000.	\$1,000.
Eli Lilly and Company Hypopituitary Control and Complications Study				
<b>Miller, Ralph E</b>	3046644900	\$0.	\$4,338.	\$4,338.
Eli Lilly and Company Hypopituitary Control and Complications Study				
<b>Morehead, Richard S</b>	3046861300	\$0.	\$4,538.	\$4,538.
Ortho McNeil Pharmaceuticals Levofloxacin Pharmacokinetics in the Severely Obese				
<b>Morris, Andrew</b>	3046978800	\$0.	\$20,094.	\$20,094.
National Institute of General Medical Sciences Lysophosphatidic Acid - Synthesis, Actions and Inactivation				
<b>Morris, Andrew</b>	3048104961	\$43,000.	\$0.	\$43,000.
American Heart Association Great Rivers Affiliate Fellowship for Hongmei Ren: Regulation of Triglyceride Synthesis by Membrane Targeting of Lipin/Type 1 Phosphatidic acid Phosphatase				
<b>Morris, Andrew</b>	3048105297	\$67,566.	\$0.	\$67,566.
National Institute of General Medical Sciences Role of Lipid Phosphatases in Cholesterol and Triglyceride Synthesis				
<b>Mukherjee, Debabrata</b>	3046910200	\$0.	\$2,205.	\$2,205.
Sanofi Synthelabo Inc SHINE: A Randomized Dose Ranging Study of Hexadecasaccharide				
<b>Mukherjee, Debabrata</b>	3046943700	\$0.	\$630.	\$630.
Conor Medsystems COSTAR II: Cobalt Chromium Stent with Antiproliferative for Restenosis II Trial Costar Paclitaxeluting Coronary Stent System				
<b>Mukherjee, Debabrata</b>	3048015400	\$0.	\$1,498.	\$1,498.
Mount Sinai FREEDOM Trial Future Revascularization in Patients with Diabetes Mellitus: Optimal Management of Multivessel Disease (FREEDOM) and all Amendments there to.				
<b>Mukherjee, Debabrata</b>	3048061600	\$0.	\$3,175.	\$3,175.
Guidant CPI CAPTURE 2 - A Post-Approval Study of the Guidant Carotid Stent Systems and Embolic Protection Systems				
<b>Mukherjee, Debabrata</b>	3048061600	\$0.	\$2,675.	\$2,675.
Guidant CPI CAPTURE 2 - A Post-Approval Study of the Guidant Carotid Stent Systems and Embolic Protection Systems				
<b>Mukherjee, Debabrata</b>	3048104415	\$0.	\$800.	\$800.
Schering Plough Co A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard Care in Subjects with Acute Coronary Syndrome (TRA CER)				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Internal Medicine</b>				
<b>Mukherjee, Debabrata</b>	3048104415	\$0.	\$1,600.	\$1,600.
Schering Plough Co A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard Care in Subjects with Acute Coronary Syndrome (TRA CER)				
<b>Mukherjee, Debabrata</b>	3048104415	\$0.	\$10,800.	\$10,800.
Schering Plough Co A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard Care in Subjects with Acute Coronary Syndrome (TRA CER)				
<b>Mukherjee, Debabrata</b>	3048104415	\$0.	\$800.	\$800.
Schering Plough Co A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard Care in Subjects with Acute Coronary Syndrome (TRA CER)				
<b>Mukherjee, Debabrata</b>	3048104415	\$0.	\$11,500.	\$11,500.
Schering Plough Co A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard Care in Subjects with Acute Coronary Syndrome (TRA CER)				
<b>Mukherjee, Debabrata</b>	3048104415	\$0.	\$12,798.	\$12,798.
Schering Plough Co A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard Care in Subjects with Acute Coronary Syndrome (TRA CER)				
<b>Mukherjee, Debabrata</b>	3048104415	\$0.	\$800.	\$800.
Schering Plough Co A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard Care in Subjects with Acute Coronary Syndrome (TRA CER)				
<b>Nickl, Nicholas J</b>	3046728400	\$0.	\$-194.	\$-194.
Medtronics Inc An Evaluation of the Medtronic Gatekeeper System in the Treatment of subjects with GERD				
<b>Nickl, Nicholas J</b>	3046728400	\$0.	\$2,007.	\$2,007.
Medtronics Inc An Evaluation of the Medtronic Gatekeeper System in the Treatment of subjects with GERD				
<b>Nickl, Nicholas J</b>	3048104763	\$2.	\$0.	\$2.
Repligen Corp A Phase III Study to Demonstrate the Efficacy and Safety of RG1068 (Synthetic Human Secretin) Enhanced Magnetic Resonance Cholangiopancreatography (MRCP) in the Evaluation of Subjects with a History of Acute or Acute Recurrent Pancreatitis				
<b>Nickl, Nicholas J</b>	3048104763	\$0.	\$7,783.	\$7,783.
Repligen Corp A Phase III Study to Demonstrate the Efficacy and Safety of RG1068 (Synthetic Human Secretin) Enhanced Magnetic Resonance Cholangiopancreatography (MRCP) in the Evaluation of Subjects with a History of Acute or Acute Recurrent Pancreatitis				
<b>Nickl, Nicholas J</b>	3048104994	\$0.	\$1,258.	\$1,258.
Eurand SPA A Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Safety and Efficacy of two doses of Zentase (EUR-1008) in Chronic Pancreatitis (CP) Patients with Exocrine Pancreatic Insufficiency (EPI)				

## Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Internal Medicine</b>				
<b>Nickl, Nicholas J</b>	3048104994	\$2.	\$0.	\$2.
Eurand SPA A Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Safety and Efficacy of two doses of Zentase (EUR-1008) in Chronic Pancreatitis (CP) Patients with Exocrine Pancreatic Insufficiency (EPI)				
<b>Pena, Luis R</b>	3048103663	\$0.	\$6,860.	\$6,860.
Solvay Pharmaceuticals A Study to Investigate the Effect of two Doses of CREON on Maldigestion in Patients with Exocrine Pancreatic Insufficiency Due to Chronic Pancreatitis				
<b>Pena, Luis R</b>	3048103663	\$0.	\$10,250.	\$10,250.
Solvay Pharmaceuticals A Study to Investigate the Effect of two Doses of CREON on Maldigestion in Patients with Exocrine Pancreatic Insufficiency Due to Chronic Pancreatitis				
<b>Pena, Luis R</b>	3048103663	\$0.	\$473.	\$473.
Solvay Pharmaceuticals A Study to Investigate the Effect of two Doses of CREON on Maldigestion in Patients with Exocrine Pancreatic Insufficiency Due to Chronic Pancreatitis				
<b>Pena, Luis R</b>	3048103663	\$0.	\$7,126.	\$7,126.
Solvay Pharmaceuticals A Study to Investigate the Effect of two Doses of CREON on Maldigestion in Patients with Exocrine Pancreatic Insufficiency Due to Chronic Pancreatitis				
<b>Pena, Luis R</b>	3048104984	\$2.	\$0.	\$2.
Roche Laboratories Prospective Observational Study on Predictors of Early-On Treatment, Response and Sustained Virological Response in a Cohort of Treatment Naive HCV-Infected Patients Treated with Pegylated Interferons				
<b>Reynolds, L Raymond</b>	3048027100	\$0.	\$2,254.	\$2,254.
Novo Nordisk Pharmaceuticals Inc Effect on Glycemic Control of Two Doses of Liraglutide versus Glimperide in Type 2 Diabetes				
<b>Rinehart, John J</b>	3046945700	\$0.	\$39.	\$39.
Berlex Laboratories Inc Randomized Phase III Trial of Leukine vs Newpogen in Patients Receiving Cisplatin and Gemcitabine for Reionally Advanced or Metastatic Urothelial Cancer				
<b>Rinehart, John J</b>	3048027400	\$0.	\$2,563.	\$2,563.
Taiho Pharma USA Inc A Phase 1, Open-Label Study Evaluating the Pharmacokinetics of Components of S-1 in Patients with Impaired Hepatic Function				
<b>Rinehart, John J</b>	3048027500	\$0.	\$9,056.	\$9,056.
Taiho Pharma USA Inc A Phase 1, Open-Label Study Evaluating the Pharmacokinetics of Components of S-1 in Patients with Varying Degrees of Renal Function				
<b>Rinehart, John J</b>	3048082900	\$0.	\$567.	\$567.
Eli Lilly and Company A Randomized Phase 3 Trial of Alimta (Premetrexed) and Carboplatin versus Etoposide and Carboplatin in Extensive-STage Small Cell Lung Cancer				

## Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Internal Medicine</b>				
<b>Rinehart, John J</b>	3048082900	\$0.	\$4,714.	\$4,714.
Eli Lilly and Company A Randomized Phase 3 Trial of Alimta (Premetrexed) and Carboplatin versus Etoposide and Carboplatin in Extensive-STage Small Cell Lung Cancer				
<b>Rinehart, John J</b>	3048082900	\$0.	\$4,714.	\$4,714.
Eli Lilly and Company A Randomized Phase 3 Trial of Alimta (Premetrexed) and Carboplatin versus Etoposide and Carboplatin in Extensive-STage Small Cell Lung Cancer				
<b>Rinehart, John J</b>	3048103857	\$0.	\$398.	\$398.
Genentech Inc A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination With Carboplatin and Paclitaxel Chemotherapy for the First-Line Treatment of Patients with Metastatic Melanoma				
<b>Rinehart, John J</b>	3048103857	\$0.	\$75.	\$75.
Genentech Inc A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination With Carboplatin and Paclitaxel Chemotherapy for the First-Line Treatment of Patients with Metastatic Melanoma				
<b>Rinehart, John J</b>	3048104413	\$0.	\$10,942.	\$10,942.
Wyeth Pharmaceuticals Inc A Randomized Trial of Temsilrolimus and Sorafenib as Second-Line Therapy in Patients With Advanced Renal Cell Carcinoma Who Have Failed First-Line Sunitinib Therapy				
<b>Rinehart, John J</b>	3048104488	\$0.	\$6,318.	\$6,318.
Schering Plough Co An Open-Label, Two-Part Study to Determine the Safety, Tolerability, and Activity of Lonafarnib and Docetaxel				
<b>Rinehart, John J</b>	3048104826	\$2.	\$0.	\$2.
Cougar Biotechnology Inc A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate (AB7630) Plus Prednisone in Patients with Metastatic Castration-Resistant Prostate Cancer Who Have Failed Docetaxel-Based Chemotherapy				
<b>Rinehart, John J</b>	3048104826	\$0.	\$4,546.	\$4,546.
Cougar Biotechnology Inc A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate (AB7630) Plus Prednisone in Patients with Metastatic Castration-Resistant Prostate Cancer Who Have Failed Docetaxel-Based Chemotherapy				
<b>Romond, Edward H</b>	3046177800	\$0.	\$10,000.	\$10,000.
NSABP Foundation NSABP Master Agreement				
<b>Romond, Edward H</b>	3046177800	\$0.	\$5,950.	\$5,950.
NSABP Foundation NSABP Master Agreement				
<b>Romond, Edward H</b>	3046177800	\$0.	\$4,100.	\$4,100.
NSABP Foundation NSABP Master Agreement				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Medicine</u></b>				
<b><u>Internal Medicine</u></b>				
<b>Romond, Edward H</b>	3046177800	\$0.	\$11,300.	\$11,300.
NSABP Foundation				
NSABP Master Agreement				
<b>Romond, Edward H</b>	3046177800	\$0.	\$13,000.	\$13,000.
NSABP Foundation				
NSABP Master Agreement				
<b>Romond, Edward H</b>	3046177800	\$0.	\$10,755.	\$10,755.
NSABP Foundation				
NSABP Master Agreement				
<b>Romond, Edward H</b>	3046177800	\$0.	\$-250.	\$-250.
NSABP Foundation				
NSABP Master Agreement				
<b>Romond, Edward H</b>	3046177800	\$0.	\$19,050.	\$19,050.
NSABP Foundation				
NSABP Master Agreement				
<b>Romond, Edward H</b>	3046177800	\$0.	\$-67.	\$-67.
NSABP Foundation				
NSABP Master Agreement				
<b>Romond, Edward H</b>	3046177800	\$0.	\$13,000.	\$13,000.
NSABP Foundation				
NSABP Master Agreement				
<b>Romond, Edward H</b>	3046177800	\$0.	\$2,000.	\$2,000.
NSABP Foundation				
NSABP Master Agreement				
<b>Romond, Edward H</b>	3046177800	\$0.	\$16,080.	\$16,080.
NSABP Foundation				
NSABP Master Agreement				
<b>Romond, Edward H</b>	3046350500	\$0.	\$25,800.	\$25,800.
NSABP Foundation				
STAR Trial Breast Cancer Prevention Trial (P-2)				
<b>Romond, Edward H</b>	3048040300	\$0.	\$33,087.	\$33,087.
Eli Lilly and Company				
A Randomized Phase II Trail of Paclitaxel and Bevacizumab versus Gemcitabine, Paclitaxel, and Bevacizumab as First Line Treatment for Locally Advanced or Metastatic Breast Cancer				
<b>Romond, Edward H</b>	3048105106	\$2.	\$0.	\$2.
NSABP Foundation				
NSABP Master Agreement (TIND)				
<b>Rowland, Randall</b>	3048103818	\$0.	\$1,325.	\$1,325.
Southwest Oncology Group				
The Selenium and Vitamin E Cancer Prevention Trial (Select)				

## Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Internal Medicine</b>				
<b>Rowland, Randall</b>	3048103818	\$0.	\$2,170.	\$2,170.
Southwest Oncology Group The Selenium and Vitamin E Cancer Prevention Trial (Select)				
<b>Rowland, Randall</b>	3048103818	\$0.	\$100.	\$100.
Southwest Oncology Group The Selenium and Vitamin E Cancer Prevention Trial (Select)				
<b>Rowland, Randall</b>	3048103819	\$0.	\$50.	\$50.
Southwest Oncology Group SWOG UCOP Urologic Cancer Outreach Program				
<b>Rowland, Randall</b>	3048103819	\$0.	\$500.	\$500.
Southwest Oncology Group SWOG UCOP Urologic Cancer Outreach Program				
<b>Rowland, Randall</b>	3048103819	\$0.	\$250.	\$250.
Southwest Oncology Group SWOG UCOP Urologic Cancer Outreach Program				
<b>Rowland, Randall</b>	3048103819	\$0.	\$50.	\$50.
Southwest Oncology Group SWOG UCOP Urologic Cancer Outreach Program				
<b>Selby, Lisbeth Ann</b>		\$2.	\$0.	\$2.
University of California San Francisco A Multicenter National Prospective Study of Pregnancy and Neonatal Outcomes in Women with Inflammatory Bowel Disease Exposed to Immunomodulators and Biologic Therapy				
<b>Shedlofsky, Steven I</b>	3046556300	\$0.	\$300.	\$300.
Hoffmann La Roche Inc NV15908-An Extension Protocol to Evaluate the Long-Term Effects of Treatment with Peg Interferon Alfa-2a (PEG-IFN) or Interferon (IFN)- Based Therapies for Patients with Chronic Hepatitis C				
<b>Smyth, Susan</b>	3048103401	\$0.	\$21,000.	\$21,000.
American Heart Association Ohio Valley Affiliate Cheng Pre-Doc Fellowship: Signaling of LPA Receptors 1 and 2 is Vital for Regulation of Pulmonary Vascular Tone				
<b>Smyth, Susan</b>	3048103403	\$0.	\$21,000.	\$21,000.
American Heart Association Ohio Valley Affiliate Federico Pre-Doc Fellowship: The Role of Pyk2 in Platelet-eukocyte Interactions and the Arterial Response to Injury				
<b>Smyth, Susan</b>	3048103742	\$0.	\$-5,516.	\$-5,516.
University of North Carolina Adhesion and Migration in Inflammation				
<b>Smyth, Susan</b>	3048103742	\$0.	\$275,848.	\$275,848.
University of North Carolina Adhesion and Migration in Inflammation				
<b>Steinhubl, Steven R</b>	3046837600	\$0.	\$-200.	\$-200.
New Millenium Pharmaceutical Research Institute Evaluating Ischemic and Restenotic Outcomes in the Drug Eluting Stent Era				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Internal Medicine</b>				
<b>Steinhubl, Steven R</b>	3046837600	\$0.	\$950.	\$950.
New Millenium Pharmaceutical Research Institute Evaluating Ischemic and Restenotic Outcomes in the Drug Eluting Stent Era				
<b>Steinhubl, Steven R</b>	3046837600	\$0.	\$450.	\$450.
New Millenium Pharmaceutical Research Institute Evaluating Ischemic and Restenotic Outcomes in the Drug Eluting Stent Era				
<b>Steinhubl, Steven R</b>	3048012900	\$0.	\$1,000.	\$1,000.
Medicines Company CHAMPION-PCI: Cangrelor: A Clinical Trail Comparing Cangrelor to C Lopidogrel in Subjects Who Require Percutaneous Coronary Intervention				
<b>Steinhubl, Steven R</b>	3048012900	\$0.	\$500.	\$500.
Medicines Company CHAMPION-PCI: Cangrelor: A Clinical Trail Comparing Cangrelor to C Lopidogrel in Subjects Who Require Percutaneous Coronary Intervention				
<b>Steinhubl, Steven R</b>	3048012900	\$0.	\$500.	\$500.
Medicines Company CHAMPION-PCI: Cangrelor: A Clinical Trail Comparing Cangrelor to C Lopidogrel in Subjects Who Require Percutaneous Coronary Intervention				
<b>Steinhubl, Steven R</b>	3048047000	\$0.	\$9,743.	\$9,743.
Bristol Myers Squibb Company APPRAISE-1: Apixaban for Prevention of Acute Ischemic Safety Events				
<b>Steinhubl, Steven R</b>	3048047000	\$0.	\$11,119.	\$11,119.
Bristol Myers Squibb Company APPRAISE-1: Apixaban for Prevention of Acute Ischemic Safety Events				
<b>Steinhubl, Steven R</b>	3048103787	\$0.	\$2,145.	\$2,145.
Johnson and Johnson A Propestive, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Even-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose				
<b>Steinhubl, Steven R</b>	3048103787	\$0.	\$4,680.	\$4,680.
Johnson and Johnson A Propestive, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Even-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose				
<b>Steinhubl, Steven R</b>	3048103787	\$0.	\$6,238.	\$6,238.
Johnson and Johnson A Propestive, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Even-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose				
<b>Steinhubl, Steven R</b>	3048103787	\$0.	\$1,130.	\$1,130.
Johnson and Johnson A Propestive, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Even-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose				

**Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Medicine</u></b>				
<b><u>Internal Medicine</u></b>				
<b>Steinhubl, Steven R</b>	3048103787	\$0.	\$3,053.	\$3,053.
Johnson and Johnson A Propeptive, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Even-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose				
<b>Tannock, Lisa R</b>	3048087500	\$0.	\$366,250.	\$366,250.
National Heart Lung and Blood Institute Angiotensin Induced Proteoglycans in Atherosclerosis				
<b>Thornton, Alice C</b>	3048104840	\$165,000.	\$0.	\$165,000.
Emory University Kentucky AIDS Educational Training Center				
<b>Thornton, Alice C</b>	3048104855	\$0.	\$-106,500.	\$-106,500.
KY Health Services Cabinet Kentucky HIV/AIDS Care Coordinator Program				
<b>Thornton, Alice C</b>	3048104855	\$654,027.	\$0.	\$654,027.
KY Health Services Cabinet Kentucky HIV/AIDS Care Coordinator Program				
<b>Van Der Westhuyzen, Deneys R</b>	3046952300	\$0.	\$308,973.	\$308,973.
National Heart Lung and Blood Institute SR-BI and SR-BII Recycling and Selective Lipid Uptake				
<b>Van Zant, Gary</b>		\$343,986.	\$0.	\$343,986.
National Institute of Child Health and Human Develop Latexin's role in parsing stem cells				
<b>Van Zant, Gary</b>	3046830100	\$0.	\$266,530.	\$266,530.
National Institute on Aging Aging Stem Cells and Their Microenvironment				
<b>Van Zant, Gary</b>	3046830100	\$0.	\$-5,556.	\$-5,556.
National Institute on Aging Aging Stem Cells and Their Microenvironment				
<b>Van Zant, Gary</b>	3048105105	\$219,612.	\$0.	\$219,612.
Ellison Medical Foundation Role of the microRNA-290 Gene Cluster in Stem Cell and Organismal Aging				
<b>Waid, Thomas</b>	3048103709	\$0.	\$2,520.	\$2,520.
Novartis A 4-Week, Multicenter, Double-Blind, Randomized, Parallel Group Study to Compare the Gastrointestinal Safety and Tolerability of myfortic and MMF (Cellcept) When Administered in Combination with Calcineurin Inhibitors in Renal Transplant Recipients				
<b>Waid, Thomas</b>	3048104654	\$0.	\$7,605.	\$7,605.
Astellas Pharma US Inc A Phase 2, Randomized, Open-Label, Parallel Group, Multi-Center Study to Assess the Safety and Efficacy of Alefacept in de novo Kidney Transplant Recipients				

## Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Internal Medicine</b>				
<b>Waid, Thomas</b>	3048104654	\$0.	\$5,145.	\$5,145.
Astellas Pharma US Inc A Phase 2, Randomized, Open-Label, Parallel Group, Multi-Center Study to Assess the Safety and Efficacy of Alefacept in de novo Kidney Transplant Recipients				
<b>Waid, Thomas</b>	3048104654	\$0.	\$4,998.	\$4,998.
Astellas Pharma US Inc A Phase 2, Randomized, Open-Label, Parallel Group, Multi-Center Study to Assess the Safety and Efficacy of Alefacept in de novo Kidney Transplant Recipients				
<b>Ziada, Khaled M</b>		\$2.	\$0.	\$2.
Abbott Laboratories XIENCE V Everolimus Eluting Coronary Stent System				
<b>Ziada, Khaled M</b>	3046900000	\$0.	\$500.	\$500.
Omnicare Clinical Research A Double-Blind, Randomized Comparator-Controlled Study in Subjects with Type II Diabetes Mellitus Comparing the Effects of Pioglitazone HCl versus Glimepiride on the Rate of Progression of Coronary Atherosclerotic Disease				
<b>Ziada, Khaled M</b>	3046944600	\$0.	\$185.	\$185.
Sanofi Synthelabo Inc STRADIVARIUS - Strategy to Reduce Atherosclerosis Development involving Rimonabant				
<b>Ziada, Khaled M</b>	3046969200	\$0.	\$47,275.	\$47,275.
Schering Plough Co Transcendence-PCI				
<b>Ziada, Khaled M</b>	3048066800	\$0.	\$4,785.	\$4,785.
Sanofi Aventis US Inc CRESCENDO: EFC5826: Randomized, Multinational, Multicenter, Double-Blind, Placebo-Controlled, Two-Arm Parallel Group Trial of Rimonabant 20 mg QD for Reducing the Risk of Major Cardiovascular Events in Abdominally Obese Patients with Clustering				
<b>Ziada, Khaled M</b>	3048066800	\$0.	\$3,330.	\$3,330.
Sanofi Aventis US Inc CRESCENDO: EFC5826: Randomized, Multinational, Multicenter, Double-Blind, Placebo-Controlled, Two-Arm Parallel Group Trial of Rimonabant 20 mg QD for Reducing the Risk of Major Cardiovascular Events in Abdominally Obese Patients with Clustering				
<b>Ziada, Khaled M</b>	3048104460	\$0.	\$1,500.	\$1,500.
Schering Plough Co A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard of Care in Subjects with a History of Atherosclerotic Disease				
<b>Ziada, Khaled M</b>	3048104460	\$0.	\$2,925.	\$2,925.
Schering Plough Co A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard of Care in Subjects with a History of Atherosclerotic Disease				
<b>Ziada, Khaled M</b>	3048104460	\$0.	\$4,500.	\$4,500.
Schering Plough Co A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard of Care in Subjects with a History of Atherosclerotic Disease				

**Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009**

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Internal Medicine</b>				
<b>Ziada, Khaled M</b>	3048104460	\$0.	\$1,775.	\$1,775.
Schering Plough Co A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard of Care in Subjects with a History of Atherosclerotic Disease				
<b>Ziada, Khaled M</b>	3048104589	\$0.	\$14,698.	\$14,698.
AstraZeneca Pharmaceuticals A 104 Week, Randomized, Double-Blind, Parallel Arm, Multi-Center Phase IIIb Study Comparing the Effects of Treatment with Rosuvastatin 40 mg or Atorvastatin 80 mg on Atherosclerotic Disease Burden As Measured By Intravascular Ultrasound in Patients				
<b>Internal Medicine</b>	<b>Totals:</b>	<b>\$6,305,453.</b>	<b>\$3,396,960.</b>	<b>\$9,702,413.</b>
<b>Microbiology, Immunology &amp; Molecular Gen</b>				
<b>Bondada, Subbarao</b>	3048105046	\$183,125.	\$0.	\$183,125.
National Institute of Allergy and Infectious Diseases Importance of CD5 for the function of regulatory T cells				
<b>Cohen, Donald A</b>	3048103719	\$0.	\$-10,000.	\$-10,000.
Danone Research Effect of the Consumption of a Fermented Dairy Product on Immune Parameters in Healthy Adults				
<b>Cohen, Donald A</b>	3048103719	\$0.	\$185,333.	\$185,333.
Danone Research Effect of the Consumption of a Fermented Dairy Product on Immune Parameters in Healthy Adults				
<b>Garvy, Beth A</b>	3048103511	\$0.	\$21,000.	\$21,000.
American Heart Association Ohio Valley Affiliate Lines Fellowship: Neonatal T cell responses to influenza virus				
<b>Garvy, Beth A</b>	3048104324	\$0.	\$366,250.	\$366,250.
National Heart Lung and Blood Institute Role of B cells in host defense against Pneumocystis				
<b>Kaetzel, Charlotte S</b>	3048104092	\$0.	\$215,575.	\$215,575.
National Institute of Allergy and Infectious Diseases Novel in Vivo Models for Cell-Type Specific MyD88 Signaling in the Intestine				
<b>Luo, Guangxiang</b>	3048103820	\$0.	\$215,575.	\$215,575.
National Institute of Allergy and Infectious Diseases Hepatitis C Virus Infection and Lipoproteins				
<b>Marti, Francesc</b>	3048104425	\$0.	\$68,818.	\$68,818.
National Institute Arthritis Musculoskeletal & Skin Lck activity in autoimmune TSAD-deficient Mice				
<b>Sinai, Anthony P</b>	3046975100	\$0.	\$36,625.	\$36,625.
National Institute of Allergy and Infectious Diseases Blockade of Host Apoptosis by Toxoplasma Gondii				
<b>Spear, Brett T</b>	3048104385	\$0.	\$294,319.	\$294,319.
National Institute Diabetes & Digestive & Kidney Albumin-AFP Gene Family Regulation in Fetal and Adult Liver				

**Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Medicine</u></b>				
<b><u>Microbiology, Immunology &amp; Molecular Gen</u></b>				
<b>Stevenson, Brian</b>	3048104946	\$219,750.	\$0.	\$219,750.
National Institute of Allergy and Infectious Diseases Leptospira interrogans Len adhesins				
<b>Woodward, Jerold G</b>	3048104077	\$0.	\$88,599.	\$88,599.
University of North Carolina Nanoparticle HIC Protein Vaccines for Cellular Responses				
<b>Woodward, Jerold G</b>	3048105035	\$256,375.	\$0.	\$256,375.
National Eye Institute To Produce Transgenic Mice Which Express T Cell Receptors Specific for (IRBP)				
<b>Yannelli, John R</b>	3048105252	\$175,800.	\$0.	\$175,800.
National Cancer Institute Cryopreparation of PBMC for Immunotherapy and Immune Assessment Studies				
<b>Microbiology, Immunology &amp; Molecular Gen</b>	<b>Totals:</b>	<b>\$835,050.</b>	<b>\$1,482,094.</b>	<b>\$2,317,144.</b>
<b><u>Family Practice &amp; Community Medicine</u></b>				
<b>Dassow, Paul</b>	3048044400	\$0.	\$-23,458.	\$-23,458.
State of Oregon Department of Justice Maximizing the Impact of a Critical Skills Curriculum for Prescribers				
<b>Dassow, Paul</b>	3048104740	\$185,548.	\$0.	\$185,548.
Health Resources and Services Administration Residency Training in Primary Care				
<b>Joyce, Jennifer M</b>	3048105013	\$10,000.	\$0.	\$10,000.
Good Samaritan Foundation Salvation Army Free Clinic				
<b>Joyce, Jennifer M</b>	3048105283	\$183,024.	\$0.	\$183,024.
Health Resources and Services Administration Pre-Doctoral Training in Rural Kentucky				
<b>Matheny, Samuel C</b>	3048105256	\$276,536.	\$0.	\$276,536.
Health Resources and Services Administration Academic Administrative Units in Primary Care: Serving the Community: Family Medicine Education and Research				
<b>Pearce, Kevin</b>	3048105236	\$5,000.	\$0.	\$5,000.
Southern KY Area Health Education Center Improvements in the Diagnosis and Treatment of Cardiac Risk Factors				
<b>Roeder, Phillip W</b>	3048103104	\$0.	\$33,902.	\$33,902.
KY Department of Corrections Department of Corrections Health Care Network Monitor & Coordinator - UK Administration				
<b>Roeder, Phillip W</b>	3048103104	\$0.	\$25,643.	\$25,643.
KY Department of Corrections Department of Corrections Health Care Network Monitor & Coordinator - UK Administration				
<b>Roeder, Phillip W</b>	3048103104	\$0.	\$24,322.	\$24,322.
KY Department of Corrections Department of Corrections Health Care Network Monitor & Coordinator - UK Administration				

**Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Medicine</u></b>				
<b><u>Family Practice &amp; Community Medicine</u></b>				
<b>Roeder, Phillip W</b>	3048104606	\$0.	\$136,173.	\$136,173.
KY Department of Corrections Department of Corrections Health Care Network Monitor & Coordinator - UK Administration				
<b>Roeder, Phillip W</b>	3048104606	\$0.	\$51,918.	\$51,918.
KY Department of Corrections Department of Corrections Health Care Network Monitor & Coordinator - UK Administration				
<b>Roeder, Phillip W</b>	3048104606	\$0.	\$33,483.	\$33,483.
KY Department of Corrections Department of Corrections Health Care Network Monitor & Coordinator - UK Administration				
<b>Roeder, Phillip W</b>	3048104606	\$0.	\$49,368.	\$49,368.
KY Department of Corrections Department of Corrections Health Care Network Monitor & Coordinator - UK Administration				
<b>Roeder, Phillip W</b>	3048104606	\$0.	\$52,794.	\$52,794.
KY Department of Corrections Department of Corrections Health Care Network Monitor & Coordinator - UK Administration				
<b>Roeder, Phillip W</b>	3048104606	\$0.	\$67,351.	\$67,351.
KY Department of Corrections Department of Corrections Health Care Network Monitor & Coordinator - UK Administration				
<b>Roeder, Phillip W</b>	3048104606	\$0.	\$2,785.	\$2,785.
KY Department of Corrections Department of Corrections Health Care Network Monitor & Coordinator - UK Administration				
<b>Roeder, Phillip W</b>	3048104606	\$0.	\$-1,000.	\$-1,000.
KY Department of Corrections Department of Corrections Health Care Network Monitor & Coordinator - UK Administration				
<b>Roeder, Phillip W</b>	3048104606	\$0.	\$65,105.	\$65,105.
KY Department of Corrections Department of Corrections Health Care Network Monitor & Coordinator - UK Administration				
<b>Roeder, Phillip W</b>	3048104606	\$0.	\$36,356.	\$36,356.
KY Department of Corrections Department of Corrections Health Care Network Monitor & Coordinator - UK Administration				
<b>Roeder, Phillip W</b>	3048104606	\$0.	\$75,114.	\$75,114.
KY Department of Corrections Department of Corrections Health Care Network Monitor & Coordinator - UK Administration				
<b>Roeder, Phillip W</b>	3048104606	\$2.	\$0.	\$2.
KY Department of Corrections Department of Corrections Health Care Network Monitor & Coordinator - UK Administration				
<b>Family Practice &amp; Community Medicine</b>	<b>Totals:</b>	<b>\$660,110.</b>	<b>\$629,856.</b>	<b>\$1,289,966.</b>
<b><u>Obstetrics &amp; Gynecology</u></b>				
<b>Ferguson, James E</b>	3048102149	\$0.	\$300.	\$300.
March of Dimes Birth Defects Foundation Prematurity Prevention Initiative in Kentucky - Healthy Babies are Worth the Wait				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Obstetrics &amp; Gynecology</b>				
<b>Ferguson, James E</b>	3048104992	\$500,000.	\$0.	\$500,000.
National Institute on Drug Abuse Building Interdisciplinary Research Careers in Women's Health in Kentucky				
<b>Muse, Kenneth N</b>	3046856500	\$0.	\$2,171.	\$2,171.
Xanodyne Pharmaceuticals Inc A Twelve-Month, Open Label, Multicenter Study to Evaluate the Safety of a 1.3 g Oral Dose of a New Modified-Release Tranexamic Acid Formulation Administered Three Times Daily as Needed for up to 5 Days During the				
<b>Muse, Kenneth N</b>	3046856500	\$0.	\$2,289.	\$2,289.
Xanodyne Pharmaceuticals Inc A Twelve-Month, Open Label, Multicenter Study to Evaluate the Safety of a 1.3 g Oral Dose of a New Modified-Release Tranexamic Acid Formulation Administered Three Times Daily as Needed for up to 5 Days During the				
<b>Muse, Kenneth N</b>	3048078700	\$0.	\$10,364.	\$10,364.
Wyeth Pharmaceuticals Inc The Effect of Dose Titration and Dose Tapering on the Tolerability of DVS SR in Women With Vasomotor Symptoms Associated With Menopause				
<b>Muse, Kenneth N</b>	3048104346	\$0.	\$5,522.	\$5,522.
Bayer Pharmaceuticals A multicenter, double-blind, randomized, placebo-controlled study to determine the lowest effective dose of oral Angeliq for their relief of moderate to severe vasomotor symptoms in postmenopausal women over a treatment period of 12 weeks.				
<b>Muse, Kenneth N</b>	3048104346	\$0.	\$893.	\$893.
Bayer Pharmaceuticals A multicenter, double-blind, randomized, placebo-controlled study to determine the lowest effective dose of oral Angeliq for their relief of moderate to severe vasomotor symptoms in postmenopausal women over a treatment period of 12 weeks.				
<b>Muse, Kenneth N</b>	3048104346	\$0.	\$5,875.	\$5,875.
Bayer Pharmaceuticals A multicenter, double-blind, randomized, placebo-controlled study to determine the lowest effective dose of oral Angeliq for their relief of moderate to severe vasomotor symptoms in postmenopausal women over a treatment period of 12 weeks.				
<b>Muse, Kenneth N</b>	3048104346	\$0.	\$893.	\$893.
Bayer Pharmaceuticals A multicenter, double-blind, randomized, placebo-controlled study to determine the lowest effective dose of oral Angeliq for their relief of moderate to severe vasomotor symptoms in postmenopausal women over a treatment period of 12 weeks.				
<b>Muse, Kenneth N</b>	3048104346	\$0.	\$1,459.	\$1,459.
Bayer Pharmaceuticals A multicenter, double-blind, randomized, placebo-controlled study to determine the lowest effective dose of oral Angeliq for their relief of moderate to severe vasomotor symptoms in postmenopausal women over a treatment period of 12 weeks.				
<b>Muse, Kenneth N</b>	3048104346	\$0.	\$1,789.	\$1,789.
Bayer Pharmaceuticals A multicenter, double-blind, randomized, placebo-controlled study to determine the lowest effective dose of oral Angeliq for their relief of moderate to severe vasomotor symptoms in postmenopausal women over a treatment period of 12 weeks.				

**Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009**

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Obstetrics &amp; Gynecology</b>				
<b>Muse, Kenneth N</b>	3048104550	\$0.	\$6,134.	\$6,134.
Biosante Pharmaceuticals Inc A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Safety and Efficacy of Libigal for the Treatment of Hypoactive Sexual Disorder in Surgically Menopausal Women(testW008)				
<b>Muse, Kenneth N</b>	3048104551	\$0.	\$8,868.	\$8,868.
Biosante Pharmaceuticals Inc A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Long Term Safety and Efficacy of Libigal for the Treatment of Hypoactive Sexual Desire in Postmenopausal Women(testW007)				
<b>Muse, Kenneth N</b>	3048104793	\$2.	\$0.	\$2.
Wyeth Pharmaceuticals Inc A double-blind, randomized, placebo-controlled study assessing the safety and efficacy of DVS SR for the treatment of vasomotor symptoms associated with menopause				
<b>Ueland, Frederick R</b>	3046897300	\$0.	\$242.	\$242.
Gynecologic Oncology Group Gynecologic Oncology Group				
<b>Ueland, Frederick R</b>	3046897300	\$0.	\$17,424.	\$17,424.
Gynecologic Oncology Group Gynecologic Oncology Group				
<b>Ueland, Frederick R</b>	3046897300	\$0.	\$15,840.	\$15,840.
Gynecologic Oncology Group Gynecologic Oncology Group				
<b>Ueland, Frederick R</b>	3046897300	\$0.	\$13,288.	\$13,288.
Gynecologic Oncology Group Gynecologic Oncology Group				
<b>Ueland, Frederick R</b>	3048098500	\$0.	\$5,166.	\$5,166.
PrecisionMed Inc Whole Blood Protocol for OvaRI Assay Clinical Trial in Women with Ovarian Tumors				
<b>Ueland, Frederick R</b>	3048098700	\$0.	\$353.	\$353.
PrecisionMed Inc CLD2: To Compare the Effect of Different Type BD Vacutainer TUNes on OvaRi Assay				
<b>Ueland, Frederick R</b>	3048103872	\$0.	\$4,007.	\$4,007.
Genentech Inc A Phase II, Multicenter, Randomized, Blinded, Placebo-Controlled Trial of Carboplatin and Gencitabine Plus Bevacizumab in Patients with Platinum-Sensitive Recurrent Ovary, Promary Peritoneal, or Fallopian Tube Carcinoma				
<b>Ueland, Frederick R</b>	3048103872	\$0.	\$3,000.	\$3,000.
Genentech Inc A Phase II, Multicenter, Randomized, Blinded, Placebo-Controlled Trial of Carboplatin and Gencitabine Plus Bevacizumab in Patients with Platinum-Sensitive Recurrent Ovary, Promary Peritoneal, or Fallopian Tube Carcinoma				
<b>VanNagell, John R</b>	3048105004	\$975,000.	\$0.	\$975,000.
KY Council on Postsecondary Education Ovarian Cancer Screening in Kentucky				
<b>Obstetrics &amp; Gynecology</b>	<b>Totals:</b>	<b>\$1,475,002.</b>	<b>\$105,877.</b>	<b>\$1,580,879.</b>

## Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Pediatrics</b>				
<b>Anstead, Michael I</b>	3048103215	\$0.	\$18,199.	\$18,199.
PPD Development Inc Multi-center, multi-national, randomized, placebo-controlled trial of Azithromycin in participants with Cystic Fibrosis 6-18 years old, Culter negative for Pseudomonas aeruginosa				
<b>Anstead, Michael I</b>	3048103215	\$0.	\$7,542.	\$7,542.
PPD Development Inc Multi-center, multi-national, randomized, placebo-controlled trial of Azithromycin in participants with Cystic Fibrosis 6-18 years old, Culter negative for Pseudomonas aeruginosa				
<b>Bada, Henrietta S</b>	3048103645	\$0.	\$7,700.	\$7,700.
Yale University Gene Targets for Prevention of Intraventricular Hemorrhage				
<b>Bada, Henrietta S</b>	3048104832	\$384,350.	\$0.	\$384,350.
KY Health Services Cabinet Infant Intensive Care				
<b>Bada, Henrietta S</b>	3048105011	\$0.	\$3,500.	\$3,500.
Yale University Gene Targets for Prevention of Intraventricular Hemorrhage				
<b>Bada, Henrietta S</b>	3048105011	\$36,273.	\$0.	\$36,273.
Yale University Gene Targets for Prevention of Intraventricular Hemorrhage				
<b>Bada, Henrietta S</b>	3048105285	\$22,083.	\$0.	\$22,083.
University of Tennessee Maternal Lifestyle Study Phase 4				
<b>Bay, Carolyn A</b>	3048104937	\$188,400.	\$0.	\$188,400.
KY Health Services Cabinet Genetic Services				
<b>Bayliff, Sherry L</b>	3048105102	\$0.	\$2,998.	\$2,998.
Quintiles Inc Randomized, Double-Blind, Placebo-Controlled Study of Efficacy and Safety of Donepezil Hydrochloride in Preadolescent and Adolescent Children with Attention Impairment Following Cancer Treatment				
<b>Bayliff, Sherry L</b>	3048105102	\$2.	\$0.	\$2.
Quintiles Inc Randomized, Double-Blind, Placebo-Controlled Study of Efficacy and Safety of Donepezil Hydrochloride in Preadolescent and Adolescent Children with Attention Impairment Following Cancer Treatment				
<b>Bricker, J Timothy</b>	3048104839	\$288,601.	\$0.	\$288,601.
KY Health Services Cabinet Newborn Screening				
<b>Greenwood, Martha F</b>	3048104875	\$0.	\$13,993.	\$13,993.
National Childhood Cancer Foundation Children's Oncology Group				
<b>Greenwood, Martha F</b>	3048104875	\$2.	\$0.	\$2.
National Childhood Cancer Foundation Children's Oncology Group				

## Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Pediatrics</b>				
<b>Hayes, Don</b>	3048103855	\$0.	\$2,013.	\$2,013.
Novartis A Randomized, Open-Label, Multicenter, Phase 3 Trial to Assess the Safety of Tobramycin Inhalation Powder Comparec to TOBI in Cystic Fibrosis Subjects				
<b>Hayes, Don</b>	3048103855	\$0.	\$3,036.	\$3,036.
Novartis A Randomized, Open-Label, Multicenter, Phase 3 Trial to Assess the Safety of Tobramycin Inhalation Powder Comparec to TOBI in Cystic Fibrosis Subjects				
<b>Hayes, Don</b>	3048105362	\$12,000.	\$0.	\$12,000.
American Academy of Pediatrics Kentucky Asthma Management Program				
<b>Kanga, Jamshed F</b>	3046872500	\$0.	\$1,027.	\$1,027.
Cystic Fibrosis Foundation The EPIC Clinical Study: Effectiveness and Safety of Intermittent Antimicrobial Therapy for the Treatment of New Onset Pseudomonas Aeruginosa (Pa) Airway Infection in Young Patients with Cystic Fibrosis				
<b>Kanga, Jamshed F</b>	3048087000	\$0.	\$26,950.	\$26,950.
Inspire Pharmaceuticals A Multicenter, Double-Blind, Palcebo Controlled, Randomized, Efficacy and Safety Study of Denufosol Tetrasodium (INS37217) Inhalation Solution in Patients with Mild Cystic Fibrosis Lung Disease				
<b>Kanga, Jamshed F</b>	3048104070	\$0.	\$5,400.	\$5,400.
Cystic Fibrosis Foundation Cystic Fibrosis Research TDN Grant				
<b>Kanga, Jamshed F</b>	3048104457	\$0.	\$6,294.	\$6,294.
Altus Pharmaceuticals Inc. A Phase III Randomized Double-Blind Placebo-Controlled Clinnical Study Evaluating the Efficacy and Safety of ALTU-135 Treatment in Patients with Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency				
<b>Kanga, Jamshed F</b>	3048104823	\$111,365.	\$0.	\$111,365.
Cystic Fibrosis Foundation Cystic Fibrosis Center Program				
<b>Kanga, Jamshed F</b>	3048105098	\$2.	\$0.	\$2.
Inspire Pharmaceuticals A Phase 3, International, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Study of Denufosol Tetrasodium Inhalation Solution in Patients with Cystic Fibrosis Lung Disease and FEV <sub>1</sub> => 75% but =<110% Predicted				
<b>Landers, Cheri D</b>	3046775600	\$0.	\$500.	\$500.
Childrens Hospital Foundation Genomic Analysis of Pediatric Systemic Inflammatory Response Syndrome (SIRS)				
<b>Li, Xiangan</b>	3048104962	\$230,738.	\$0.	\$230,738.
National Institute of General Medical Sciences Role of SR-BI LPS detoxification				
<b>Liu, Jun</b>	3048105084	\$146,500.	\$0.	\$146,500.
National Institute Diabetes & Digestive & Kidney The Roles of Integrin Receptors in Adipocyte Differentiation				

**Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Medicine</u></b>				
<b><u>Pediatrics</u></b>				
<b>Lomenick, Jefferson</b>	3048015500	\$0.	\$200.	\$200.
AstraZeneca Pharmaceuticals An Open -Label, Non-Comparative Trial to Evaluate the Saefty, Efficacy and Pharmacokinetics of FASLODEX (Fulvestrant) in Girls with Progressive Precocious Puberty Associated with McCune-Albright Syndrome				
<b>Moscow, Jeffrey</b>	3048104214	\$0.	\$150,000.	\$150,000.
Susan G Komen Breast Cancer Foundation Thiamine Starvation with Thiaminase I for Breast Cancer Therapy				
<b>Moscow, Jeffrey</b>	3048104680	\$170,800.	\$0.	\$170,800.
KY Commission for Children with Special Health Comprehensive Diagnosis				
<b>Moscow, Jeffrey</b>	3048104681	\$2,000.	\$0.	\$2,000.
KY Commission for Children with Special Health Comprehensive Hemophilia Program				
<b>Moscow, Jeffrey</b>	3048104776	\$2.	\$0.	\$2.
AAIPharma Inc An Open-Label Study to Assess the Pharmacokinetics of Leucovorin in Patients Receiving High Dose Methotrexate, with or without Voraxaze Treatment.				
<b>Omar, Hatim</b>	3048105047	\$303,094.	\$0.	\$303,094.
KY Health Services Cabinet Young Parents Program				
<b>Perman, Jay A</b>	3048105239	\$73,250.	\$0.	\$73,250.
National Institute of Child Health and Human Develop Academic-Community Coalition for a School-Based Obesity Prevention/Treatment Program				
<b>Perman, Jay A</b>	3048105240	\$25,000.	\$0.	\$25,000.
KY Diabetes Research Trust Fund Academic-Community Coalition for a School-Based Obesity Prevention/Treatment Program				
<b>Pinkstaff, Thomas H</b>	3048104765	\$390,592.	\$0.	\$390,592.
KY Health Services Cabinet Medically Fragile Foster Family Practice FY09				
<b>Radulescu, Vlad</b>	3048104276	\$0.	\$800.	\$800.
Covance Hemophilia and Thrombosis Research Registry				
<b>Radulescu, Vlad</b>	3048105090	\$2.	\$0.	\$2.
Grifols Biologicals Inc A Postmarketing Observational Study to Assess the Efficacy and Safety of the Factor VIII/von Willebrand Factor Complex (Human), Alphanate, in Preventing Excessive Bleeding During Surgery in Subjects with Congenital Type 3 von Willebrand Disease				
<b>Radulescu, Vlad</b>	3048105260	\$2.	\$0.	\$2.
Baxter Healthcare Co A Phase I, Randomized, Crossover Study to Compare the Pharmacokinetics and Daefy of rAHF-PFM Reconstituted in 2mL versus 5mL in Previously Treated Severe Hemophilia A Patients				

**Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Medicine</u></b>				
<b><u>Pediatrics</u></b>				
<b>Radulescu, Vlad</b>	3048105316	\$18,196.	\$0.	\$18,196.
American Thrombosis and Hemostasis Network ATHNdata.quality.Counts				
<b>Radulescu, Vlad</b>	3048105393	\$2.	\$0.	\$2.
Novartis reGISTry				
<b>Reynolds, Eric W</b>	3048065500	\$0.	\$108,000.	\$108,000.
National Institute of Child Health and Human Develop Cervical (Neck) Auscultation and Development Outcomes				
<b>Shashidhar, Harohalli</b>	3048059500	\$0.	\$-1,179.	\$-1,179.
Wyeth Pharmaceuticals Inc A Multi-Center, Open -label Pharmacokintic, Pharmacodynamic, Clinical Synptoms, and Safety Study of Pantoprazole Delayed-Released Granules Administered as A Suspension in Neonates and Preterm Infants with a Clinical Diagnosis of Gatroesophageal Disease.				
<b>Shashidhar, Harohalli</b>	3048072400	\$0.	\$-2,248.	\$-2,248.
Wyeth Pharmaceuticals Inc A Multicenter, Randomized Double-Blind Study of the Clinical Outcomes, Safety and Tolerability of Multiple Doses of Pantoprazole Sodium Enteric-coated Spheroids in Children Ages 1 to 5				
<b>Smart, Eric J</b>	3048048400	\$0.	\$285,783.	\$285,783.
National Institute Diabetes & Digestive & Kidney Protective Effects of Stearic Acid on Gestational and Acquired Diabetes Mellitus				
<b>Wallace, Carmel</b>	3048105110	\$432,900.	\$0.	\$432,900.
KY Cabinet for Health and Family Services Pediatric Assessment, Case Management and Training				
<b>Young, Thomas L</b>	3048104762	\$16,000.	\$0.	\$16,000.
Lexington Fayette County Health Department William Wells Brown Elementary School Center				
<b>Young, Thomas L</b>	3048104764	\$16,000.	\$0.	\$16,000.
Lexington Fayette County Health Department Arlington Elementary School Center				
<b>Young, Thomas L</b>	3048104766	\$8,000.	\$0.	\$8,000.
Lexington Fayette County Health Department Tates Creek Elementary School Center				
<b>Young, Thomas L</b>	3048104833	\$31,200.	\$0.	\$31,200.
Lexington Fayette County Health Department Harrison Elementary School Center				
<b>Pediatrics</b>	<b>Totals:</b>	<b>\$2,907,356.</b>	<b>\$640,508.</b>	<b>\$3,547,864.</b>
<b><u>Molecular &amp; Biomedical Pharmacology</u></b>				
<b>Kaetzal, David M</b>	3048058700	\$0.	\$203,946.	\$203,946.
National Cancer Institute Molecular Mechanisms of Metastasis Suppression by NM23				

## Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b><u>Molecular &amp; Biomedical Pharmacology</u></b>				
<b>Landfield, Philip W</b>	3046818000	\$0.	\$1,621,491.	\$1,621,491.
National Institute on Aging Calcium Regulation in Brain Aging and Alzheimer's Disease - Core A				
<b>Plattner, Rina</b>	3048103677	\$0.	\$269,444.	\$269,444.
National Cancer Institute ABI kinases in growth factor signaling, motility, and invasion.				
<b>Swanson, Hollie</b>	3048042200	\$0.	\$260,130.	\$260,130.
National Institute of Environmental Health Sciences AHR-Protac, a Novel Aryl Hydrocarbon Receptor Antagonist				
<b>Molecular &amp; Biomedical Pharmacology</b>	<b>Totals:</b>	<b>\$0.</b>	<b>\$2,355,011.</b>	<b>\$2,355,011.</b>
<b><u>Physiology</u></b>				
<b>Andrade, Francisco H</b>	3048104851	\$28,132.	\$0.	\$28,132.
National Institute of General Medical Sciences NRSA Fellowship for Gamboa: Skeletal Muscle Adaptation to Hypoxia				
<b>Andrade, Francisco H</b>	3048105205	\$329,625.	\$0.	\$329,625.
National Eye Institute Determinants of Extraocular Muscle Function				
<b>Campbell, Kenneth S</b>	3048105039	\$329,625.	\$0.	\$329,625.
National Heart Lung and Blood Institute Myocardial Stiffness in Diastolic Heart Failure				
<b>Delisle, Brian P.</b>	3048104544	\$0.	-\$65,000.	-\$65,000.
American Heart Association Abnormal Protein Folding caused by KCNH2 Mutations with Long QT Syndrome				
<b>Delisle, Brian P.</b>	3048104544	\$0.	\$65,000.	\$65,000.
American Heart Association Abnormal Protein Folding caused by KCNH2 Mutations with Long QT Syndrome				
<b>Delisle, Brian P.</b>	3048105124	\$65,000.	\$0.	\$65,000.
American Heart Association Abnormal Protein Folding caused by KCNH2 Mutations with Long QT Syndrome				
<b>Derbenev, Andrei V.</b>	3048105032	\$60,500.	\$0.	\$60,500.
American Heart Association Great Rivers Affiliate Regulation of Presympathetic RVLM Neurons by Cannabinoids				
<b>Esser, Karyn A</b>	3048105059	\$43,000.	\$0.	\$43,000.
American Heart Association Great Rivers Affiliate Fellowship Miyazaki: Hypertension, Skeletal Muscle Disease and the Circadian Clock				
<b>Frazier, Donald T</b>	3048104948	\$118,789.	\$0.	\$118,789.
National Institute of General Medical Sciences Interactive Learning Modules for Writing Grant Proposals				
<b>Frolenkov, Gregory I</b>	3048105300	\$0.	\$49,444.	\$49,444.
National Institute on Deafness & Other Communications Role of Staircase Hair Bundle Morphology in Auditory Mechanotransduction				

## Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Physiology</b>				
<b>Frolenkov, Gregory I</b>	3048105300	\$280,181.	\$0.	\$280,181.
National Institute on Deafness & Other Communications Role of Staircase Hair Bundle Morphology in Auditory Mechanotransduction				
<b>Gu, Qihai</b>	3048105048	\$73,250.	\$0.	\$73,250.
National Institute of Allergy and Infectious Diseases PAR2, Bronchopulmonary Sensory Nerve and Pathogenesis of Asthma				
<b>GU, QIHAI</b>	3048104860	\$77,000.	\$0.	\$77,000.
American Heart Association Modulation of Acid Sensing in Pulmonary C-Fiber Sensory Nerves by Protease-activated Receptor-2				
<b>Lee, Lu Yuan</b>	3046925700	\$0.	\$235,419.	\$235,419.
National Heart Lung and Blood Institute Chemosensitivity of Tachykinin-Containing Lung Afferents				
<b>Nikolova-Karakashian, Mariana</b>	3048103526	\$0.	\$21,000.	\$21,000.
American Heart Association Ohio Valley Affiliate Rozenova Fellowship: The role of Acid Sphingomyelinase as a regulator of TNF-alpha levels in endotoxic shock model				
<b>Reid, Michael B</b>	3048103527	\$0.	\$44,000.	\$44,000.
American Heart Association Ohio Valley Affiliate Fellowship: Leonardo Ferreira: Intracellular Signaling of Cytokine Stimulated Protein Degradation in Skeletal Muscle				
<b>Reid, Michael B</b>	3048105233	\$329,625.	\$0.	\$329,625.
National Space Biomedical Research Institute Redox Modulation of Skeletal Muscle Function in Microgravity				
<b>Satin, Jonathan</b>	3048103529	\$0.	\$21,000.	\$21,000.
American Heart Association Ohio Valley Affiliate Byse Fellowship: The L-Type Calcium Channel as a Signaling Molecule in Cardiac Development				
<b>Smart, Eric J</b>	3048103528	\$0.	\$21,000.	\$21,000.
American Heart Association Ohio Valley Affiliate Fellowship for Bradshaw: EG-VEGF Mediated Angiogenesis				
<b>Smith, Bret N.</b>	3048104952	\$219,750.	\$0.	\$219,750.
National Institute Diabetes & Digestive & Kidney Neural circuitry in the dorsal vagal complex				
<b>Smith, George M</b>	3046853900	\$0.	\$262,199.	\$262,199.
National Institute of Neurological Disorders & Stroke Axonal Growth and Guidance for Nervous System Repair				
<b>Smith, George M</b>	3046853900	\$0.	\$58,266.	\$58,266.
National Institute of Neurological Disorders & Stroke Axonal Growth and Guidance for Nervous System Repair				
<b>Snyder, Carol T</b>	3048011900	\$0.	\$24,428.	\$24,428.
KY Council on Postsecondary Education Professional Education Preparation Program				

**Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009**

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Physiology</b>				
<b>Snyder, Carol T</b>	3048104856	\$137,500.	\$0.	\$137,500.
KY Council on Postsecondary Education Professional Education Preparation Program (PEPP)				
<b>Stocker, Sean D</b>	3048105094	\$21,000.	\$0.	\$21,000.
American Heart Association Great Rivers Affiliate Fellowship Bardgett: Neural Mechanisms of Sympathetic Activation During Hyperinsulinemia and Obesity-Induced Hypertension				
<b>Physiology</b>	<b>Totals:</b>	<b>\$2,112,977.</b>	<b>\$736,756.</b>	<b>\$2,849,733.</b>
<b>Psychiatry</b>				
<b>Carvalho, Cletus Savio</b>	3048011800	\$0.	\$2,520.	\$2,520.
Bristol Myers Squibb Company A Multicenter, Double-Blind, Study on the Efficacy and Safety of Aripiprazole in Combination				
<b>De Leon, Jose</b>	3048103703	\$0.	\$83,997.	\$83,997.
Genomas Inc SBIR: DNA Diagnostics for Minimizing Side-Effects of Psychotropics				
<b>Glaser, Paul E</b>	3046986400	\$0.	\$9,324.	\$9,324.
Eli Lilly and Company Study of Atomoxetine HC1 in Treatment of Adults with ADHD & Comorbid Social Anxiety				
<b>Glaser, Paul E</b>	3048103808	\$0.	\$1,685.	\$1,685.
Eli Lilly and Company A Double Blind Study of Atomoxetine Hydrochloride vs. Placebo for the Treatment of ADHA in Young Adults with an Assessment of Associated Functional Outcomes				
<b>Glaser, Paul E</b>	3048103808	\$0.	\$20,658.	\$20,658.
Eli Lilly and Company A Double Blind Study of Atomoxetine Hydrochloride vs. Placebo for the Treatment of ADHA in Young Adults with an Assessment of Associated Functional Outcomes				
<b>Glaser, Paul E</b>	3048103808	\$0.	\$6,837.	\$6,837.
Eli Lilly and Company A Double Blind Study of Atomoxetine Hydrochloride vs. Placebo for the Treatment of ADHA in Young Adults with an Assessment of Associated Functional Outcomes				
<b>Glaser, Paul E</b>	3048103808	\$0.	\$6,263.	\$6,263.
Eli Lilly and Company A Double Blind Study of Atomoxetine Hydrochloride vs. Placebo for the Treatment of ADHA in Young Adults with an Assessment of Associated Functional Outcomes				
<b>Glaser, Paul E</b>	3048103808	\$0.	\$6,467.	\$6,467.
Eli Lilly and Company A Double Blind Study of Atomoxetine Hydrochloride vs. Placebo for the Treatment of ADHA in Young Adults with an Assessment of Associated Functional Outcomes				
<b>Glaser, Paul E</b>	3048103808	\$0.	\$3,771.	\$3,771.
Eli Lilly and Company A Double Blind Study of Atomoxetine Hydrochloride vs. Placebo for the Treatment of ADHA in Young Adults with an Assessment of Associated Functional Outcomes				

**Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009**

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Psychiatry</b>				
<b>Glaser, Paul E</b>	3048103808	\$0.	\$18,152.	\$18,152.
Eli Lilly and Company A Double Blind Study of Atomoxetine Hydrochloride vs. Placebo for the Treatment of ADHA in Young Adults with an Assessment of Associated Functional Outcomes				
<b>Glaser, Paul E</b>	3048103808	\$0.	\$11,429.	\$11,429.
Eli Lilly and Company A Double Blind Study of Atomoxetine Hydrochloride vs. Placebo for the Treatment of ADHA in Young Adults with an Assessment of Associated Functional Outcomes				
<b>Glaser, Paul E</b>	3048103808	\$0.	\$4,635.	\$4,635.
Eli Lilly and Company A Double Blind Study of Atomoxetine Hydrochloride vs. Placebo for the Treatment of ADHA in Young Adults with an Assessment of Associated Functional Outcomes				
<b>Glaser, Paul E</b>	3048103808	\$0.	\$8,812.	\$8,812.
Eli Lilly and Company A Double Blind Study of Atomoxetine Hydrochloride vs. Placebo for the Treatment of ADHA in Young Adults with an Assessment of Associated Functional Outcomes				
<b>Glaser, Paul E</b>	3048103808	\$0.	\$12,087.	\$12,087.
Eli Lilly and Company A Double Blind Study of Atomoxetine Hydrochloride vs. Placebo for the Treatment of ADHA in Young Adults with an Assessment of Associated Functional Outcomes				
<b>Kaak, Hans O</b>	3048105254	\$10,000.	\$0.	\$10,000.
KY Cabinet for Health and Family Services UK CATS Project SJPC: Early Mental Health Training				
<b>Lofwall, Michelle Renee</b>	3048103695	\$0.	\$1,075.	\$1,075.
CRS Associates LLC Product Familiarity Interview: Post marketing Surveillance Project for Subutex and Suboxone				
<b>Martin, Catherine A</b>	3048104416	\$0.	\$42,501.	\$42,501.
Yaupon Therapeutics Inc SBIR: Lobeline Clinical Study in ADHD				
<b>Psychiatry Totals:</b>		<b>\$10,000.</b>	<b>\$240,213.</b>	<b>\$250,213.</b>
<b>Surgery</b>				
<b>Bernard, Andrew C</b>	3046779000	\$0.	\$-12,180.	\$-12,180.
Northfield Laboratories A Phase III Randomized, Controlled, Open-Label, Multicenter, Parallel Group Study Using Provisions for Exception from Informed Consent Requirements Designed to Evaluate the Safety and Efficacy of Poly SFH-P Injection				
<b>Bernard, Andrew C</b>	3046779000	\$0.	\$1,272.	\$1,272.
Northfield Laboratories A Phase III Randomized, Controlled, Open-Label, Multicenter, Parallel Group Study Using Provisions for Exception from Informed Consent Requirements Designed to Evaluate the Safety and Efficacy of Poly SFH-P Injection				
<b>Bernard, Andrew C</b>	3048104408	\$0.	\$92,595.	\$92,595.
AstraZeneca Pharmaceuticals A Placebo-Controlled, Double-Blind, Dose-Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Intravenous Infusions of CytoFab (AZD9773) in Patients with Severe Sepsis				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Surgery</b>				
<b>Bernard, Andrew C</b>	3048104408	\$0.	\$2,000.	\$2,000.
AstraZeneca Pharmaceuticals A Placebo-Controlled, Double-Blind, Dose-Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Intravenous Infusions of CytoFab (AZD9773) in Patients with Severe Sepsis				
<b>Bernard, Andrew C</b>	3048104408	\$0.	\$3,240.	\$3,240.
AstraZeneca Pharmaceuticals A Placebo-Controlled, Double-Blind, Dose-Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Intravenous Infusions of CytoFab (AZD9773) in Patients with Severe Sepsis				
<b>Bernard, Andrew C</b>	3048104408	\$0.	\$28,108.	\$28,108.
AstraZeneca Pharmaceuticals A Placebo-Controlled, Double-Blind, Dose-Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Intravenous Infusions of CytoFab (AZD9773) in Patients with Severe Sepsis				
<b>Bernard, Andrew C</b>	3048105127	\$2.	\$0.	\$2.
Pfizer Inc Prospective Evaluation of Sputum Staphylococcus Aureus Resistance Patterns				
<b>Bonnell, Mark</b>	3048105264	\$0.	\$6,298.	\$6,298.
Levitronix LLC Levitronix CentriMag VAS Failure-to-Wean from Cardiopulmonary Bypass Trial				
<b>Bonnell, Mark</b>	3048105264	\$2.	\$0.	\$2.
Levitronix LLC Levitronix CentriMag VAS Failure-to-Wean from Cardiopulmonary Bypass Trial				
<b>Chang, Phillip K</b>	3048105310	\$2.	\$0.	\$2.
Canica Design Inc A Prospective Evaluation of ABRA Abdominal Wall Closure System in Combination with V.A.C. Therapy Compared V.A.C. Therapy Alone in the Management of Open Abdomen				
<b>Ferraris, Victor</b>	3048079900	\$0.	\$6,150.	\$6,150.
Medicure Inc A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Cardioprotective Effects of MC-1 in Patients Undergoing High-Risk coronary Artery Bypass Graft (CABG) Surgery				
<b>Ferraris, Victor</b>	3048079900	\$0.	\$-6,150.	\$-6,150.
Medicure Inc A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Cardioprotective Effects of MC-1 in Patients Undergoing High-Risk coronary Artery Bypass Graft (CABG) Surgery				
<b>Ferraris, Victor</b>	3048079900	\$0.	\$6,150.	\$6,150.
Medicure Inc A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Cardioprotective Effects of MC-1 in Patients Undergoing High-Risk coronary Artery Bypass Graft (CABG) Surgery				
<b>Ferraris, Victor</b>	3048079900	\$0.	\$-2,000.	\$-2,000.
Medicure Inc A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Cardioprotective Effects of MC-1 in Patients Undergoing High-Risk coronary Artery Bypass Graft (CABG) Surgery				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Surgery</b>				
<b>Gagliardi, Raymond</b>	3048104040	\$0.	\$70,000.	\$70,000.
United States Surgical Corp Tyco Healthcare Minimally Invasive Surgery Fellowship				
<b>HANNA, NADER</b>	3046440200	\$0.	\$18,085.	\$18,085.
GenVec Inc GV 001.002.An Open-Label, Phase I, Dose-Escalation Study of Tumor Necrosis Factor-alpha (TNFerade Biologic) Gene Therapy with Radiation for Locally Advanced, Recurrent or Metastatic Solid Tumors				
<b>HANNA, NADER</b>	3046561400	\$0.	\$12,121.	\$12,121.
GenVec Inc An Open Label Phase 1 Dose-Escalation Study of TNFerade Biologic with Radiation Therapy as an Adjunct to Surgery or for Palliation in Soft Tissue Sarcoma of the Extremities				
<b>Jeon, Hoonbae</b>	3048103203	\$0.	\$4,198.	\$4,198.
Albert Einstein College of Medicine Cellcept (Mycophenolate Mofetil, MMF) Maintenance Immunosuppression in Liver Transplant Recipients with Long-Term Follow-up Post-Transplantation for Non Autoimmune				
<b>Johnston, Thomas</b>	3046661300	\$0.	\$2,910.	\$2,910.
Wyeth Research A Randomized, Open-Label, Comparative Evaluation of Conversion from Calcineurin Inhibitors to Sirolimus vs Continued use of Calcineurin inhibitors in Renal Allograft Recipients				
<b>Johnston, Thomas</b>	3046661300	\$0.	\$456.	\$456.
Wyeth Research A Randomized, Open-Label, Comparative Evaluation of Conversion from Calcineurin Inhibitors to Sirolimus vs Continued use of Calcineurin inhibitors in Renal Allograft Recipients				
<b>Johnston, Thomas</b>	3046661300	\$0.	\$-16,999.	\$-16,999.
Wyeth Research A Randomized, Open-Label, Comparative Evaluation of Conversion from Calcineurin Inhibitors to Sirolimus vs Continued use of Calcineurin inhibitors in Renal Allograft Recipients				
<b>Johnston, Thomas</b>	3046771800	\$0.	\$2,687.	\$2,687.
Novartis DIRECT-Study: Diabetes Incidence after Renal Transplantation Neoral C-2 Monitoring versus Tacrolimus				
<b>Johnston, Thomas</b>	3046816700	\$0.	\$16,999.	\$16,999.
Wyeth Pharmaceuticals Inc A Randomized, Open-label Study to Compare the Safety and Efficacy of Two Different Rapamune Regimens with a Tacrolimus + Mycophenolate Mofetil Regimen in De Novo Renal Allograft Recipients				
<b>Johnston, Thomas</b>	3046816700	\$0.	\$732.	\$732.
Wyeth Pharmaceuticals Inc A Randomized, Open-label Study to Compare the Safety and Efficacy of Two Different Rapamune Regimens with a Tacrolimus + Mycophenolate Mofetil Regimen in De Novo Renal Allograft Recipients				
<b>Johnston, Thomas</b>	3046944500	\$0.	\$25,704.	\$25,704.
Novartis A 24-month, Multicenter, Randomized, Open Label Non-Inferiority Study of Efficacy and Safety Comparing Concentration Controlled Certican in Two Doses (1.5 and 3.0mg/day starting doses) with Reduced Neoral versus 1.44 Myfortic with Standard Dose Neoral				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Surgery</b>				
<b>Johnston, Thomas</b>	3046944500	\$0.	\$5,017.	\$5,017.
Novartis A 24-month, Multicenter, Randomized, Open Label Non-Inferiority Study of Efficacy and Safety Comparing Concentration Controlled Certican in Two Doses (1.5 and 3.0mg/day starting doses) with Reduced Neoral versus 1.44 Myfortic with Standard Dose Neoral				
<b>Johnston, Thomas</b>	3048064300	\$0.	\$2,856.	\$2,856.
Bristol Myers Squibb Company Belatacept Evaluation of Nephroprotection and Efficacy as First-Line Immunosuppression Trial (BENEFIT) BMS IM103008				
<b>Johnston, Thomas</b>	3048064300	\$0.	\$1,029.	\$1,029.
Bristol Myers Squibb Company Belatacept Evaluation of Nephroprotection and Efficacy as First-Line Immunosuppression Trial (BENEFIT) BMS IM103008				
<b>Johnston, Thomas</b>	3048104315	\$0.	\$6,360.	\$6,360.
Bristol Myers Squibb Company A Randomized, Open-Label, Multicenter, Parallel-Group Study of Belatacept-Based Corticosteroid-Free Regimens in Renal Transplant				
<b>Kearney, Paul A</b>	3046969400	\$0.	\$9,339.	\$9,339.
Pfizer Inc Linezolid in the Treatment of Subjects iwth Nosocomial Pneumonia Proven to be due to Methicillin-Resistant Staphylococcus Aureus				
<b>Kearney, Paul A</b>	3048104280	\$0.	\$21,468.	\$21,468.
Wyeth Pharmaceuticals Inc A Multicenter, Randomized, Double-Blind, Placebo Controlled, Paralledl-Group Study of Intravenous Methylnaltrexone (MOA-728) for the Treatment of Postoperative Ileus After Ventral Hernia Repair				
<b>Kearney, Paul A</b>	3048104280	\$0.	\$1,148.	\$1,148.
Wyeth Pharmaceuticals Inc A Multicenter, Randomized, Double-Blind, Placebo Controlled, Paralledl-Group Study of Intravenous Methylnaltrexone (MOA-728) for the Treatment of Postoperative Ileus After Ventral Hernia Repair				
<b>Kenady, Daniel E</b>	3046633200	\$0.	\$1,729.	\$1,729.
GenVec Inc A Randomized, Phase II, Study of TNFerade Biologic with-5-FU and Radiation Therapy for First-Line Treatment of Unresectable Locally Advanced Pancreatic Cancer				
<b>Kenady, Daniel E</b>	3046633200	\$0.	\$938.	\$938.
GenVec Inc A Randomized, Phase II, Study of TNFerade Biologic with-5-FU and Radiation Therapy for First-Line Treatment of Unresectable Locally Advanced Pancreatic Cancer				
<b>Kenady, Daniel E</b>	3046633200	\$0.	\$8,463.	\$8,463.
GenVec Inc A Randomized, Phase II, Study of TNFerade Biologic with-5-FU and Radiation Therapy for First-Line Treatment of Unresectable Locally Advanced Pancreatic Cancer				
<b>Kenady, Daniel E</b>	3046633200	\$0.	\$50.	\$50.
GenVec Inc A Randomized, Phase II, Study of TNFerade Biologic with-5-FU and Radiation Therapy for First-Line Treatment of Unresectable Locally Advanced Pancreatic Cancer				

## Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Surgery</b>				
<b>Kenady, Daniel E</b>	3046633200	\$0.	\$156.	\$156.
GenVec Inc A Randomized, Phase II, Study of TNFerade Biologic with-5-FU and Radiation Therapy for First-Line Treatment of Unresectable Locally Advanced Pancreatic Cancer				
<b>Kenady, Daniel E</b>	3046633200	\$0.	\$1,633.	\$1,633.
GenVec Inc A Randomized, Phase II, Study of TNFerade Biologic with-5-FU and Radiation Therapy for First-Line Treatment of Unresectable Locally Advanced Pancreatic Cancer				
<b>Kenady, Daniel E</b>	3046633200	\$0.	\$1,729.	\$1,729.
GenVec Inc A Randomized, Phase II, Study of TNFerade Biologic with-5-FU and Radiation Therapy for First-Line Treatment of Unresectable Locally Advanced Pancreatic Cancer				
<b>Kenady, Daniel E</b>	3046633200	\$0.	\$13,867.	\$13,867.
GenVec Inc A Randomized, Phase II, Study of TNFerade Biologic with-5-FU and Radiation Therapy for First-Line Treatment of Unresectable Locally Advanced Pancreatic Cancer				
<b>Kenady, Daniel E</b>	3046633200	\$0.	\$16,788.	\$16,788.
GenVec Inc A Randomized, Phase II, Study of TNFerade Biologic with-5-FU and Radiation Therapy for First-Line Treatment of Unresectable Locally Advanced Pancreatic Cancer				
<b>Kenady, Daniel E</b>	3046919900	\$0.	\$2,658.	\$2,658.
IRx Therapeutics Inc A Phase 2, Open Label Trial of the Safety and Biological Effect of Pre-Operative Peri-Lymphatic Ultralow Dose of IRX-2 (with Cyclophamide, Indomethacin, and Zinc) in Patients with Locally Advanced, Resectable Cancer of the Head and Neck				
<b>Kenady, Daniel E</b>	3046919900	\$0.	\$939.	\$939.
IRx Therapeutics Inc A Phase 2, Open Label Trial of the Safety and Biological Effect of Pre-Operative Peri-Lymphatic Ultralow Dose of IRX-2 (with Cyclophamide, Indomethacin, and Zinc) in Patients with Locally Advanced, Resectable Cancer of the Head and Neck				
<b>Kyprianou, Natasha</b>	3048105153	\$437,021.	\$0.	\$437,021.
US Army Medical Research and Materiel Command Biomarker Discovery and Mechanistic Studies of Prostate Cancer using Targeted Proteomic Approaches				
<b>Kyprianou, Natasha</b>	3048105187	\$30,000.	\$0.	\$30,000.
American Urological Association Foundation Fellowship for Sakamoto: The Role of Talin in Prostate Cancer Progression				
<b>McKeown, John W</b>	3046972800	\$0.	\$10,000.	\$10,000.
Isotechnika Inc A Phase IIb, Randomized, Multicenter, Open-Label, Concentration-Controlled, Safety Study of ISA247 and Tacrolimus (Prograf) in De Novo Renal Transplant Patients				
<b>McKeown, John W</b>	3046972800	\$0.	\$3,150.	\$3,150.
Isotechnika Inc A Phase IIb, Randomized, Multicenter, Open-Label, Concentration-Controlled, Safety Study of ISA247 and Tacrolimus (Prograf) in De Novo Renal Transplant Patients				

**Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009**

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Surgery</b>				
<b>Minion, David</b>	3046336100	\$0.	\$9,096.	\$9,096.
Edwards Lifesciences Pivotal, Multicenter, Prospective, Concurrent Control, Non Randomized Trial to Evaluate the Safety and Effectiveness of the Baxter Lifepath AAA Bifurcated Graft in Patients with Infrarenal Abdominal Aortic Aneurysm				
<b>Mullett, Timothy</b>	3048104442	\$0.	\$1,566.	\$1,566.
Fresenius Biotech North America Protocol EZ-2053-001: A Double-Blind, Placebo-Controlled, Multicenter, Dose-Ranging Study of an Anti-T Lymphocyte Immune Globulin (EZ-2053) in the Prophylaxis of Acute Pulmonary Allograft Rejection in Adult Recipients of Primary				
<b>Ramaiah, Chandrashekhar</b>	3048105082	\$2.	\$0.	\$2.
IFlow Corp Multicenter Infection Surveillance Study Following Cardiac Surgical Procedures				
<b>Ramaiah, Chandrashekhar</b>	3048105352	\$0.	\$6,972.	\$6,972.
Merck and Company Inc A Randomized, Multicenter, Double-Blind, Group-Sequential Study to Evaluate the Efficacy, Immunogenicity and Safety of a Single Dose of Merck 0657nl Staphylococcus Aureus Vaccine V710 in Adult Patients Scheduled for Cardiothoracic Surgery				
<b>Ramaiah, Chandrashekhar</b>	3048105352	\$2.	\$0.	\$2.
Merck and Company Inc A Randomized, Multicenter, Double-Blind, Group-Sequential Study to Evaluate the Efficacy, Immunogenicity and Safety of a Single Dose of Merck 0657nl Staphylococcus Aureus Vaccine V710 in Adult Patients Scheduled for Cardiothoracic Surgery				
<b>Ranjan, Dinesh</b>	3046639300	\$0.	\$-12,853.	\$-12,853.
Wyeth Pharmaceuticals Inc A Randomized, Open-Label, Comparative evaluation of Conversion from Calcineurin Inhibitor Treatment to Sirolimus Treatment vs. Continued Calcineurin Inhibitor Treatment in Liver Allograft Recipients Undergoing Maintenance Therapy				
<b>Ranjan, Dinesh</b>	3046639300	\$0.	\$12,853.	\$12,853.
Wyeth Pharmaceuticals Inc A Randomized, Open-Label, Comparative evaluation of Conversion from Calcineurin Inhibitor Treatment to Sirolimus Treatment vs. Continued Calcineurin Inhibitor Treatment in Liver Allograft Recipients Undergoing Maintenance Therapy				
<b>Ranjan, Dinesh</b>	3046639300	\$0.	\$12,853.	\$12,853.
Wyeth Pharmaceuticals Inc A Randomized, Open-Label, Comparative evaluation of Conversion from Calcineurin Inhibitor Treatment to Sirolimus Treatment vs. Continued Calcineurin Inhibitor Treatment in Liver Allograft Recipients Undergoing Maintenance Therapy				
<b>Ranjan, Dinesh</b>	3048103804	\$0.	\$1,742.	\$1,742.
ViroPharma Inc A Randomized, Double-Blind Study to Assess the Efficacy and Safety of Prophylactic Use of Maribavir Versus Oral Ganciclovir for the Prevention of Cytomegalovirus Disease in Recipients of Orthotopic Liver Transplants				
<b>Ranjan, Dinesh</b>	3048103804	\$0.	\$13,214.	\$13,214.
ViroPharma Inc A Randomized, Double-Blind Study to Assess the Efficacy and Safety of Prophylactic Use of Maribavir Versus Oral Ganciclovir for the Prevention of Cytomegalovirus Disease in Recipients of Orthotopic Liver Transplants				

**Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Medicine</u></b>				
<b><u>Surgery</u></b>				
<b>Ranjan, Dinesh</b>	3048103804	\$0.	\$6,095.	\$6,095.
ViroPharma Inc A Randomized, Double-Blind Study to Assess the Efficacy and Safety of Prophylactic Use of Maribavir Versus Oral Ganciclovir for the Prevention of Cytomegalovirus Disease in Recipients of Orthotopic Liver Transplants				
<b>Ranjan, Dinesh</b>	3048105361	\$2.	\$0.	\$2.
Novartis A 24 Month, Multi-Center, Open-Label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Concentration-Controlled Everolimus to Eliminate or to Reduce Tacrolimus Compared to Tacrolimus in de novo Liver Transplant Recipients				
<b>Saha, Sibü</b>	3048103829	\$0.	\$100.	\$100.
CVRx Inc Rheos Pivotal Trial				
<b>Saha, Sibü</b>	3048103829	\$0.	\$755.	\$755.
CVRx Inc Rheos Pivotal Trial				
<b>Saha, Sibü</b>	3048103829	\$0.	\$25.	\$25.
CVRx Inc Rheos Pivotal Trial				
<b>Saha, Sibü</b>	3048103829	\$0.	\$23,974.	\$23,974.
CVRx Inc Rheos Pivotal Trial				
<b>Saha, Sibü</b>	3048103829	\$0.	\$5,132.	\$5,132.
CVRx Inc Rheos Pivotal Trial				
<b>Saha, Sibü</b>	3048104218	\$0.	\$16,506.	\$16,506.
Baxter Healthcare Co Clinical Evaluation of Efficacy and Safety of FS VH S/D 500 S-APR for Hemostasis in Subjects Undergoing Vascular Surgery				
<b>Saha, Sibü</b>	3048104218	\$0.	\$1,260.	\$1,260.
Baxter Healthcare Co Clinical Evaluation of Efficacy and Safety of FS VH S/D 500 S-APR for Hemostasis in Subjects Undergoing Vascular Surgery				
<b>Saha, Sibü</b>	3048104218	\$0.	\$5,002.	\$5,002.
Baxter Healthcare Co Clinical Evaluation of Efficacy and Safety of FS VH S/D 500 S-APR for Hemostasis in Subjects Undergoing Vascular Surgery				
<b>Tibbs, Phillip A</b>	3046722800	\$0.	\$3,558.	\$3,558.
DePuy Spine A Post-Approval Evaluation of the Lumbar I/F Cage with VSP Spine System for PLIF				
<b>Tibbs, Phillip A</b>	3048082800	\$0.	\$4,968.	\$4,968.
DePuy Spine SLIM-Loc Plating fusion vs. DISCOVER Artificial Disc				

**Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Medicine</u></b>				
<b><u>Surgery</u></b>				
<b>Tibbs, Phillip A</b>	3048082800	\$0.	\$4,870.	\$4,870.
DePuy Spine SLIM-Loc Plating fusion vs. DISCOVER Artificial Disc				
<b>Tibbs, Phillip A</b>	3048104419	\$0.	\$410.	\$410.
Kyphon Inc Treatment of Lumbar Spinal Stenosis with X-Stop IPD in Moderately Symptomatic Patients to Assess the Long-Term Safety and Performance of X-Stop Interspinous Decompression System				
<b>Tibbs, Phillip A</b>	3048104419	\$0.	\$4,597.	\$4,597.
Kyphon Inc Treatment of Lumbar Spinal Stenosis with X-Stop IPD in Moderately Symptomatic Patients to Assess the Long-Term Safety and Performance of X-Stop Interspinous Decompression System				
<b>Toborek, Michal</b>	3046928600	\$0.	\$265,994.	\$265,994.
National Institute of Neurological Disorders & Stroke Tat-Mediated Brain Endothelial Cell Dysfunction				
<b>Toborek, Michal</b>	3046939200	\$0.	\$277,817.	\$277,817.
National Institute of Mental Health Tat, Amyloid Beta and Brain Endothelial Barrier Function				
<b>Toborek, Michal</b>	3048105020	\$366,250.	\$0.	\$366,250.
National Institute of Mental Health Implications of Caveolae in Tat Signaling and Integrity of Brain Endothelium				
<b>Waid, Thomas</b>	3046750500	\$0.	\$630.	\$630.
Roche Pharmaceutical Research Associates Inc An Open Label, Randomized, Multicenter Study To Evaluate The Efficacy and Safety of Early Calcineurin Inhibitor Withdrawal in Recipients of Primary Renal Allografts Maintained Long-Term on Mycophenolate Mofetil and Sirolimus				
<b>Waid, Thomas</b>	3046750500	\$0.	\$24,923.	\$24,923.
Roche Pharmaceutical Research Associates Inc An Open Label, Randomized, Multicenter Study To Evaluate The Efficacy and Safety of Early Calcineurin Inhibitor Withdrawal in Recipients of Primary Renal Allografts Maintained Long-Term on Mycophenolate Mofetil and Sirolimus				
<b>Waid, Thomas</b>	3046750500	\$0.	\$-1,817.	\$-1,817.
Roche Pharmaceutical Research Associates Inc An Open Label, Randomized, Multicenter Study To Evaluate The Efficacy and Safety of Early Calcineurin Inhibitor Withdrawal in Recipients of Primary Renal Allografts Maintained Long-Term on Mycophenolate Mofetil and Sirolimus				
<b>Waid, Thomas</b>	3046750500	\$0.	\$1,260.	\$1,260.
Roche Pharmaceutical Research Associates Inc An Open Label, Randomized, Multicenter Study To Evaluate The Efficacy and Safety of Early Calcineurin Inhibitor Withdrawal in Recipients of Primary Renal Allografts Maintained Long-Term on Mycophenolate Mofetil and Sirolimus				
<b>Waid, Thomas</b>	3046863600	\$0.	\$630.	\$630.
Roche Laboratories An Open Label, Prospective, Randomized, Controlled, Multi-Center Study Assessing Fixed Dose vs Concentration Controlled CellCept Regimens for Patients Following a Single Organ Renal Transplantation in Comb				

## Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Surgery</b>				
<b>Waid, Thomas</b>	3046863600	\$0.	\$-24,923.	\$-24,923.
Roche Laboratories An Open Label, Prospective, Randomized, Controlled, Multi-Center Study Assessing Fixed Dose vs Concentration Controlled CellCept Regimens for Patients Following a Single Organ Renal Transplantation in Comb				
<b>Waid, Thomas</b>	3046863600	\$0.	\$4,429.	\$4,429.
Roche Laboratories An Open Label, Prospective, Randomized, Controlled, Multi-Center Study Assessing Fixed Dose vs Concentration Controlled CellCept Regimens for Patients Following a Single Organ Renal Transplantation in Comb				
<b>Waid, Thomas</b>	3048103550	\$0.	\$3,911.	\$3,911.
Astellas Pharma US Inc A Phase III, Randomized, Open-Label, Comparative, Multi-Center Study to Assess the Safety and Efficacy of Prograf (tacrolimus)/MMF, Modified Release (MR) Tacrolimus/MMF and Neoral (cyclosporine)/MMF in De Nove Kidney Trans Recip.				
<b>Waid, Thomas</b>	3048103550	\$0.	\$1,722.	\$1,722.
Astellas Pharma US Inc A Phase III, Randomized, Open-Label, Comparative, Multi-Center Study to Assess the Safety and Efficacy of Prograf (tacrolimus)/MMF, Modified Release (MR) Tacrolimus/MMF and Neoral (cyclosporine)/MMF in De Nove Kidney Trans Recip.				
<b>Waid, Thomas</b>	3048103550	\$0.	\$11,718.	\$11,718.
Astellas Pharma US Inc A Phase III, Randomized, Open-Label, Comparative, Multi-Center Study to Assess the Safety and Efficacy of Prograf (tacrolimus)/MMF, Modified Release (MR) Tacrolimus/MMF and Neoral (cyclosporine)/MMF in De Nove Kidney Trans Recip.				
<b>Young, Alfred B</b>		\$2.	\$0.	\$2.
Adnexus Phase 1, Open-Label, Multi-Center Study to Evaluate the Safety and Tolerability of CT-322 Administered in Combination with Focal Brain Radiotherapy and Temozolomide to Subjects with Newly Diagnosed Glioblastoma Multiforme				
<b>Young, Alfred B</b>	3048103840	\$0.	\$-2,000.	\$-2,000.
Virginia Commonwealth University A Multicenter Observational Study to Evaluate Dynamics of Endothelin and Markers of Cellular Apoptosis in Cerebrospinal Fluid and Plasma in Moderate and Severe Human Head Injury				
<b>Young, Alfred B</b>	3048103840	\$0.	\$1,998.	\$1,998.
Virginia Commonwealth University A Multicenter Observational Study to Evaluate Dynamics of Endothelin and Markers of Cellular Apoptosis in Cerebrospinal Fluid and Plasma in Moderate and Severe Human Head Injury				
<b>Young, Alfred B</b>	3048104383	\$0.	\$-2.	\$-2.
National Institute of Neurological Disorders & Stroke CASTBI Trial Planning Grant: Cyclosporine in Traumatic Brain Injury				
<b>Yurek, David M</b>	3046851500	\$0.	\$275,018.	\$275,018.
National Institute of Neurological Disorders & Stroke Stem Cell Adaptability in Parkinson's Disease				
<b>Yurek, David M</b>	3048105192	\$137,321.	\$0.	\$137,321.
Michael J Fox Foundation for Parkinsons Disease DNA Nanoparticle Therapy for Parkinson's Disease				

## Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Surgery</b>				
<b>Zwischenberger, Joseph</b>	3048104857	\$0.	-\$291,361.	-\$291,361.
Medarray Inc SBIR: Novel Dense Hollow Fiber for Blood Gas Exchange				
<b>Zwischenberger, Joseph</b>	3048104857	\$291,361.	\$0.	\$291,361.
Medarray Inc SBIR: Novel Dense Hollow Fiber for Blood Gas Exchange				
<b>Zwischenberger, Joseph</b>	3048105207	\$291,361.	\$0.	\$291,361.
Medarray Inc SBIR: Novel Dense Hollow Fiber for Blood Gas Exchange				
<b>Zwischenberger, Joseph</b>	3048105367	\$20,000.	\$0.	\$20,000.
MC3 Inc STTR: Development of a Perfusion-induced Systemic Hyperthermia Delivery Apparatus				
<b>Surgery</b>	<b>Totals:</b>	<b>\$1,573,328.</b>	<b>\$1,044,335.</b>	<b>\$2,617,663.</b>
<b>Neurology</b>				
<b>Bensalem Owen, Meriem Katre nec</b>	3048104422	\$0.	\$671.	\$671.
Inc Research Inc A Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Clobazam (0.25, 0.5 and 1.0 mg/kg/day) in Patients with Lennox-Gastaut Syndrome				
<b>Bensalem Owen, Meriem Katre nec</b>	3048104422	\$0.	\$152.	\$152.
Inc Research Inc A Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Clobazam (0.25, 0.5 and 1.0 mg/kg/day) in Patients with Lennox-Gastaut Syndrome				
<b>Bensalem Owen, Meriem Katre nec</b>	3048104422	\$0.	\$236.	\$236.
Inc Research Inc A Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Clobazam (0.25, 0.5 and 1.0 mg/kg/day) in Patients with Lennox-Gastaut Syndrome				
<b>Bensalem Owen, Meriem Katre nec</b>	3048104422	\$0.	\$8,902.	\$8,902.
Inc Research Inc A Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Clobazam (0.25, 0.5 and 1.0 mg/kg/day) in Patients with Lennox-Gastaut Syndrome				
<b>Bensalem Owen, Meriem Katre nec</b>	3048104797	\$0.	\$60.	\$60.
Inc Research Inc Safety and Effectiveness of Open-Label clobazam in Subjects with Lennox-Gastaut Syndrome				
<b>Bensalem Owen, Meriem Katre nec</b>	3048104797	\$0.	\$7,564.	\$7,564.
Inc Research Inc Safety and Effectiveness of Open-Label clobazam in Subjects with Lennox-Gastaut Syndrome				
<b>Bensalem Owen, Meriem Katre nec</b>	3048104797	\$2.	\$0.	\$2.
Inc Research Inc Safety and Effectiveness of Open-Label clobazam in Subjects with Lennox-Gastaut Syndrome				
<b>Berger, Joseph R</b>	3048102204	\$0.	\$18,292.	\$18,292.
UCB Pharma Double-blind Placebo Controlled, Randomized, Parallel-group, Phase II study in subjects with relapsing forms of Multiple Sclerosis to evaluate the effects of two doses of CDP323 over 24 weeks with a rater blind MRI follow up over 12 weeks				

## Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Neurology</b>				
<b>Berger, Joseph R</b>	3048102204	\$0.	\$14,736.	\$14,736.
UCB Pharma Double-blind Placebo Controlled, Randomized, Parallel-group, Phase II study in subjects with relapsing forms of Multiple Sclerosis to evaluate the effects of two doses of CDP323 over 24 weeks with a rater blind MRI follow up over 12 weeks				
<b>Berger, Joseph R</b>	3048104087	\$0.	\$6,833.	\$6,833.
PPD Development Inc A Randomized, Double-Blind, Placebo-Controlled, Dose-Titration Study to Assess the Safety, Tolerability, and Efficacy of C105 in Persons with Multiple Sclerosis with Cognitive Impairment				
<b>Berger, Joseph R</b>	3048105403	\$2.	\$0.	\$2.
Biogen Research Co A Randomized, Rater-Blinded Study to Explore the Effect of Mefloquine in Subjects with Progressive Multifocal Leukoencephalopathy (PML)				
<b>Cambi, Franca</b>	3048079000	\$0.	\$288,422.	\$288,422.
National Institute of Neurological Disorders & Stroke PLP Alternative Splicing and Oligodendrocyte Differentiation				
<b>Cambi, Franca</b>	3048105159	\$5,500.	\$0.	\$5,500.
Jacobs Ladder PLP/DM20 Alternative Splicing: Studies on Regulatory Sequences in Exon 3B				
<b>Cambi, Franca</b>	3048105397	\$79,285.	\$0.	\$79,285.
ELA Conseil Scientifique PLP/DM20 Alternative Splicing: Studies on Regulatory Sequences, Splicing Factors and Mutations Affecting Splicing in PMD Patients				
<b>Chan, Jane</b>	3048105211	\$0.	\$4,408.	\$4,408.
Sanofi Aventis US Inc An International, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Year Treatment with Teriflunomide 7mg Once Daily vs. and 14mg Once Daily vs				
<b>Chan, Jane</b>	3048105211	\$2.	\$0.	\$2.
Sanofi Aventis US Inc An International, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Year Treatment with Teriflunomide 7mg Once Daily vs. and 14mg Once Daily vs				
<b>Fakhoury, Toufic A</b>	3046843900	\$0.	\$762.	\$762.
Schwarz BioSciences Inc An Open Label-Extension Trial to Determine Safety and Efficacy of Long Term SPM 927 in Patients with Partial Seizures. SP 756				
<b>Fakhoury, Toufic A</b>	3046843900	\$0.	\$3,818.	\$3,818.
Schwarz BioSciences Inc An Open Label-Extension Trial to Determine Safety and Efficacy of Long Term SPM 927 in Patients with Partial Seizures. SP 756				
<b>Fakhoury, Toufic A</b>	3046843900	\$0.	\$5,239.	\$5,239.
Schwarz BioSciences Inc An Open Label-Extension Trial to Determine Safety and Efficacy of Long Term SPM 927 in Patients with Partial Seizures. SP 756				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Neurology</b>				
<b>Fakhoury, Toufic A</b>	3046978500	\$0.	\$12,132.	\$12,132.
Quintiles Inc A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Phase 3 Study to Determine the Efficacy and Safety of Retigabine (1200 MG/DAY) Used as Adjunctive Therapy in Refractory Epilepsy Patients with Partial-Onset Seizures				
<b>Fakhoury, Toufic A</b>	3046978500	\$0.	\$1,645.	\$1,645.
Quintiles Inc A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Phase 3 Study to Determine the Efficacy and Safety of Retigabine (1200 MG/DAY) Used as Adjunctive Therapy in Refractory Epilepsy Patients with Partial-Onset Seizures				
<b>Fakhoury, Toufic A</b>	3048103108	\$0.	\$9,391.	\$9,391.
Eisai Medical Research Inc A Double-Blind, Placebo-Controlled, Parallel-Group, Study of Rufinamide Given as Adjunctive Therapy in Patients with Refractory Partial Seizures				
<b>Fakhoury, Toufic A</b>	3048103882	\$0.	\$9,943.	\$9,943.
UCB Pharma An International, Double-Blind, Parallel-Group, Placebo-Controlled, Randomized Study: Evaluation of the Efficacy and Safety of Brivaracetam in Subjects (16 to 70 years old) with Partial Onset Seizures				
<b>Fakhoury, Toufic A</b>	3048103882	\$0.	\$12,472.	\$12,472.
UCB Pharma An International, Double-Blind, Parallel-Group, Placebo-Controlled, Randomized Study: Evaluation of the Efficacy and Safety of Brivaracetam in Subjects (16 to 70 years old) with Partial Onset Seizures				
<b>Fakhoury, Toufic A</b>	3048103891	\$0.	\$19,233.	\$19,233.
Pharmaceutical Research Associates A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Ganaxolone as Add-On Therapy in Adult Subjects with Epilepsy Consisting of Uncontrolled Partial-Onset Seizures				
<b>Fakhoury, Toufic A</b>	3048103891	\$0.	\$21,467.	\$21,467.
Pharmaceutical Research Associates A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Ganaxolone as Add-On Therapy in Adult Subjects with Epilepsy Consisting of Uncontrolled Partial-Onset Seizures				
<b>Fakhoury, Toufic A</b>	3048104048	\$0.	\$1,596.	\$1,596.
Eisai Medical Research Inc An Open Label Extension Study of Rufinamide Given as Adjunctive Therapy in Patients with Refractory Partial Onset Seizures				
<b>Fakhoury, Toufic A</b>	3048104396	\$0.	\$21,533.	\$21,533.
Pfizer Inc A Double-Blind, Multicenter Efficacy Safety Study of Pregabalin (Lyrica) as a Monotherapy in Patients with partial Seziures				
<b>Fakhoury, Toufic A</b>	3048104396	\$0.	\$5,857.	\$5,857.
Pfizer Inc A Double-Blind, Multicenter Efficacy Safety Study of Pregabalin (Lyrica) as a Monotherapy in Patients with partial Seziures				
<b>Fakhoury, Toufic A</b>	3048104574	\$0.	\$-2,000.	\$-2,000.
Ortho McNeil Pharmaceuticals A Randomized, Double-Blind, Parallel-Group, Multicenter Study to Evaluate the Retention Rate, Efficacy, Safety and Tolerability of Carisbamate, Topiramate and Levetiracetam as Adjunctive Therapy in Subjects with Partial Onset Seizures				

## Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Neurology</b>				
<b>Fakhoury, Toufic A</b>	3048104574	\$0.	\$2,000.	\$2,000.
Ortho McNeil Pharmaceuticals A Randomized, Double-Blind, Parallel-Group, Multicenter Study to Evaluate the Retention Rate, Efficacy, Safety and Tolerability of Carisbamate, Topiramate and Levetiracetam as Adjunctive Therapy in Subjects with Partial Onset Seizures				
<b>Fakhoury, Toufic A</b>	3048104596	\$0.	\$16,184.	\$16,184.
UCB Pharma An Open-Label, Multicenter, Follow-up Trial to Evaluate the Long-Term Safety and Efficacy of Brivaracetam Used as Adjunctive Treatment at a Flexible Dose Up to a Maximum of 150 mg/day in Subjects Aged 16 years or Older Suffering from Epilepsy				
<b>Fakhoury, Toufic A</b>	3048105126	\$0.	\$1,998.	\$1,998.
Pfizer Inc An Open Label Multicenter Extension Study to Determine Long Term Safety and Efficacy of Pregabalin (Lyrica) as Monotherapy in Patients with Partial Seizures				
<b>Fakhoury, Toufic A</b>	3048105126	\$2.	\$0.	\$2.
Pfizer Inc An Open Label Multicenter Extension Study to Determine Long Term Safety and Efficacy of Pregabalin (Lyrica) as Monotherapy in Patients with Partial Seizures				
<b>Fakhoury, Toufic A</b>	3048105381	\$2.	\$0.	\$2.
PPD Development Inc An International, Double-Blind, Randomized, Multi-Center, Parallel Group, Historical-Control Conversion to Monotherapy Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (16 to 75 years old) With Partial Onset Seizures With or Without				
<b>Fakhoury, Toufic A</b>	3048105382	\$2.	\$0.	\$2.
PPD Development Inc An Open-Label, Multinational, Multicenter, Follow-Up Study to Evaluate the Long-Term Safety and Efficacy of Brivaracetam, Used at a Flexible Dose up to a Maximum of 150 mg/day, in Subjects aged 16 years or older suffering from Epilepsy				
<b>Houff, Sidney A</b>	3048103412	\$0.	\$292.	\$292.
Serono Laboratories Inc A Randomized, Multicenter, Two-arm, Open Label, 12 Week Phase IIIB Study to Evaluate the Tolerability of Rebif (IFN Beta-LA) and Betaseron (IFN Beta-1B) in IFN-Naive Subjects with Relapsing Remitting Multiple Sclerosis; Followed by a Single-Arm 24				
<b>Houff, Sidney A</b>	3048103412	\$0.	\$391.	\$391.
Serono Laboratories Inc A Randomized, Multicenter, Two-arm, Open Label, 12 Week Phase IIIB Study to Evaluate the Tolerability of Rebif (IFN Beta-LA) and Betaseron (IFN Beta-1B) in IFN-Naive Subjects with Relapsing Remitting Multiple Sclerosis; Followed by a Single-Arm 24				
<b>Houff, Sidney A</b>	3048103412	\$0.	\$773.	\$773.
Serono Laboratories Inc A Randomized, Multicenter, Two-arm, Open Label, 12 Week Phase IIIB Study to Evaluate the Tolerability of Rebif (IFN Beta-LA) and Betaseron (IFN Beta-1B) in IFN-Naive Subjects with Relapsing Remitting Multiple Sclerosis; Followed by a Single-Arm 24				
<b>Houff, Sidney A</b>	3048104530	\$0.	\$1,260.	\$1,260.
Genzyme Corp A Phase 3 Randomized, Rater-Blinded Study Comparing Two Annual Cycles of Intravenous Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta-1a (Rebif) in Treatment-Naive Patients with Relapsing Multiple Sclerosis				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Neurology</b>				
<b>Houff, Sidney A</b>	3048104530	\$0.	\$6,629.	\$6,629.
Genzyme Corp A Phase 3 Randomized, Rater-Blinded Study Comparing Two Annual Cycles of Intravenous Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta-1a (Rebif) in Treatment-Naive Patients with Relapsing Multiple Sclerosis				
<b>Kasarskis, Edward J</b>	3048105231	\$2.	\$0.	\$2.
Kendle International A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy and to Determine the Pharmacokinetics of Two Doses of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Pseudobulbar Affect (PBA) in Patients				
<b>Maragos, William F</b>	3048104750	\$100,000.	\$0.	\$100,000.
American Heart Association Targeted Mitochondrial Uncoupling in Focal Cerebral Ischemia				
<b>Pettigrew, Luther C</b>	3046450600	\$0.	\$1,859.	\$1,859.
Mayo Foundation Siblings with Ischemic Stroke (SWISS)				
<b>Pettigrew, Luther C</b>	3046749700	\$0.	\$2,200.	\$2,200.
AGA Medical Co Randomized Evaluation of Recurrent Stroke Comparing PFO Closure to Established Current Standard of Care Treatment (RESPECT Trial)				
<b>Pettigrew, Luther C</b>	3046749700	\$0.	\$10,100.	\$10,100.
AGA Medical Co Randomized Evaluation of Recurrent Stroke Comparing PFO Closure to Established Current Standard of Care Treatment (RESPECT Trial)				
<b>Pettigrew, Luther C</b>	3046749700	\$0.	\$1,500.	\$1,500.
AGA Medical Co Randomized Evaluation of Recurrent Stroke Comparing PFO Closure to Established Current Standard of Care Treatment (RESPECT Trial)				
<b>Pettigrew, Luther C</b>	3046749700	\$0.	\$2,500.	\$2,500.
AGA Medical Co Randomized Evaluation of Recurrent Stroke Comparing PFO Closure to Established Current Standard of Care Treatment (RESPECT Trial)				
<b>Pettigrew, Luther C</b>	3048038100	\$0.	\$30,033.	\$30,033.
Miami University Albumin in Stroke (ALIAS) Trial				
<b>Pettigrew, Luther C</b>	3048103228	\$0.	\$10,998.	\$10,998.
Parexel International Co NeuroThera Effectiveness and Safety Trial - 2 (NEST-2)				
<b>Pettigrew, Luther C</b>	3048103228	\$0.	\$4,999.	\$4,999.
Parexel International Co NeuroThera Effectiveness and Safety Trial - 2 (NEST-2)				
<b>Slevin, John T</b>		\$36,752.	\$0.	\$36,752.
American Parkinsons Disease Association Parkinson Disease Infomation and Referral Center				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Neurology</b>				
<b>Slevin, John T</b>	3046609500	\$0.	\$278,531.	\$278,531.
AMGen Within Subject, Dose-Escalation Trial of Continuously Infused Intraputamental (Ipu) Recombinant-Methionyl Human Glial Cell Line-Derived Neurotrophic Factor for the Treatment of Subjects with Idiopathic Parkinson's Disease				
<b>Slevin, John T</b>	3048072800	\$0.	\$1,018.	\$1,018.
Quintiles Inc A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy, Safety, and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients with Motor Fluctuations				
<b>Slevin, John T</b>	3048072800	\$0.	\$887.	\$887.
Quintiles Inc A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy, Safety, and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients with Motor Fluctuations				
<b>Slevin, John T</b>	3048103836	\$0.	\$1,750.	\$1,750.
American Parkinsons Disease Association American Parkinson Disease Association Information Center				
<b>Slevin, John T</b>	3048104006	\$0.	\$187.	\$187.
Quintiles Inc A Multi-Centre, Open Label Extension Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of E2007 as an Adjunctive Therapy in Levodopa Treated Parkinsons' Disease Patients with Motor Fluctuations				
<b>Slevin, John T</b>	3048104006	\$0.	\$57.	\$57.
Quintiles Inc A Multi-Centre, Open Label Extension Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of E2007 as an Adjunctive Therapy in Levodopa Treated Parkinsons' Disease Patients with Motor Fluctuations				
<b>Slevin, John T</b>	3048105130	\$2.	\$0.	\$2.
University of Rochester Study of Anti-Depresants in Parkinson's Disease (SAD PD)				
<b>Smith, Charles D</b>	3048104409	\$0.	\$3,544.	\$3,544.
Neuronetrix Inc Evaluation of Handheld Evoked Response Potentials (ERP) System as an Effective Method to Diagnose Alzheimer's Disease				
<b>Smith, Charles D</b>	3048104409	\$0.	\$-2.	\$-2.
Neuronetrix Inc Evaluation of Handheld Evoked Response Potentials (ERP) System as an Effective Method to Diagnose Alzheimer's Disease				
<b>Smith, Charles D</b>	3048104409	\$0.	\$4,343.	\$4,343.
Neuronetrix Inc Evaluation of Handheld Evoked Response Potentials (ERP) System as an Effective Method to Diagnose Alzheimer's Disease				
<b>Tucker, Tarvez</b>	3048104872	\$0.	\$2,500.	\$2,500.
Merck and Company Inc A Multicenter, Randomized, Double-Blind, Placebo and Active Controlled, Crossover Study to Evaluate the Safety and Efficacy of MK-0974 iin Treatment of Acute Migraine in Patients with Stable Vascular Disease				

**Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009**

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Neurology</b>				
<b>Tucker, Tarvez</b>	3048104872	\$0.	\$4,410.	\$4,410.
Merck and Company Inc A Multicenter, Randomized, Double-Blind, Placebo and Active Controlled, Crossover Study to Evaluate the Safety and Efficacy of MK-0974 in Treatment of Acute Migraine in Patients with Stable Vascular Disease				
<b>Tucker, Tarvez</b>	3048104872	\$2.	\$0.	\$2.
Merck and Company Inc A Multicenter, Randomized, Double-Blind, Placebo and Active Controlled, Crossover Study to Evaluate the Safety and Efficacy of MK-0974 in Treatment of Acute Migraine in Patients with Stable Vascular Disease				
<b>Vaishnav, Anand G</b>	3046746400	\$0.	\$3,080.	\$3,080.
University of Texas Health Science Center at Sa Secondary Prevention of Small Subcortical Strokes (SPS3)				
<b>Vaishnav, Anand G</b>	3046746400	\$0.	\$19,725.	\$19,725.
University of Texas Health Science Center at Sa Secondary Prevention of Small Subcortical Strokes (SPS3)				
<b>Vaishnav, Anand G</b>	3046746400	\$0.	\$10,750.	\$10,750.
University of Texas Health Science Center at Sa Secondary Prevention of Small Subcortical Strokes (SPS3)				
<b>Vaishnav, Anand G</b>	3046746400	\$0.	\$15,810.	\$15,810.
University of Texas Health Science Center at Sa Secondary Prevention of Small Subcortical Strokes (SPS3)				
<b>Vaishnav, Anand G</b>	3046746400	\$0.	\$2,760.	\$2,760.
University of Texas Health Science Center at Sa Secondary Prevention of Small Subcortical Strokes (SPS3)				
<b>Vaishnav, Anand G</b>	3046746400	\$0.	\$1,670.	\$1,670.
University of Texas Health Science Center at Sa Secondary Prevention of Small Subcortical Strokes (SPS3)				
<b>Vaishnav, Anand G</b>	3046788400	\$0.	\$2,273.	\$2,273.
Boehringer Ingelheim Prevention Regimen for Effectively Avoiding Second Strokes: A Double-Blind, Active and Placebo-Controlled Study of Aggrenox vs. Clopidogrel + Aspirin, With and Without Micardis (PRoFESS)				
<b>Vaishnav, Anand G</b>	3046788400	\$0.	\$131.	\$131.
Boehringer Ingelheim Prevention Regimen for Effectively Avoiding Second Strokes: A Double-Blind, Active and Placebo-Controlled Study of Aggrenox vs. Clopidogrel + Aspirin, With and Without Micardis (PRoFESS)				
<b>Vaishnav, Anand G</b>	3048103205	\$0.	\$1,714.	\$1,714.
Merck and Company Inc A Phase IIa Randomized, Double-Blind, Parallel-Groups, Placebo Controlled Clinical Trial to Study the Efficacy and Safety of MK-0724 Intravenous Infusion on the Amelioration of Neurological Damage and Recovery from Middle Cerebral Artery Ischemic Stroke				
<b>Vaishnav, Anand G</b>	3048103205	\$0.	\$9,924.	\$9,924.
Merck and Company Inc A Phase IIa Randomized, Double-Blind, Parallel-Groups, Placebo Controlled Clinical Trial to Study the Efficacy and Safety of MK-0724 Intravenous Infusion on the Amelioration of Neurological Damage and Recovery from Middle Cerebral Artery Ischemic Stroke				

**Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Medicine</u></b>				
<b><u>Neurology</u></b>				
<b>Vaishnav, Anand G</b>	3048103205	\$0.	\$5,326.	\$5,326.
Merck and Company Inc A Phase IIa Randomized, Double-Blind, Parallel-Groups, Placebo Controlled Clinical Trial to Study the Efficacy and Safety of MK-0724 Intravenous Infusion on the Amelioration of Neurological Damage and Recovery from Middle Cerebral Artery Ischemic Stroke				
<b>Vaishnav, Anand G</b>	3048103205	\$0.	\$-100.	\$-100.
Merck and Company Inc A Phase IIa Randomized, Double-Blind, Parallel-Groups, Placebo Controlled Clinical Trial to Study the Efficacy and Safety of MK-0724 Intravenous Infusion on the Amelioration of Neurological Damage and Recovery from Middle Cerebral Artery Ischemic Stroke				
<b>Vaishnav, Anand G</b>	3048103205	\$0.	\$201.	\$201.
Merck and Company Inc A Phase IIa Randomized, Double-Blind, Parallel-Groups, Placebo Controlled Clinical Trial to Study the Efficacy and Safety of MK-0724 Intravenous Infusion on the Amelioration of Neurological Damage and Recovery from Middle Cerebral Artery Ischemic Stroke				
<b>Vaishnav, Anand G</b>	3048103205	\$0.	\$201.	\$201.
Merck and Company Inc A Phase IIa Randomized, Double-Blind, Parallel-Groups, Placebo Controlled Clinical Trial to Study the Efficacy and Safety of MK-0724 Intravenous Infusion on the Amelioration of Neurological Damage and Recovery from Middle Cerebral Artery Ischemic Stroke				
<b>Neurology</b>	<b>Totals:</b>	<b>\$221,555.</b>	<b>\$937,770.</b>	<b>\$1,159,325.</b>
<b><u>Ophthalmology</u></b>				
<b>Ambati, Jayakrishna</b>	3048102202	\$0.	\$75,000.	\$75,000.
Burroughs Wellcome Fund Target-Independent Suppression of Angiogenesis by siRNAs				
<b>Ambati, Jayakrishna</b>	3048103313	\$0.	\$500.	\$500.
American Health Assistance Foundation The Role of SPARC in Macular Propensity for CNV				
<b>Ambati, Jayakrishna</b>	3048103313	\$0.	\$12,000.	\$12,000.
American Health Assistance Foundation The Role of SPARC in Macular Propensity for CNV				
<b>Ambati, Jayakrishna</b>	3048103313	\$0.	\$37,500.	\$37,500.
American Health Assistance Foundation The Role of SPARC in Macular Propensity for CNV				
<b>Ambati, Jayakrishna</b>	3048103629	\$0.	\$355,097.	\$355,097.
National Eye Institute Pro- and Anti-Angiogenic Effect of Vascular Endothelial Growth Factor-A				
<b>Ambati, Jayakrishna</b>	3048104229	\$0.	\$50,585.	\$50,585.
Taigen Biotechnology Co Ltd Taigen Antagonist: Prevention and Regression of Laser-Induced Choroidal Neovascularization.				
<b>Ambati, Jayakrishna</b>	3048105168	\$35,000.	\$0.	\$35,000.
International Retinal Research Foundation The Heterogeneous Immunovascular Effects of Small Interfering RNA in the Posterior Segment				

**Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Medicine</u></b>				
<b><u>Ophthalmology</u></b>				
<b>Ambati, Jayakrishna</b>	3048105276	\$20,000.	\$0.	\$20,000.
Fight for Sight Inc Fellowship for Albuquerque: Establishing the Role of the Novel Endogenous sVEGFR-2 in Corneal Lymphangiogenesis and Transplant Rejection				
<b>Ambati, Jayakrishna</b>	3048105306	\$280,616.	\$0.	\$280,616.
Doris Duke Charitable Foundation Short non-Interfering RNAs as Novel Therapies for Age Related Macular Degeneration				
<b>Blackburn, Peter</b>	3046948500	\$0.	\$59,285.	\$59,285.
Control Delivery Systems Inc A Randomized, Double-Masked, Parallel Group, Multi-Center Dose-Finding Comparison of the Safety and Efficacy of ASI-001A 0.5 pg/day and				
<b>Capoor, Seema</b>	3048105202	\$0.	\$3,914.	\$3,914.
Allergan Pharmaceuticals Inc A 6 Day, Phase 3, Multicenter, Randomized, Double-Masked, Parallel Study to Compare the Safety and Efficacy of Gatifloxacin 0.5% Ophthalmic Solution BID with that of Vehicle in the Treatment of Acute Bacterial Conjunctivitis				
<b>Capoor, Seema</b>	3048105202	\$2.	\$0.	\$2.
Allergan Pharmaceuticals Inc A 6 Day, Phase 3, Multicenter, Randomized, Double-Masked, Parallel Study to Compare the Safety and Efficacy of Gatifloxacin 0.5% Ophthalmic Solution BID with that of Vehicle in the Treatment of Acute Bacterial Conjunctivitis				
<b>Mohan, Royce</b>	3048103665	\$0.	\$358,925.	\$358,925.
National Eye Institute Molecular Targets of Corneal Antianangiogenesis				
<b>Mohan, Royce</b>	3048104877	\$289,553.	\$0.	\$289,553.
National Cancer Institute Novel Modular Vascular Patterning Assay for HTS				
<b>Pearson, Paul A</b>	3048050700	\$0.	\$4,177.	\$4,177.
University of Wisconsin Standard Care Versus Corticosteriod for Retinal Vein Occlusion( SCORE) Study				
<b>Pearson, Paul A</b>	3048050700	\$0.	\$234.	\$234.
University of Wisconsin Standard Care Versus Corticosteriod for Retinal Vein Occlusion( SCORE) Study				
<b>Pearson, Paul A</b>	3048050700	\$0.	\$7,429.	\$7,429.
University of Wisconsin Standard Care Versus Corticosteriod for Retinal Vein Occlusion( SCORE) Study				
<b>Ophthalmology Totals:</b>		<b>\$625,171.</b>	<b>\$964,646.</b>	<b>\$1,589,817.</b>
<b><u>Radiation Medicine</u></b>				
<b>Kudrimoti, Mahesh</b>		\$2.	\$0.	\$2.
SciClone Pharmaceuticals Inc A Phase 2, Multi-center, Randomized, Double-Blind, Placebo-controlled, Dose Ranging Study to Assess the Safety and Efficacy of SCV-07 for the Delay to Onset of Severe Oral Mucositis in Subjects				
<b>Kudrimoti, Mahesh</b>	3048044300	\$0.	\$200.	\$200.
TRIAD Burden of Illness Inc Risk and Outcomes of Mucositis in Subjects Being Treated for Breast, Colorectal, Head and Neck, Non-small Cell Lung or Ovarian Cancers				

**Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009**

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b><u>Radiation Medicine</u></b>				
<b>Kudrimoti, Mahesh</b>	3048104578	\$0.	\$-2.	\$-2.
Endo Pharmaceutical Inc A Phase 3, Multi-center, Randomized, Double-Blind, Placebo-Controlled study to assess the Efficacy and Safety of ENDO3285 for Prevention or Delay to Onset of Severe Oral Mucositis in Patients with Head and Neck Cancer Receiving Chemoradiotherapy				
<b>Kudrimoti, Mahesh</b>	3048104578	\$0.	\$1,800.	\$1,800.
Endo Pharmaceutical Inc A Phase 3, Multi-center, Randomized, Double-Blind, Placebo-Controlled study to assess the Efficacy and Safety of ENDO3285 for Prevention or Delay to Onset of Severe Oral Mucositis in Patients with Head and Neck Cancer Receiving Chemoradiotherapy				
<b>Kudrimoti, Mahesh</b>	3048105244	\$2.	\$0.	\$2.
AMGen A Phase 2 Randomized Trial of Chemoradiation with or without Panitumumab in Subjects with Unresected, Locally Advanced Squamous Cell Carcinoma of the Head and Neck				
<b>Randall, Marcus</b>	3048105280	\$8,800.	\$0.	\$8,800.
Gynecologic Oncology Group Chair or Co-Chair of the Corpus Committee				
<b>Rangnekar, Vivek M</b>	3048105266	\$302,065.	\$0.	\$302,065.
National Cancer Institute Mechanism of Apoptosis and Inhibition of Tumor Progression and Metastasis by Par-4				
<b>St Clair, William H</b>	3048103792	\$0.	\$250,538.	\$250,538.
National Cancer Institute Redox Modulation Of Prostate Cancer				
<b>Warren, Graham W</b>	3048104845	\$50,000.	\$0.	\$50,000.
American Society of Clinical Oncology ASCO Young Investigator Award: Nicotine in the Regulation of Lung Cancer Treatment Response				
<b>Radiation Medicine</b>	<b>Totals:</b>	<b>\$360,869.</b>	<b>\$252,536.</b>	<b>\$613,405.</b>
<b><u>Physical Medicine and Rehabilitation</u></b>				
<b>Adams, Lumy Sawaki</b>	3048104590	\$0.	\$-5,481.	\$-5,481.
American Heart Association Enhancing Cortical Plasticity with Nerve Stimulation in Stroke Patients with Severe Motor Deficit				
<b>Adams, Lumy Sawaki</b>	3048104591	\$0.	\$-59,100.	\$-59,100.
National Institute of Child Health and Human Develop Sensory-driven Motor Recovery in Poorly Recovered Subacute Stroke Patients				
<b>Adams, Lumy Sawaki</b>	3048104592	\$0.	\$10,998.	\$10,998.
National Institute of Child Health and Human Develop Driving Neuroplasticity with Nerve Stimulation and Modified CIT				
<b>Adams, Lumy Sawaki</b>	3048104753	\$0.	\$-194.	\$-194.
Charles A Dana Foundation Enhancement of Post-Stroke Neural Plasticity with Atomoxetine: A Pilot Study				
<b>Adams, Lumy Sawaki</b>	3048104753	\$36,600.	\$0.	\$36,600.
Charles A Dana Foundation Enhancement of Post-Stroke Neural Plasticity with Atomoxetine: A Pilot Study				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Physical Medicine and Rehabilitation</b>				
<b>McEwen, Melanie L</b>	3048104272	\$0.	\$111,267.	\$111,267.
Craig H Neilsen Foundation NIM811 Treatment for Pediatric Spinal Cord Injury				
<b>Shahid Salles, Sara</b>	3048105345	\$6,700.	\$0.	\$6,700.
University of California Irvine United States multi-center study to access the validity and reliability of the Spinal Cord Independence Measure (SCIM) III				
<b>Physical Medicine and Rehabilitation</b>	<b>Totals:</b>	<b>\$43,300.</b>	<b>\$57,490.</b>	<b>\$100,790.</b>
	<b>Medicine Totals:</b>	<b>\$45,498,683.</b>	<b>\$24,439,206.</b>	<b>\$69,937,889.</b>
<b>Pharmacy</b>				
<b>Pharmacy</b>				
<b>Stinchcomb, Audra L</b>	3048104879	\$7,325.	\$0.	\$7,325.
AllTranz Evaluation of a Drug for Dermal Delivery				
<b>Pharmacy</b>	<b>Totals:</b>	<b>\$7,325.</b>	<b>\$0.</b>	<b>\$7,325.</b>
<b>Pharmaceutical Tech</b>				
<b>Al-Ghananeem, Abeer</b>	3048103825	\$0.	\$88,971.	\$88,971.
US Worldmeds LLC Formulation Development of Intravenous and Oral Dosage Forms				
<b>Anderson, Bradley D</b>	3048105301	\$60,001.	\$0.	\$60,001.
Boehringer Ingelheim Optimizing Oral Absorption of Poorly Water Soluble Drug Candidates: Mechanisms and Predictive Models for the Selection of Excipients to Maintain Supersaturation by Inhibiting Nucleation and Crystallization				
<b>Black, Esther P</b>	3048103763	\$0.	\$72,310.	\$72,310.
KY Lung Cancer Research Fund Dusp4 Activity in Non-Small Cell Lung Cancers: An Opportunity for Intervention?				
<b>Bummer, Paul M</b>	3048103769	\$0.	\$290,101.	\$290,101.
National Cancer Institute Development of Dosage Forms and Delivery Systems for Anti-Tumor Agents				
<b>Crooks, Peter A</b>	3046581000	\$0.	\$99,000.	\$99,000.
US Worldmeds LLC KSTC R & D Voucher: Product development and formulation				
<b>Crooks, Peter A</b>	3046698800	\$0.	\$15,000.	\$15,000.
Yaupon Therapeutics Inc Post Doctoral Fellowship				
<b>Crooks, Peter A</b>	3046831000	\$0.	\$65,800.	\$65,800.
Washington University Radiosensitization by the Cellular Heat Shock Response				
<b>Crooks, Peter A</b>	3046989300	\$0.	\$4,520.	\$4,520.
Yaupon Therapeutics Inc Lobeline Epimer Ratio Determination Study				

## Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009

		New Accounts	Adjustments to Existing Accounts	Total
<b>Pharmacy</b>				
<b>Pharmaceutical Tech</b>				
<b>Crooks, Peter A</b>	3048048700	\$0.	\$9,000.	\$9,000.
Pradama Inc Novel Bone-Targeting Agents				
<b>Crooks, Peter A</b>	3048105198	\$72,550.	\$0.	\$72,550.
University of Rochester A Novel Thiadiazolidine-Dione Targets Human Leukemia Stem Cells				
<b>Dwoskin, Linda P</b>	3046930400	\$0.	\$545,671.	\$545,671.
National Institute on Drug Abuse Development of Novel Therapies for Methamphetamine Abuse				
<b>Dwoskin, Linda P</b>	3048103421	\$0.	\$21,000.	\$21,000.
American Heart Association Ohio Valley Affiliate Fellowship for Vidya Narayanaswami: The Role of Angiotensin in Nicotine Reward and Nicotine Induced Hypertension				
<b>Li, Tonglei</b>	3048103700	\$0.	\$20,000.	\$20,000.
PhRMA Foundation Fellowship for Aubrey-Medendorp: Investigation of Surface Energy Using Atomic Force Microscopy				
<b>Loftin, Charles D</b>	3048104759	\$20,000.	\$0.	\$20,000.
PhRMA Foundation Fellowship for Julie Oestreich: The Effects of P2Y12 Polymorphisms on Platelet Receptor Expression and Activation				
<b>Nixon, Kimberly</b>	3048104311	\$0.	\$292,729.	\$292,729.
National Institute on Alcohol Abuse and Alcoholism Ethanol Alteration of the Neurogenic Niche				
<b>Rohr, Jurgen</b>	3048105065	\$251,484.	\$0.	\$251,484.
National Cancer Institute Novel Aureolic Acid-Type Antitumor Agents				
<b>Stinchcomb, Audra L</b>	3048105002	\$30,524.	\$0.	\$30,524.
National Institute on Drug Abuse NRSA Fellowship for Swadley: Transdermal Delivery of Hydroxyphenylarachidonylamides				
<b>Van Lanen, Steven</b>	3048105216	\$10,000.	\$0.	\$10,000.
Daiichi Pharmaceutical Corp Biosynthesis of Nucleoside Antibiotics				
<b>Zhan, Chang-Guo</b>	3048046900	\$0.	\$446,186.	\$446,186.
National Institute on Drug Abuse Redesign of Butyrylcholinesterase for Cocaine Metabolism				
<b>Zhan, Chang-Guo</b>	3048105116	\$498,945.	\$0.	\$498,945.
National Institute on Drug Abuse High-Activity Mutants of Cocaine Esterase for Treatment of Drug Addiction				
<b>Pharmaceutical Tech</b>	<b>Totals:</b>	<b>\$943,504.</b>	<b>\$1,970,288.</b>	<b>\$2,913,792.</b>

**Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Pharmacy</u></b>				
<b><u>Pharmacy Practice &amp; Science</u></b>				
<b>Blumenschein, Karen M</b>	3048104895	\$5,000.	\$0.	\$5,000.
American Foundation for Pharmaceutical Ed Do Patients and Pharmacists Agree on the Interpretation of Verbal Probability Statements				
<b>Gatz, Jennifer L</b>	3048090700	\$0.	\$40,000.	\$40,000.
PhRMA Foundation Predictors of Absconding from State Psychiatric Hospitals				
<b>Talbert, Jeffery C</b>	3048104965	\$905,686.	\$0.	\$905,686.
Department for Mental Health Mental Retardation Service Research Information Systems Management for KY Department for Mental Health/Mental Retardation				
<b>Talbert, Jeffery C</b>	3048105182	\$1,722,468.	\$0.	\$1,722,468.
KY Cabinet for Health and Family Services Money Follows the Person (MFP)				
<b>Pharmacy Practice &amp; Science</b>	<b>Totals:</b>	<b>\$2,633,154.</b>	<b>\$40,000.</b>	<b>\$2,673,154.</b>
	<b>Pharmacy Totals:</b>	<b>\$3,583,983.</b>	<b>\$2,010,288.</b>	<b>\$5,594,271.</b>
<b><u>Health Sciences</u></b>				
<b><u>Rehabilitation Sciences</u></b>				
<b>Capilouto, Gilson J</b>	3048104021	\$0.	\$114,012.	\$114,012.
Arizona State University Discourse Processing in Healthy Aging				
<b>Dupont-Versteegden, Esther</b>	3048049900	\$0.	\$277,005.	\$277,005.
National Institute on Aging Integrated Study of Musculoskeletal Loss and Restoration				
<b>Kitzman, Patrick H</b>	3048104899	\$16,706.	\$0.	\$16,706.
KY Science and Technology Co Inc Planning Grant for Establishing a Collaborative Team to Investigate: Health and Quality of Life Related Challenges for Individuals with Spinal Cord Injury, Living in Medically Underserved Areas of Kentucky, Receiving Rehabilitation Services				
<b>Kleinert, Jane</b>	3048105322	\$0.	\$2,160.	\$2,160.
KY Health Services Cabinet Kentucky Youth Advocacy Project				
<b>Kleinert, Jane</b>	3048105322	\$150,000.	\$0.	\$150,000.
KY Health Services Cabinet Kentucky Youth Advocacy Project				
<b>Rehabilitation Sciences</b>	<b>Totals:</b>	<b>\$166,706.</b>	<b>\$393,177.</b>	<b>\$559,883.</b>
<b><u>Administrative Services</u></b>				
<b>Peterson, Charlotte A.</b>	3048049700	\$0.	\$269,470.	\$269,470.
National Institute on Aging Changes in Myogenic Progenitor Potential with Age				
<b>Administrative Services</b>	<b>Totals:</b>	<b>\$0.</b>	<b>\$269,470.</b>	<b>\$269,470.</b>

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Health Sciences</u></b>				
<b><u>Clinical Sciences</u></b>				
<b>Baker, Doris J</b>	3048105077	\$2.	\$0.	\$2.
Genzyme Corp Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis: CAMMS323 and 324				
<b>Bruckner, Geza G</b>	3048104972	\$25,000.	\$0.	\$25,000.
KY Diabetes Research Trust Fund Developing Health Sciences Students to Be Health Navigators for Diabetes Prevention and Care				
<b>Powdrill, Samuel G</b>	3048104898	\$107,130.	\$0.	\$107,130.
Health Resources and Services Administration Targeted Training for Physician Assistant Students Caring for At Risk Populations in Kentucky				
<b>Clinical Sciences</b>	<b>Totals:</b>	<b>\$132,132.</b>	<b>\$0.</b>	<b>\$132,132.</b>
	<b>Health Sciences Totals:</b>	<b>\$298,838.</b>	<b>\$662,647.</b>	<b>\$961,485.</b>
<b><u>Public Health</u></b>				
<b><u>Public Health Leadership Institute</u></b>				
<b>Scutchfield, F Douglas</b>	3048104880	\$150,000.	\$0.	\$150,000.
KY Department for Public Health KY Public Health Leadership Institute				
<b>Public Health Leadership Institute</b>	<b>Totals:</b>	<b>\$150,000.</b>	<b>\$0.</b>	<b>\$150,000.</b>
<b><u>Preventive Med &amp; Environmental Health</u></b>				
<b>Allweiss, Pamela H</b>	3048105242	\$154,334.	\$0.	\$154,334.
Center for Disease Control and Prevention IPA for Centers for Disease Control and Prevention				
<b>Brion, Gail</b>	3046936300	\$0.	\$72,808.	\$72,808.
University of Louisville Health Effects of Occupational Exposure in PGDP Workers				
<b>Preventive Med &amp; Environmental Health</b>	<b>Totals:</b>	<b>\$154,334.</b>	<b>\$72,808.</b>	<b>\$227,142.</b>
<b><u>Health Behavior</u></b>				
<b>Alexander, Linda</b>	3048105074	\$74,973.	\$0.	\$74,973.
American Legacy Foundation Exploring Organizational, Cultural and Individual Barriers Associated with the Utilization of a Worksite Tobacco Cessation Program				
<b>Cecil, James C</b>	3048105009	\$0.	\$127,460.	\$127,460.
KY Health Services Cabinet Institute for Maternal and Child Health Education and Training				
<b>Cecil, James C</b>	3048105009	\$65,100.	\$0.	\$65,100.
KY Health Services Cabinet Institute for Maternal and Child Health Education and Training				
<b>Crosby, Richard</b>	3048012800	\$0.	\$596,178.	\$596,178.
National Institute of Allergy and Infectious Diseases Do Condoms Protect from Non-Viral Sexually Transmitted Infections?				
<b>Crosby, Richard</b>	3048105243	\$366,250.	\$0.	\$366,250.
National Institute of Mental Health A Brief, Clinic-Based, HIV Prevention Program for African American Teen Males				

**Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Public Health</u></b>				
<b><u>Health Behavior</u></b>				
<b>Crosby, Richard</b>	3048105330	\$5,869.	\$0.	\$5,869.
Charm Inc Intent for Collaborating Project between CHARM, Inc. and the University of Kentucky Research Foundation				
<b>Crosby, Richard</b>	3048105344	\$23,729.	\$0.	\$23,729.
Charm Inc Intent for Collaborating Project between CHARM, Inc. and the University of Kentucky Research Foundation				
<b>Health Behavior</b>	<b>Totals:</b>	<b>\$535,921.</b>	<b>\$723,638.</b>	<b>\$1,259,559.</b>
<b><u>Health Services Management</u></b>				
<b>Costich, Julia F</b>	3048103756	\$0.	\$-15,456.	\$-15,456.
University of Southern Mississippi Public Health Finance: Advancing a Field of Study				
<b>Costich, Julia F</b>	3048103756	\$0.	\$15,456.	\$15,456.
University of Southern Mississippi Public Health Finance: Advancing a Field of Study				
<b>Costich, Julia F</b>	3048104871	\$63,000.	\$0.	\$63,000.
KY Department for Public Health Core Curriculum for Bioterrorism Preparedness				
<b>Hill, Raymond E</b>	3048104955	\$5,000.	\$0.	\$5,000.
KY Department for Public Health SCBD Diabetes Education/Training				
<b>Scutchfield, F Douglas</b>	3048103603	\$0.	\$2,107,904.	\$2,107,904.
Robert Wood Johnson Foundation Public Health Systems and Services Research Center				
<b>Health Services Management</b>	<b>Totals:</b>	<b>\$68,000.</b>	<b>\$2,107,904.</b>	<b>\$2,175,904.</b>
<b><u>Epidemiology</u></b>				
<b>Browning, Steven</b>	3048104983	\$15,720.	\$0.	\$15,720.
St Elizabeth Medical Center Evaluation of Northern Kentucky Womens Cardiovascular Assessment, Risk Reduction and Care Collaborative				
<b>Hopenhayn, Claudia</b>	3048104991	\$20,069.	\$0.	\$20,069.
KY Health Services Cabinet SCBL - Behavioral Risk Factor Surveillance System Analysis				
<b>Robl, Joyce M</b>	3048104903	\$55,700.	\$0.	\$55,700.
KY Department for Public Health KY Birth Surveillance Registry				
<b>Epidemiology</b>	<b>Totals:</b>	<b>\$91,489.</b>	<b>\$0.</b>	<b>\$91,489.</b>
<b><u>Biostatistics</u></b>				
<b>Mendondo, Marta S</b>	3048105172	\$25,000.	\$0.	\$25,000.
Florida Department of Elder Affairs Evaluation of Florida's Public Guardianship Program				
<b>Biostatistics</b>	<b>Totals:</b>	<b>\$25,000.</b>	<b>\$0.</b>	<b>\$25,000.</b>

**Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Public Health</u></b>				
<b><u>Center for Prevention Research</u></b>				
<b>Clayton, R R</b>	3048076300	\$0.	\$257,355.	\$257,355.
Robert Wood Johnson Foundation Tobacco Etiology Research Network: Analysis and Dissemination				
<b>Harris, Torrie</b>	3048104838	\$38,150.	\$0.	\$38,150.
KY River Community Care Inc Using Medications Safely: Prevention for Generation Rx Evaluation of a Prescription Drug Abuse Prevention Program				
<b>Jones, Jeffery A</b>	3048104854	\$0.	\$800.	\$800.
KY Department of Education School Health Atlas: Spatial Analysis of Coordinated School Health Data				
<b>Jones, Jeffery A</b>	3048104854	\$10,000.	\$0.	\$10,000.
KY Department of Education School Health Atlas: Spatial Analysis of Coordinated School Health Data				
<b>Jones, Jeffery A</b>	3048104904	\$83,723.	\$0.	\$83,723.
Foundation for a Healthy KY Foundation for a Healthy Kentucky, Coordinated School Health Grants Evaluation				
<b>Jones, Jeffery A</b>	3048105356	\$3,000.	\$0.	\$3,000.
Lexington Fayette Urban County Government Evaluation of 21st Century Grant				
<b>Center for Prevention Research</b>	<b>Totals:</b>	<b>\$134,873.</b>	<b>\$258,155.</b>	<b>\$393,028.</b>
<b><u>KY Injury Prevention &amp; Research Center</u></b>				
<b>Bunn, Terry L</b>	3048104873	\$38,184.	\$0.	\$38,184.
KY Department for Public Health Occupational Safety and Health Surveillance				
<b>Bunn, Terry L</b>	3048104889	\$268,150.	\$0.	\$268,150.
National Institute of Occupational Safety and Health Kentucky Occupational Safety and Health Surveillance				
<b>Costich, Julia F</b>	3048104742	\$311,688.	\$0.	\$311,688.
KY Department for Public Health State Injury Prevention Program				
<b>Costich, Julia F</b>	3048104743	\$66,000.	\$0.	\$66,000.
KY Department for Public Health KIPRC Consumer Product Safety Commission				
<b>Costich, Julia F</b>	3048105076	\$124,260.	\$0.	\$124,260.
Center for Disease Control and Prevention Public Health Injury Surveillance and Prevention Program				
<b>Costich, Julia F</b>	3048105314	\$23,921.	\$0.	\$23,921.
Northern Kentucky Chamber of Commerce Northern KY Small Business Health Insurance Feasibility Study				

**Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Public Health</u></b>				
<b><u>KY Injury Prevention &amp; Research Center</u></b>				
<b>McCool, Robert H</b>	3048104997	\$143,470.	\$0.	\$143,470.
Center for Disease Control and Prevention Kentucky Residential Fire Injury Prevention Project				
<b>Pollack, Susan H</b>	3048005000	\$0.	\$10,000.	\$10,000.
Allstate Foundation Injury Free/Allstate Safe Playgrounds 2004				
<b>Pollack, Susan H</b>	3048104945	\$179,300.	\$0.	\$179,300.
KY Department for Public Health Pediatric and Adolescent Injury Prevention Program				
<b>Singleton, Michael</b>	3048105061	\$134,331.	\$0.	\$134,331.
KY Department for Public Health Acquired Brain Injury and Spinal Cord Injury Surveillance				
<b>Singleton, Michael</b>	3048105079	\$40,000.	\$0.	\$40,000.
National Highway Traffic Safety Administration The Crash Outcome Data Evaluation System (CODES) Data Network Program				
<b>Walsh, Sabrina L</b>	3048105075	\$206,774.	\$0.	\$206,774.
Center for Disease Control and Prevention National Violent Death Reporting System (NVDRS)				
<b>KY Injury Prevention &amp; Research Center</b>	<b>Totals:</b>	<b>\$1,536,078.</b>	<b>\$10,000.</b>	<b>\$1,546,078.</b>
<b><u>Southeast Cntr for Ag Health &amp; Injury Pr</u></b>				
<b>Donovan, Teresa</b>	3048105262	\$6,000.	\$0.	\$6,000.
Colorado State University Developing and Testing Interactive CD Health and Safety Curricula for 4-H Youth (Year 2)				
<b>McKnight, Robert H</b>	3048104770	\$60,148.	\$0.	\$60,148.
Center for Disease Control and Prevention Agricultural Safety and Health Training for Public Health Graduate Students				
<b>McKnight, Robert H</b>	3048105073	\$63,346.	\$0.	\$63,346.
KY Department for Medicaid Services Dept. of Medicaid Services KCHIP Migrant Outreach Project				
<b>McKnight, Robert H</b>	3048105180	\$1,036,294.	\$0.	\$1,036,294.
National Institute of Occupational Safety and Health Southeast Center for Agricultural Health and Injury Prevention				
<b>McKnight, Robert H</b>	3048105357	\$10,000.	\$0.	\$10,000.
Colorado State University High Plains Intermountain Center for Agriculture Health & Safety - Agriculture Center Evaluation for Kentucky				
<b>Southeast Cntr for Ag Health &amp; Injury Pr</b>	<b>Totals:</b>	<b>\$1,175,788.</b>	<b>\$0.</b>	<b>\$1,175,788.</b>
<b><u>Council on Aging</u></b>				
<b>Johnson, Helen A</b>	3048104769	\$0.	\$95,091.	\$95,091.
KY Department for Public Health UK 2008 2009 Emergency Preparedness for Aging Training				

**Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Public Health</u></b>				
<b><u>Council on Aging</u></b>				
<b>Johnson, Helen A</b>	3048104769	\$96,000.	\$0.	\$96,000.
KY Department for Public Health UK 2008 2009 Emergency Preparedness for Aging Training				
<b>Johnson, Helen A</b>	3048104874	\$361,631.	\$0.	\$361,631.
Health Resources and Services Administration OVAR/GEC Interdisciplinary Care				
<b>Johnson, Helen A</b>	3048105128	\$23,036.	\$0.	\$23,036.
Department for Mental Health Mental Retardation Service 2008 PASRR Skills Training				
<b>Smith, Michael D</b>		\$100,000.	\$0.	\$100,000.
Bernard Osher Foundation Osher Lifelong Learning Institute				
<b>Council on Aging</b>	<b>Totals:</b>	<b>\$580,667.</b>	<b>\$95,091.</b>	<b>\$675,758.</b>
<b><u>Center for Public Health Syst &amp; Svcs Res</u></b>				
<b>Scutchfield, F Douglas</b>	3048105268	\$25,000.	\$0.	\$25,000.
National Library of Medicine Increasing the Availability and Promoting the Use of the National Library of Medicine's Datasets for Public Health Systems Research				
<b>Scutchfield, F Douglas</b>	3048105321	\$115,000.	\$0.	\$115,000.
Public Health Foundation Center of Excellence for Public Health Workforce Research and Policy				
<b>Scutchfield, F Douglas</b>	3048105395	\$17,552.	\$0.	\$17,552.
Ohio State University Buckeye Bluegrass Regional Leadership Academy				
<b>Center for Public Health Syst &amp; Svcs Res</b>	<b>Totals:</b>	<b>\$157,552.</b>	<b>\$0.</b>	<b>\$157,552.</b>
	<b>Public Health Totals:</b>	<b>\$4,609,702.</b>	<b>\$3,267,596.</b>	<b>\$7,877,298.</b>
<b><u>Agriculture</u></b>				
<b><u>International Programs</u></b>				
<b>Reed, Michael R</b>	3046123000	\$0.	\$7,201.	\$7,201.
Thai Ministry of Agriculture and Cooperatives Scholarships for Thai Ministry of Agriculture Officials				
<b>Reed, Michael R</b>	3046900500	\$0.	\$20,389.	\$20,389.
Foreign Agricultural Service Technical Assistance to the Extension System in Serbia				
<b>Reed, Michael R</b>	3048105051	\$13,000.	\$0.	\$13,000.
Department of Agriculture The Norman E. Borlaug International Agricultural Science and Technology Fellows Program for El Salvador				
<b>International Programs</b>	<b>Totals:</b>	<b>\$13,000.</b>	<b>\$27,590.</b>	<b>\$40,590.</b>
<b><u>Assoc Dean Research/Director AES</u></b>				
<b>Cox, Nancy Marguerite</b>	3048087900	\$0.	\$5,590.	\$5,590.
Agricultural Research Service ARS/SCA Cooperative Agreement				

**Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Agriculture</u></b>				
<b><u>Assoc Dean Research/Director AES</u></b>				
<b>Cox, Nancy Marguerite</b>	3048104698	\$487,426.	\$0.	\$487,426.
KY Horse Racing Authority Equine Medical Director				
<b>Cox, Nancy Marguerite</b>	3048105003	\$80,000.	\$0.	\$80,000.
KY Council on Postsecondary Education Equine Trust Fund				
<b>Cox, Nancy Marguerite</b>	3048105135	\$0.	\$3,264.	\$3,264.
Agricultural Research Service Acquisition of Goods and Services for USDA offices in Ag North -- 2008-09				
<b>Cox, Nancy Marguerite</b>	3048105135	\$31,500.	\$0.	\$31,500.
Agricultural Research Service Acquisition of Goods and Services for USDA offices in Ag North -- 2008-09				
<b>Assoc Dean Research/Director AES</b>	<b>Totals:</b>	<b>\$598,926.</b>	<b>\$8,854.</b>	<b>\$607,780.</b>
<b><u>Tracy Farmer Cntr for the Environment</u></b>				
<b>Hanley, Carol D</b>	3048104808	\$205,000.	\$0.	\$205,000.
KY Department of Military Affairs 4-H Community-Based Science				
<b>Tracy Farmer Cntr for the Environment</b>	<b>Totals:</b>	<b>\$205,000.</b>	<b>\$0.</b>	<b>\$205,000.</b>
<b><u>Agr Economics</u></b>				
<b>Meyer, Alphonse L</b>	3048105088	\$51,169.	\$0.	\$51,169.
University of Georgia Supporting and Enhancing the Role of SARE in Extension and Other Land Grant University Programs				
<b>Meyer, Alphonse L</b>	3048105122	\$20,000.	\$0.	\$20,000.
University of Georgia Sustainable Agriculture Research and Education (SARE) Model State Program Assistant				
<b>Meyer, Alphonse L</b>	3048105123	\$10,000.	\$0.	\$10,000.
University of Georgia Kentucky's SARE 2008-2009 Model State Program and Professional Development Program Plan of Work				
<b>Meyer, Alphonse L</b>	3048105176	\$8,528.	\$0.	\$8,528.
University of Georgia Agent Training for the Development of a Program in Farm Transitions				
<b>Pushkarskaya, Helen N</b>	3048104888	\$142,756.	\$0.	\$142,756.
Cooperative State Research Education and Extension On-line Math Modules				
<b>Robbins, Lynn W</b>	3048103813	\$0.	\$-2,000.	\$-2,000.
KY Governor's Office of Agricultural Policy KADB: Pilot Farm Management Cost-Share Program				
<b>Woods, Timothy A</b>	3046997000	\$0.	\$1,500.	\$1,500.
KY Center for Cooperative Development Cooperatives Intern Program				

**Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Agriculture</u></b>				
<b><u>Agr Economics</u></b>				
<b>Woods, Timothy A</b>	3048105373	\$17,909.	\$0.	\$17,909.
Iowa State University Using MarketMaker Demographics Tools to Estimate Market Potential for Value-Added Agriculture Products				
<b>Agr Economics</b>	<b>Totals:</b>	<b>\$250,362.</b>	<b>\$-500.</b>	<b>\$249,862.</b>
<b><u>Biosystems &amp; Ag Eng</u></b>				
<b>Colliver, Donald G</b>	3048104967	\$54,520.	\$0.	\$54,520.
KY Office of Energy Policy Renewable Energy/Energy Efficiency (REEE) Program Support				
<b>Fehr, Robert L</b>	3048104782	\$95,651.	\$0.	\$95,651.
KY Office of Energy Policy Energy - A Cooperative Extension Program for Kentucky's Building Systems Energy Needs				
<b>Fehr, Robert L</b>	3048105017	\$89,200.	\$0.	\$89,200.
KY Health Services Cabinet Radon: Cooperative Extension Radon and Indoor Air Quality Education				
<b>Higgins, Stephen F</b>	3048104835	\$5,000.	\$0.	\$5,000.
Fayette County Conservation District On-Farm Water Enhancement Program for a Spring Development				
<b>Higgins, Stephen F</b>	3048104836	\$1,500.	\$0.	\$1,500.
Fayette County Conservation District On-Farm Water Enhancement Program for a Forage Area				
<b>Payne, Frederick A</b>	3048105108	\$1,175,481.	\$0.	\$1,175,481.
National Institute for Hometown Security Technology Optimization of a Milk Transport Security System				
<b>Shearer, Scott A</b>	3048105137	\$97,579.	\$0.	\$97,579.
Case New Holland America LLC CNH Master Agreement				
<b>Shearer, Scott A</b>	3048105185	\$468,551.	\$0.	\$468,551.
Cooperative State Research Education and Extension Precision Agriculture: Precision Resource Management Phase IV				
<b>Workman, Stephen R</b>	3048104900	\$100,000.	\$0.	\$100,000.
Cooperative State Research Education and Extension International Education and Training for Food, Fiber, and Energy Production				
<b>Workman, Stephen R</b>	3048105389	\$20,000.	\$0.	\$20,000.
Texas A&M University 2008 Southern Regional Water Resource Project				
<b>Biosystems &amp; Ag Eng</b>	<b>Totals:</b>	<b>\$2,107,482.</b>	<b>\$0.</b>	<b>\$2,107,482.</b>
<b><u>Plant &amp; Soil Sciences</u></b>				
<b>Bertsch, Paul M</b>	3048104999	\$51,598.	\$0.	\$51,598.
Environmental Protection Agency Bioavailability, Toxicity, and Trophic Transfer of Manufactured ZnO Nanoparticles: A View from the Bottom				

## Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Agriculture</u></b>				
<b><u>Plant &amp; Soil Sciences</u></b>				
<b>Bertsch, Paul M</b>	3048105034	\$50,000.	\$0.	\$50,000.
Department of Energy Environmental Remediation Science at Beamline X26A at the National Synchrotron Light Source				
<b>Bertsch, Paul M</b>	3048105332	\$110,000.	\$0.	\$110,000.
Duke University Center for the Environmental Implications of Nanotechnology (CEIN)				
<b>Bruening, William P</b>		\$50,000.	\$0.	\$50,000.
KY Soybean Promotion Board Performance of Soybean Varieties in Kentucky				
<b>Chappell, Joseph</b>	3048105226	\$249,925.	\$0.	\$249,925.
National Science Foundation Development of a Sustainable Production Platform for Renewable Petroleum Based Oils in Algae				
<b>D'Angelo, Elisa Marie</b>	3048105209	\$10,000.	\$0.	\$10,000.
University of Georgia S. Lucas-SARE: Effects of organic amendments on aggregation and microbial community dynamics in soils				
<b>Davies, H Maelor</b>	3048105197	\$531,337.	\$0.	\$531,337.
Philip Morris International Management SA Nicotiana Germplasm Survey				
<b>Davies, H Maelor</b>	3048105376	\$31,800.	\$0.	\$31,800.
Tobacco Education and Research Council Inc A Survey of 'GM' Technologies Appropriate to Tobacco Production for its Traditional Markets				
<b>Green, Jonathan D</b>	3048104665	\$116,188.	\$0.	\$116,188.
Cooperative State Research Education and Extension Integrated Weed Management Strategies to Increase Pasture Productivity				
<b>Hildebrand, David F</b>	3048105189	\$90,000.	\$0.	\$90,000.
Consortium for Plant Biotechnology Research Inc Oilseeds as a Renewable Source of Epoxy Fatty Acids				
<b>Hildebrand, David F</b>	3048105380	\$59,474.	\$0.	\$59,474.
United Soybean Board Further Development of Soybeans with Higher Levels of Improved Oil and Enhanced Fungal Resistance				
<b>Hunt, Arthur G</b>	3048105143	\$224,991.	\$0.	\$224,991.
National Science Foundation Collaborative Proposal: CPSF30 at the Convergence of RNA Processing, Cellular Signaling and Development in Plants				
<b>Karathanasis, Anastasios D</b>	3048104924	\$2.	\$0.	\$2.
KY Health Services Cabinet Soil Morphology Training for On-Site Sewage Disposal Systems				
<b>Lee, Chad D</b>	3048105104	\$74,128.	\$0.	\$74,128.
Iowa State University Agronomic Limitations of Soybean Yield and Seed Quality in U.S.				

**Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Agriculture</u></b>				
<b><u>Plant &amp; Soil Sciences</u></b>				
<b>Lee, Chad D</b>	3048105353	\$6,000.	\$0.	\$6,000.
KY Small Grain Promotion Council Wheat Yield in 15-inch Rows				
<b>Lee, Chad D</b>	3048105354	\$10,000.	\$0.	\$10,000.
KY Small Grain Promotion Council Wheat Yield Response to Old Corn Rows				
<b>Martin, James R</b>	3048105161	\$3,000.	\$0.	\$3,000.
KY Small Grain Growers Association Application Timing for Italian Ryegrass Control in Conventional & No-tillage Wheat				
<b>Martin, James R</b>	3048105162	\$2,800.	\$0.	\$2,800.
KY Small Grain Growers Association Influence of Timing of Topdressing Nitrogen Fertilizer Relative to Application of Osprey Herbicide				
<b>McCulley, Rebecca L</b>	3048105142	\$50,419.	\$0.	\$50,419.
National Science Foundation Collaborative Research: Decomposition in Drylands: Soil Erosion and UV Interactions				
<b>McNear, David H</b>	3048105203	\$397,500.	\$0.	\$397,500.
Cooperative State Research Education and Extension Response to Soil Processes to an Above Ground Plant-Fungal Symbiosis from Rhizosphere to Regional Scales				
<b>Murdock, Lloyd W</b>	3048105163	\$5,000.	\$0.	\$5,000.
KY Small Grain Growers Association Improving Nitrogen Application Technology Under Kentucky Conditions				
<b>Schwab, Gregory J</b>	3048105165	\$6,000.	\$0.	\$6,000.
KY Small Grain Growers Association Wheat Management for Wet-Natured Soils				
<b>Smith, Samuel Ray</b>	3048104784	\$150,889.	\$0.	\$150,889.
Ceres Inc Biomass Field Trials				
<b>Tsyusko, Olga V</b>	3048105259	\$58,998.	\$0.	\$58,998.
University of Georgia Collaborative Research: The Evolution of Heterostylous Breeding Systems in Populations of Oxalis Alpina in the Sky Islands of the United States and Mexico				
<b>Urine, Jason M</b>	3048104803	\$0.	\$158,770.	\$158,770.
Environmental Protection Agency The Fate and Effects of Nanosized Metal Particles Along a Simulated Terrestrial Food Chain Investigated Using Genomic and Microspectroscopic Techniques				
<b>Urine, Jason M</b>	3048104803	\$159,127.	\$0.	\$159,127.
Environmental Protection Agency The Fate and Effects of Nanosized Metal Particles Along a Simulated Terrestrial Food Chain Investigated Using Genomic and Microspectroscopic Techniques				
<b>VanSanford, D A</b>	3048104461	\$0.	\$2,160.	\$2,160.
Virginia Polytechnic Institute and State University Wheat CAP Grant				

**Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Agriculture</u></b>				
<b><u>Plant &amp; Soil Sciences</u></b>				
<b>VanSanford, D A</b>	3048105167	\$39,750.	\$0.	\$39,750.
KY Small Grain Growers Association Soft Red Winter Wheat Breeding and Variety Development				
<b>Wendroth, Ole Otto</b>	3048105052	\$324,000.	\$0.	\$324,000.
Cooperative State Research Education and Extension Dynamics of Soil State Variables and Related Processes Across a Land Use Gradient in Spatial and Temporal Transition				
<b>Wendroth, Ole Otto</b>	3048105166	\$4,500.	\$0.	\$4,500.
KY Small Grain Growers Association Soil Mineral Nitrogen and Crop Biomass Dynamics of Winter Wheat in Space and Time in a Farmer's Field				
<b>Plant &amp; Soil Sciences</b>	<b>Totals:</b>	<b>\$2,867,426.</b>	<b>\$160,930.</b>	<b>\$3,028,356.</b>
<b><u>Animal and Food Sciences</u></b>				
<b>Boatright, William L</b>	3048105000	\$0.	\$401,222.	\$401,222.
Cooperative State Research Education and Extension Formation and Reactivity of Carbon-Centered Radicals in Isolated Soy Proteins				
<b>Boatright, William L</b>	3048105000	\$23,662.	\$0.	\$23,662.
Cooperative State Research Education and Extension Formation and Reactivity of Carbon-Centered Radicals in Isolated Soy Proteins				
<b>Bullock, Kevin D</b>	3048104807	\$50,000.	\$0.	\$50,000.
Cornell University National Beef Cattle Evaluation Consortium				
<b>Cantor, Austin H</b>	3048104339	\$0.	\$11,042.	\$11,042.
Alltech Biotechnology Inc Student Sponsorship Agreement for Lizza Macalintal				
<b>Cromwell, Gary L</b>	3048105115	\$5,000.	\$0.	\$5,000.
Department of Agriculture Developing Nutrient Requiement and Feeding Guidelines				
<b>Harmon, David L</b>		\$28,506.	\$0.	\$28,506.
Elanco Animal Health Elanco Animal Health Clinical Research Study Agreement - UKYDH0803				
<b>Harmon, David L</b>		\$5,685.	\$0.	\$5,685.
Elanco Animal Health Elanco Animal Health Clinical Research Study Agreement - UKYDH0802				
<b>Harmon, David L</b>	3048104079	\$0.	\$30,000.	\$30,000.
Alltech Biotechnology Inc Student Sponsorship Agreement - Holder				
<b>Harmon, David L</b>	3048105375	\$299,750.	\$0.	\$299,750.
Hills Pet Nutrition Inc Nutrient Utilization in the Dog 2009-1010				

**Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Agriculture</u></b>				
<b><u>Animal and Food Sciences</u></b>				
<b>Lawrence, Laurie M</b>	3048104078	\$0.	\$30,000.	\$30,000.
Alltech Biotechnology Inc Sponsored Student Stipend - Brummer				
<b>Lindemann, Merlin D</b>	3048105271	\$20,000.	\$0.	\$20,000.
Agricultural Research Service Impact of Fibrous Feedstuff on Marker Appearance and Disappearance, and on Nutrient Digestibility in Finishing Pigs				
<b>McLeod, Kyle R</b>	3048105398	\$224,614.	\$0.	\$224,614.
Hills Pet Nutrition Inc Essential Amino Acid and Fatty Acid Studies in Cats 2009-2010				
<b>Pescatore, Anthony J</b>	3048105347	\$32,400.	\$0.	\$32,400.
Alltech Biotechnology Inc Student Sponsorship Agreement for Anthony Quant				
<b>Suman, Surendranath P</b>	3048105343	\$99,999.	\$0.	\$99,999.
Cooperative State Research Education and Extension Differentiating Sarcoplasmic Proteomes of Color-Stable and Color-Labile Beef Muscles				
<b>Vanzant, Eric S</b>	3048105349	\$906,841.	\$0.	\$906,841.
National Institute for Hometown Security Animal Health Sensing and Surveillance: Early Disease Detection for Food Supply and Public Health Protection				
<b>Xiong, Youling</b>	3048104806	\$15,000.	\$0.	\$15,000.
KY State University Sensory evaluation of prawns from different genetic strains				
<b>Animal and Food Sciences</b>	<b>Totals:</b>	<b>\$1,711,457.</b>	<b>\$472,264.</b>	<b>\$2,183,721.</b>
<b><u>Entomology</u></b>				
<b>Dobson, Stephen Leonard</b>	3046961000	\$0.	\$71,354.	\$71,354.
University of Queensland Genetic Modification of Mosquito Populations to Make Them Incapable of Transmitting Dengue Virus				
<b>Dobson, Stephen Leonard</b>	3048035600	\$0.	\$310,665.	\$310,665.
National Institute of Allergy and Infectious Diseases Eradication of a Primary Filariasis Vector Population at an Endemic Field Site				
<b>Harwood, James Douglas</b>	3048104921	\$95,733.	\$0.	\$95,733.
KY Science and Technology Co Inc KSEF R&D Excellence: A Molecular Approach to Elucidate the Role of Invasive Mollusk Pests in Kentucky Agriculture				
<b>Johnson, Douglas W</b>	3048105164	\$2,404.	\$0.	\$2,404.
KY Small Grain Growers Association Migration Patterns for Aphid Pests of Small Grains as Indexed by Capture in an Aphid Suction Trap (Year 3)				
<b>Obrycki, John J</b>		\$10,000.	\$0.	\$10,000.
KY Energy and Environment Cabinet Hemlock Woolly Adelgid Sampling Surveys				

**Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Agriculture</u></b>				
<b><u>Entomology</u></b>				
<b>Obrycki, John J</b>	3048104886	\$68,565.	\$0.	\$68,565.
Animal and Plant Health Inspection Service Light Brown Apple Moth National Survey				
<b>Obrycki, John J</b>	3048104920	\$211,000.	\$0.	\$211,000.
Cooperative State Research Education and Extension Intraguild Predation between Aphidophagous Lady Beetles: Chemical Perspectives on Community Effects				
<b>Palli, Subba R</b>	3046862500	\$0.	\$193,429.	\$193,429.
National Institute of General Medical Sciences Molecular Analysis of Juvenile Hormone Action				
<b>Potter, Daniel A</b>	3048105072	\$26,530.	\$0.	\$26,530.
Dow AgroSciences Evaluation of Transgenic Turfgrasses for Resistance to Root-Feeding White Grubs				
<b>Potter, Daniel A</b>	3048105160	\$10,000.	\$0.	\$10,000.
ParaTechs Corp Development of a new production system for baculovirus pesticides				
<b>Potter, Daniel A</b>	3048105253	\$9,750.	\$0.	\$9,750.
University of Georgia Hammons - SARE: Sustainable Management for Scarab Pests Impacting Grape Production in the Southern Region				
<b>Webb, Bruce Allen</b>	3048104390	\$0.	\$137,632.	\$137,632.
ParaTechs Corp Enhancement of the Baculovirus Expression Vector System				
<b>Zhou, Xuguo</b>		\$50,271.	\$0.	\$50,271.
KY Science and Technology Co Inc Integration of Double Stranded RNA into Baiting System: A Novel Genetic Control Strategy for Termites				
<b>Entomology</b>	<b>Totals:</b>	<b>\$484,253.</b>	<b>\$713,080.</b>	<b>\$1,197,333.</b>
<b><u>Forestry</u></b>				
<b>Barton, Christopher D</b>	3048105156	\$25,000.	\$0.	\$25,000.
American Chestnut Foundation American Chestnut Restoration on Surface Mined Sites in Appalachia				
<b>Connors, Terrance E</b>	3048104944	\$17,000.	\$0.	\$17,000.
University of Georgia Forest Biomass Training for Kentucky				
<b>Cox, John J</b>	3048105007	\$0.	\$8,500.	\$8,500.
KY Department of Fish and Wildlife Terrestrial Nuisance Species Management Plan				
<b>Cox, John J</b>	3048105007	\$8,500.	\$0.	\$8,500.
KY Department of Fish and Wildlife Terrestrial Nuisance Species Management Plan				

**Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Agriculture</u></b>				
<b><u>Forestry</u></b>				
<b>Cox, John J</b>	3048105307	\$70,000.	\$0.	\$70,000.
KY Department of Fish and Wildlife Calf Survival, Meningeal Worm Impacts, Dispersal, and Population Expansion in an Eastern Kentucky Elk Herd				
<b>Cox, John J</b>	3048105338	\$30,000.	\$0.	\$30,000.
KY Department of Fish and Wildlife The Common Raven in Cliff Habitat: Detection and Occupancy				
<b>Cox, John J</b>	3048105390	\$98,000.	\$0.	\$98,000.
KY Department of Fish and Wildlife Dispersal & Population Expansion of the Black Bear in Eastern Kentucky				
<b>Cushing, Tamara L</b>	3048104929	\$24,100.	\$0.	\$24,100.
KY Environmental and Public Protection Cabinet Development of a Property Tax Assessment Guidelines for Woodland Owners in Kentucky				
<b>Fei, Songlin</b>	3048104996	\$15,000.	\$0.	\$15,000.
KY Environmental and Public Protection Cabinet Crosswalk and Develop GIS Mapping Applications and Accomplishment Monitoring Geospatial Database				
<b>Lacki, Michael J</b>	3048105309	\$48,703.	\$0.	\$48,703.
KY Department of Fish and Wildlife Status, Distribution, and Reproductive Characteristics of River Otters in Kentucky				
<b>Lhotka, John M</b>	3048104887	\$5,683.	\$0.	\$5,683.
Forest Service Evaluating Seedling Development, Stand Structure, and Understory Microenvironment Six Growing Seasons Following Midstory Removal				
<b>Stringer, Jeffrey W</b>	3048104998	\$20,000.	\$0.	\$20,000.
KY Environmental and Public Protection Cabinet Forest Stewardship Public Awareness, Publicity, and Training				
<b>Stringer, Jeffrey W</b>	3048105014	\$20,000.	\$0.	\$20,000.
KY Environmental and Public Protection Cabinet Kentucky Woodland Magazine Special Forest Health Issue				
<b>Stringer, Jeffrey W</b>	3048105015	\$20,000.	\$0.	\$20,000.
KY Environmental and Public Protection Cabinet Kentucky Woodland Magazine Special Pine Management Issue				
<b>Stringer, Jeffrey W</b>	3048105339	\$24,435.	\$0.	\$24,435.
KY Department of Fish and Wildlife Technical Support for Paul VanBooven Wildlife Management Area				
<b>Forestry</b>	<b>Totals:</b>	<b>\$426,421.</b>	<b>\$8,500.</b>	<b>\$434,921.</b>
<b><u>Family &amp; Consumer Sciences</u></b>				
<b>Adler, Linda C</b>	3048105012	\$5,500.	\$0.	\$5,500.
Auburn University Kentucky Healthy Homes and Communities				

**Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Agriculture</u></b>				
<b><u>Family &amp; Consumer Sciences</u></b>				
<b>Ashurst, Kerri Lynn</b>	3048105210	\$0.	\$50,000.	\$50,000.
Kansas State University Kentucky Operation: Military Kids				
<b>Ashurst, Kerri Lynn</b>	3048105210	\$50,000.	\$0.	\$50,000.
Kansas State University Kentucky Operation: Military Kids				
<b>Vail, Ann</b>	3048104885	\$602,473.	\$0.	\$602,473.
Cooperative State Research Education and Extension Health Education Leadership, KY				
<b>Family &amp; Consumer Sciences</b>	<b>Totals:</b>	<b>\$657,973.</b>	<b>\$50,000.</b>	<b>\$707,973.</b>
<b><u>Horticulture</u></b>				
<b>Fulcher, Amy F</b>	3048105336	\$3,000.	\$0.	\$3,000.
University of Florida Efficacy of PGRs on Branch Architecture of Container-Grown Shrubs				
<b>Jones, Richard T</b>		\$10,000.	\$0.	\$10,000.
KY Department of Agriculture Ginseng Monitoring and Research Project				
<b>Horticulture</b>	<b>Totals:</b>	<b>\$13,000.</b>	<b>\$0.</b>	<b>\$13,000.</b>
<b><u>Plant Pathology</u></b>				
<b>Ghabrial, Said A</b>	3048103102	\$0.	\$34,000.	\$34,000.
University of Illinois Soybean Health: Rust Gene Discovery Initiative				
<b>Ghabrial, Said A</b>	3048105010	\$36,380.	\$0.	\$36,380.
University of Illinois Construction of a DNA-Based Virus Induced Gene Silencing Tools for Functional Genomics of Soybeans				
<b>Hershman, Donald E</b>		\$31,246.	\$0.	\$31,246.
KY Soybean Promotion Board 2009 Kentucky Soybean Rust Monitoring and Early Warning Systems				
<b>Kachroo, Aardra P</b>	3048104449	\$0.	\$102,908.	\$102,908.
United Soybean Board Enhancing Soybean Yield by Manipulating the Expression of Seed Trait-Determining Genes				
<b>Nagy, Peter D</b>	3048086400	\$0.	\$36,924.	\$36,924.
National Institute of Allergy and Infectious Diseases Roles of host RNA binding proteins in virus replication				
<b>Nagy, Peter D</b>	3048105025	\$98,010.	\$0.	\$98,010.
KY Science and Technology Co Inc KSEF R&D Excellence: Identification of Anti-Prion Drugs Active against Plant Viruses				
<b>Nagy, Peter D</b>	3048105026	\$150,000.	\$0.	\$150,000.
National Science Foundation The Role of a Host Ion Pump in RNA Virus Recombination				

**Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Agriculture</u></b>				
<b><u>Plant Pathology</u></b>				
<b>Scharld, Christopher L</b>	3048105181	\$448,178.	\$0.	\$448,178.
Cooperative State Research Education and Extension Advanced Genetic Technologies				
<b>Vaillancourt, Lisa</b>	3048104901	\$140,010.	\$0.	\$140,010.
Cooperative State Research Education and Extension The Role of Signal Peptidase in the Pathogenic Association of the Anthracnose Stalk Rot Fungus Colletotrichum Graminicola with Maize				
<b>Vincelli, Paul</b>	3048104024	\$0.	\$39,000.	\$39,000.
University of Florida Southern Region Plant Diagnostic Network, IPM PIPE 2007, KY Component				
<b>Plant Pathology</b>	<b>Totals:</b>	<b>\$903,824.</b>	<b>\$212,832.</b>	<b>\$1,116,656.</b>
<b><u>Community &amp; Leadership Devel</u></b>				
<b>Hains, Bryan</b>	3048105365	\$15,000.	\$0.	\$15,000.
Fayette County Public Schools Eastside Technical Center's Secondary Veterinary Science Program				
<b>Nah, Seungahn</b>	3048105038	\$12,000.	\$0.	\$12,000.
American University The Kentucky Citizen Media Project: The Lexington Commons (via New Voices)				
<b>Community &amp; Leadership Devel</b>	<b>Totals:</b>	<b>\$27,000.</b>	<b>\$0.</b>	<b>\$27,000.</b>
<b><u>Veterinary Science</u></b>				
<b>Artiushin, Sergey C</b>	3048104963	\$42,393.	\$0.	\$42,393.
KY Science and Technology Co Inc KSEF R&D Excellence: Rapid Test for S. Equi and L. Interrogans in Clinical Specimens from Horses				
<b>Chambers, Thomas M</b>	3048105193	\$10,371.	\$0.	\$10,371.
Science Applications International Co Testing Methods for Influenza Infection in Equine Models				
<b>Issel, Charles J</b>	3046978700	\$0.	\$235,485.	\$235,485.
IDEXX Laboratories Inc Equine Infectious Anemia Diagnostics				
<b>Veterinary Science</b>	<b>Totals:</b>	<b>\$52,764.</b>	<b>\$235,485.</b>	<b>\$288,249.</b>
<b><u>Landscape Architecture</u></b>				
<b>Crankshaw, Ned</b>	3048105311	\$48,923.	\$0.	\$48,923.
City of Bardstown Rural Heritage Development Initiative Design Guidelines				
<b>Landscape Architecture</b>	<b>Totals:</b>	<b>\$48,923.</b>	<b>\$0.</b>	<b>\$48,923.</b>
<b><u>Regulatory Services</u></b>				
<b>McMurry, Stephen W</b>	3048104801	\$31,028.	\$0.	\$31,028.
Food and Drug Administration Medicated Feed Mill & BSE Rule Inspections				
<b>Regulatory Services</b>	<b>Totals:</b>	<b>\$31,028.</b>	<b>\$0.</b>	<b>\$31,028.</b>

**Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Agriculture</u></b>				
<b><u>Livestock Diag Disease Center</u></b>				
<b>Carter, Craig N</b>	3048104664	\$0.	\$-39,224.	\$-39,224.
KY Department for Public Health CHFS/DPH UK West Nile Virus Testing and Related Services				
<b>Carter, Craig N</b>	3048104664	\$40,000.	\$0.	\$40,000.
KY Department for Public Health CHFS/DPH UK West Nile Virus Testing and Related Services				
<b>Carter, Craig N</b>	3048105173	\$31,128.	\$0.	\$31,128.
Texas A&M University R Equi Phneumonia: Airborne Exposure and Foal Immunity / Rhodococcus Equi Airborne Environmental Study				
<b>Carter, Craig N</b>	3048105224	\$400,000.	\$0.	\$400,000.
KY Department of Agriculture Diagnostic Laboratory Services for Farmers and Agribusinesses				
<b>Carter, Craig N</b>	3048105394	\$271,315.	\$0.	\$271,315.
Cooperative State Research Education and Extension Kentucky Statewide Food Animal Health Risk Surveillance and Disease Cluster Detection Initiative				
<b>Livestock Diag Disease Center</b>	<b>Totals:</b>	<b>\$742,443.</b>	<b>\$-39,224.</b>	<b>\$703,219.</b>
<b><u>Area Extension Field Programs</u></b>				
<b>Adkins, Gwenda L</b>	3048104913	\$113,000.	\$0.	\$113,000.
Steele Reese Foundation Family Consumer Science Program Assistant for Environmental Education				
<b>Jacobs, Charlene W</b>	3048104973	\$10,000.	\$0.	\$10,000.
KY Arts Council Extension and Arts Grant				
<b>Area Extension Field Programs</b>	<b>Totals:</b>	<b>\$123,000.</b>	<b>\$0.</b>	<b>\$123,000.</b>
<b><u>Family &amp; Consumer Sciences</u></b>				
<b>Vail, Ann</b>	3048104902	\$0.	\$1,964,566.	\$1,964,566.
KY Health Services Cabinet Food Stamp Nutrition Education ZABE				
<b>Vail, Ann</b>	3048104902	\$343,470.	\$0.	\$343,470.
KY Health Services Cabinet Food Stamp Nutrition Education ZABE				
<b>Family &amp; Consumer Sciences</b>	<b>Totals:</b>	<b>\$343,470.</b>	<b>\$1,964,566.</b>	<b>\$2,308,036.</b>
<b><u>e-Extension</u></b>				
<b>Craycraft, Carla G</b>	3048104096	\$0.	\$295,913.	\$295,913.
University of Nebraska The Transformation of Cooperative Extension				
<b>Griffin, Ashley S</b>	3048104498	\$0.	\$-4,000.	\$-4,000.
University of Nebraska HorseQuest Community of Practice				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Agriculture</u></b>				
<b><u>e-Extension</u></b>				
<b>Wood, Craig H</b>	3046887200	\$0.	\$101,000.	\$101,000.
University of Nebraska ECOP/CSREES E-eXtension-Supplement				
<b>e-Extension</b>	<b>Totals:</b>	<b>\$0.</b>	<b>\$392,913.</b>	<b>\$392,913.</b>
<b><u>Agr Programs</u></b>				
<b>Husband, Andrea L</b>	3048105154	\$43,941.	\$0.	\$43,941.
Cooperative State Research Education and Extension Addressing Animal and Agriculture Issues in Community Emergency Planning				
<b>Palmer, Gary K</b>	3048104777	\$45,901.	\$0.	\$45,901.
KY Natural Resources Environmental Protection Cabinet University of Kentucky Cooperative Extension Service Liaison				
<b>Agr Programs</b>	<b>Totals:</b>	<b>\$89,842.</b>	<b>\$0.</b>	<b>\$89,842.</b>
<b><u>Family Studies</u></b>				
<b>Mimbs, Cheryl A.</b>	3048105175	\$10,000.	\$0.	\$10,000.
KY Department of Education Teacher Educators' Professional Development Grant - FY 09				
<b>Vail, Ann</b>	3048104829	\$33,220.	\$0.	\$33,220.
KY Health Services Cabinet Healthy Marriage Child Support Community Demonstration Program				
<b>Werner-Wilson, Ronald J.</b>	3048104829	\$0.	\$192,662.	\$192,662.
KY Health Services Cabinet Healthy Marriage Child Support Community Demonstration Program				
<b>Family Studies</b>	<b>Totals:</b>	<b>\$43,220.</b>	<b>\$192,662.</b>	<b>\$235,882.</b>
<b><u>Merchandising, Apparel &amp; Textiles</u></b>				
<b>Easter, Elizabeth P</b>	3046898300	\$0.	\$38,608.	\$38,608.
National Association of Institutional Linen Management Quality Control Laboratory For NAILM				
<b>Wesley, Scarlett Clouse</b>		\$35,890.	\$0.	\$35,890.
KY Department of Agriculture Marketing Potential of Fresh Food Products to Hispanic Consumers: Exploring a New Market Opportunity				
<b>Merchandising, Apparel &amp; Textiles</b>	<b>Totals:</b>	<b>\$35,890.</b>	<b>\$38,608.</b>	<b>\$74,498.</b>
<b><u>Ky Tobacco Research &amp; Dev Center</u></b>				
<b>Chambers, Orlando D</b>	3048105391	\$9,973.	\$0.	\$9,973.
Metabolix Inc Industrial Product Field Test				
<b>Ky Tobacco Research &amp; Dev Center</b>	<b>Totals:</b>	<b>\$9,973.</b>	<b>\$0.</b>	<b>\$9,973.</b>
	<b>Agriculture Totals:</b>	<b>\$11,786,677.</b>	<b>\$4,438,560.</b>	<b>\$16,225,237.</b>

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Minority Affairs</u></b>				
<b><u>Minority Affairs</u></b>				
<b>Thomas, Toni</b>	3048105087	\$69,769.	\$0.	\$69,769.
KY Council on Postsecondary Education Governor's Minority Student College Preparation Program				
<b>Minority Affairs</b>	<b>Totals:</b>	<b>\$69,769.</b>	<b>\$0.</b>	<b>\$69,769.</b>
<b><u>Student Support Services</u></b>				
<b>Wims, Lydia E</b>	3046933700	\$0.	\$284,207.	\$284,207.
Department of Education Student Support Services				
<b>Student Support Services</b>	<b>Totals:</b>	<b>\$0.</b>	<b>\$284,207.</b>	<b>\$284,207.</b>
	<b>Minority Affairs Totals:</b>	<b>\$69,769.</b>	<b>\$284,207.</b>	<b>\$353,976.</b>
<b><u>Student Affairs</u></b>				
<b><u>Student Affairs</u></b>				
<b>Edwards, Dorothy Jo</b>	3048102109	\$0.	\$176,309.	\$176,309.
Department of Justice Grants to Reduce Violent Crimes Against Women on Campus--Supplemental				
<b>Student Affairs</b>	<b>Totals:</b>	<b>\$0.</b>	<b>\$176,309.</b>	<b>\$176,309.</b>
	<b>Student Affairs Totals:</b>	<b>\$0.</b>	<b>\$176,309.</b>	<b>\$176,309.</b>
<b><u>Library Administration</u></b>				
<b><u>Library Administration</u></b>				
<b>Birdwhistell, Terry L</b>	3046673500	\$0.	\$10,000.	\$10,000.
KY Oral History Commission Kentucky Legislature Oral History Interviewing and Transcribing Project				
<b>Boyd, Douglas A.</b>	3048104841	\$3,200.	\$0.	\$3,200.
KY Historical Society The Horse Industry in Kentucky Oral History Project				
<b>Weig, Eric C</b>	3048104781	\$212,581.	\$0.	\$212,581.
KY Council on Postsecondary Education Kentuckiana Digital Library Program				
<b>Library Administration</b>	<b>Totals:</b>	<b>\$215,781.</b>	<b>\$10,000.</b>	<b>\$225,781.</b>
	<b>Library Administration Totals:</b>	<b>\$215,781.</b>	<b>\$10,000.</b>	<b>\$225,781.</b>
<b><u>Office of the Provost</u></b>				
<b><u>Art Museum</u></b>				
<b>Walsh-Piper, Kathleen A</b>	3048105068	\$10,000.	\$0.	\$10,000.
Lexarts Teacher Outreach Initiative				
<b>Walsh-Piper, Kathleen A</b>	3048105169	\$20,000.	\$0.	\$20,000.
Keeneland Foundation Hoof Beats and Heart Beats: The American Horse				
<b>Walsh-Piper, Kathleen A</b>	3048105183	\$1,200.	\$0.	\$1,200.
KY Humanities Council Master Works by Kentucky Painters, 1819-1930 Lecture and Book Signing				
<b>Art Museum</b>	<b>Totals:</b>	<b>\$31,200.</b>	<b>\$0.</b>	<b>\$31,200.</b>

**Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Office of the Provost</u></b>				
<b><u>Partnership Inst. for Math and Science</u></b>				
<b>Eakin, Paul M</b>	3048104971	\$57,000.	\$0.	\$57,000.
Northern KY University KCM Regional Coordinator / Mathematics Outreach Specialist				
<b>Toma, E F</b>	3048105112	\$960,150.	\$0.	\$960,150.
National Science Foundation Research, Evaluation, and Technical Assistance: Student Outcome Effects of the Appalachian Math and Science Partnership				
<b>Yopp, John H</b>	3048105364	\$34,995.	\$0.	\$34,995.
AT&T Foundation An Innovative Approach to Promoting Success for At-Risk Students: The Partnership Enhancement Program of				
<b>Zeidler-Watters, Kimberly Jean</b>	3048105080	\$200,000.	\$0.	\$200,000.
KY Department of Education Developing Algebraic Thinking				
<b>Zeidler-Watters, Kimberly Jean</b>	3048105081	\$200,000.	\$0.	\$200,000.
KY Department of Education Partnering to Progress				
<b>Zeidler-Watters, Kimberly Jean</b>	3048105139	\$180,000.	\$0.	\$180,000.
KY Department of Education Math and Science Leadership Network				
<b>Zeidler-Watters, Kimberly Jean</b>	3048105248	\$46,000.	\$0.	\$46,000.
KY Science and Technology Co Inc ARSI- Math / Science PD Project				
<b>Partnership Inst. for Math and Science</b>	<b>Totals:</b>	<b>\$1,678,145.</b>	<b>\$0.</b>	<b>\$1,678,145.</b>
<b><u>International Affairs</u></b>				
<b>Bettez, David J</b>	3048104939	\$49,000.	\$0.	\$49,000.
German American Fulbright Summer Institute for Students with Immigrant Backgrounds from Germany				
<b>Herron, Shana L</b>	3048104969	\$40,000.	\$0.	\$40,000.
Freeman Foundation National Consortium for Teaching About Asia - Year XI and XII				
<b>Herron, Shana L</b>	3048105305	\$150,000.	\$0.	\$150,000.
Freeman Foundation Undergraduate Asian Studies Program				
<b>International Affairs</b>	<b>Totals:</b>	<b>\$239,000.</b>	<b>\$0.</b>	<b>\$239,000.</b>
<b>Office of the Provost Totals:</b>		<b>\$1,948,345.</b>	<b>\$0.</b>	<b>\$1,948,345.</b>
<b><u>Arts &amp; Sciences</u></b>				
<b><u>Anthropology</u></b>				
<b>Ahler, Steven R</b>	3048104779	\$5,839.	\$0.	\$5,839.
KY Department of Fish and Wildlife Phase i Archaeological Survey of Proposed Cape Hills Lake Construction Site at Henderson Sloughs Wildlife Management Area				

**Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Arts &amp; Sciences</u></b>				
<b><u>Anthropology</u></b>				
<b>Ahler, Steven R</b>	3048105342	\$11,455.	\$0.	\$11,455.
Boone County Planning Commission A Proposal to Perform Phase I Archaeological Survey on Selected Tracts within the Woolper Creek Valley in Boone County, Kentucky				
<b>Anglin, Mary Kivas</b>	3048105111	\$7,991.	\$0.	\$7,991.
National Science Foundation Doctoral Dissertation Social Categories and Health Care Outcomes: HIV Positive African American Women and Survival in the Urban South				
<b>Cliggett, Lisa C</b>	3048104701	\$0.	\$15,012.	\$15,012.
National Science Foundation Semiar: Tonga Timeline-Appraising 60 years of multidisciplinary research in Southern Province, Zambia				
<b>McBride, Kim A</b>	3048105069	\$89,000.	\$0.	\$89,000.
KY Heritage Council Kentucky Archaeological Survey				
<b>Pollack, David</b>	3048105328	\$79,364.	\$0.	\$79,364.
KY Finance and Administration Cabinet Proposal for Cultural Resources Survey of Eastern State Hospital, Lexington, Kentucky				
<b>Stottman, Michael Jay</b>	3048105067	\$41,598.	\$0.	\$41,598.
Riverside the Farnsley Moremen Landing Farnsley-Moreman Landing, Building Blocks of History Education Program, 2008-2009				
<b>Anthropology</b>	<b>Totals:</b>	<b>\$235,247.</b>	<b>\$15,012.</b>	<b>\$250,259.</b>
<b><u>Ky Archaeoloigcal Survey</u></b>				
<b>McBride, Kim A</b>	3048104746	\$75,000.	\$0.	\$75,000.
KY Heritage Council Historic Preservation Initiative				
<b>Pollack, David</b>	3048104824	\$80,000.	\$0.	\$80,000.
KY Department of Military Affairs Historic Preservation of Select Kentucky Army National Guard Facilities and Locations				
<b>Pollack, David</b>	3048104968	\$16,000.	\$0.	\$16,000.
KY Nature Preserves Commission Archaeological Survey of HLCF Tracts at Various State Nature Preserves and Natual Areas				
<b>Pollack, David</b>	3048105213	\$100,000.	\$0.	\$100,000.
National Park Service Archaeological Site Inventory of Chestnut Mountain				
<b>Stottman, Michael Jay</b>	3048104907	\$4,500.	\$0.	\$4,500.
Canfield Development Company Archaeological Survey of Glenview Woods, Jefferson County, Kentucky				
<b>Ky Archaeoloigcal Survey</b>	<b>Totals:</b>	<b>\$275,500.</b>	<b>\$0.</b>	<b>\$275,500.</b>
<b><u>Chemistry</u></b>				
<b>Anthony, John Edward</b>	3046842200	\$0.	\$107,000.	\$107,000.
US Office of Naval Research Photovoltaic Devices from Self-Assembled Organic Semiconductors				

## Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009

		New Accounts	Adjustments to Existing Accounts	Total
<b>Arts &amp; Sciences</b>				
<b>Chemistry</b>				
<b>Anthony, John Edward</b>	3048104433	\$0.	\$115,000.	\$115,000.
National Science Foundation A Exploration of Higher Acenes				
<b>Anthony, John Edward</b>	3048105188	\$103,696.	\$0.	\$103,696.
Pennsylvania State University TiO2 Nanotube Array-Organic Semiconductor Heterojunction Solar Cells for Efficient, Low Cost, Large Area Scalable Energy Conversion				
<b>Atwood, David A</b>	3048105308	\$15,000.	\$0.	\$15,000.
Land O Lakes Inc Inhibition of Phosphate Crystalization				
<b>Butterfield, David A</b>	3048104986	\$81,666.	\$0.	\$81,666.
United Negro College Fund Redox Proteomics Analysis of the Sence-Accelerated Prone Mouse (SAMP8) as a Model of Immunosenescence following in vivo Ferulic Acid Treatment				
<b>Clouthier, Dennis J</b>	3048104912	\$161,800.	\$0.	\$161,800.
National Science Foundation Laser Spectroscopy of Main Group Reactive Intermediates				
<b>Daunert, Sylvia</b>	3048104224	\$0.	\$96,431.	\$96,431.
University of California Irvine C-MEMS/C-NEMS for Miniature Biofuels Cells				
<b>Daunert, Sylvia</b>	3048104893	\$51,524.	\$0.	\$51,524.
National Science Foundation Collaborative Research: Extended Life Implantable Biosensor Platform				
<b>Daunert, Sylvia</b>	3048105125	\$48,729.	\$0.	\$48,729.
Binational Agricultural Research & Development Fun A Whole-Cell Biosensor Panel for Agriculture Endocrine Disruptors				
<b>Grossman, Robert B</b>	3048105341	\$218,913.	\$0.	\$218,913.
National Science Foundation Web-Based Interactive Organic Chemistry Homework				
<b>Holmes, Stephen M</b>	3048074800	\$0.	\$52,429.	\$52,429.
KY Science and Technology Co Inc KSEF R&D Excellence: Molecule-Based Magnetic Clusters Constructed from Poly(pyrazolyl) borate Acetylide and Butadiynylide Building Blocks				
<b>Holmes, Stephen M</b>	3048074800	\$0.	-\$76,214.	-\$76,214.
KY Science and Technology Co Inc KSEF R&D Excellence: Molecule-Based Magnetic Clusters Constructed from Poly(pyrazolyl) borate Acetylide and Butadiynylide Building Blocks				
<b>Holmes, Stephen M</b>	3048080800	\$0.	-\$298,136.	-\$298,136.
National Science Foundation CAREER: Construction of Magnetic Cyanide-, Acetylide-, and Butadiynylide-Based Clusters				
<b>Ji, Tae H</b>	3046875900	\$0.	\$284,764.	\$284,764.
National Institute of General Medical Sciences Intermolecular Activation of GPCR				

**Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Arts &amp; Sciences</u></b>				
<b><u>Chemistry</u></b>				
<b>Knecht, Marc R.</b>	3048104966	\$25,000.	\$0.	\$25,000.
Petroleum Research Fund Biomimetic Synthesis of Heterogeneous Catalysts				
<b>Lynn, Bert C</b>	3046839000	\$0.	\$164,695.	\$164,695.
National Institute on Aging Mitochondrial Proteome Changes in Alzheimer's Disease				
<b>Selegue, J P</b>	3046856800	\$0.	\$24,167.	\$24,167.
Research Co Organometallic Heterocycles: Synthesis, Structure, and Applications				
<b>Chemistry</b>	<b>Totals:</b>	<b>\$706,328.</b>	<b>\$470,136.</b>	<b>\$1,176,464.</b>
<b><u>Geography</u></b>				
<b>Karan, P P</b>	3048105089	\$9,000.	\$0.	\$9,000.
Society of Woman Geographers Fellowship Kedzoir: Pollution Knowledge and Hydropolitics in the Ganges River Basin				
<b>Roberts, Susan</b>	3048105054	\$7,800.	\$0.	\$7,800.
National Science Foundation Doctoral Dissertation Research: African Oil Palm Plantation Expansion and Geographies of Hope in Ecuadorian Choco Region				
<b>Secor, Anna J</b>	3048104982	\$9,504.	\$0.	\$9,504.
National Science Foundation Doctoral Dissertation Research: Immigrant Family Detention: The Family, Law, Security, and Space in U.S Immigration Policy and Practice				
<b>Sherriff, Rosemary Lynne</b>	3048104015	\$0.	\$35,152.	\$35,152.
National Park Service Tree-ring Reconstruction of Insect Outbreaks in Lake Clark and Katmai National Park and Preserve				
<b>Geography</b>	<b>Totals:</b>	<b>\$26,304.</b>	<b>\$35,152.</b>	<b>\$61,456.</b>
<b><u>Geology</u></b>				
<b>Moecher, David P</b>	3048068900	\$0.	\$51,117.	\$51,117.
National Science Foundation Identifying the Limitations and Expanding the Utility of Detrital Mineral U-Pb Geochronology to Tectonic Studies				
<b>Moecher, David P</b>	3048105337	\$168,650.	\$0.	\$168,650.
National Science Foundation Upgrade of the University of Kentucky ARL SEMQ Electron Probe Microanalyzer				
<b>Thomas, William A</b>	3048104970	\$13,357.	\$0.	\$13,357.
US Geological Survey Palinspastic Reconstruction Around a Recess in the Appalachian Thrust Belt in Georgia				
<b>Geology</b>	<b>Totals:</b>	<b>\$182,007.</b>	<b>\$51,117.</b>	<b>\$233,124.</b>
<b><u>Mathematics</u></b>				
<b>Braun, Benjamin J.</b>	3048104679	\$70,262.	\$0.	\$70,262.
National Science Foundation Topological and Algebraic Combinatorics				

**Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Arts &amp; Sciences</u></b>				
<b><u>Mathematics</u></b>				
<b>Eakin, Paul M</b>	3046635800	\$0.	\$599,177.	\$599,177.
National Science Foundation Appalachian Mathematics and Science Partnership				
<b>Hislop, Peter D</b>	3048104748	\$130,889.	\$0.	\$130,889.
National Science Foundation Correlations and Transport for Random Schrodinger Operators				
<b>Kang, Sung</b>	3048103694	\$0.	\$-82,287.	\$-82,287.
National Science Foundation Image Deblurring and Decomposition: Texture and Color Image Analysis				
<b>Lee, C W</b>	3048105223	\$143,552.	\$0.	\$143,552.
University of Louisville Geometry Assessments for Secondary Teachers (GAST)				
<b>Man, Chi-Sing</b>	3048105050	\$166,198.	\$0.	\$166,198.
National Science Foundation Some Studies in the Mathematics and Mechanics of Textured and Prestressed Polycrystalline Materials				
<b>Wang, Changyou</b>	3048000400	\$0.	\$40,000.	\$40,000.
National Science Foundation Collaborative Research: L-Infinity Variational Problems and the Aronsson Equation				
<b>Mathematics</b>	<b>Totals:</b>	<b>\$510,901.</b>	<b>\$556,890.</b>	<b>\$1,067,791.</b>
<b><u>Physics and Astronomy</u></b>				
<b>Brill, J W</b>	3048104621	\$160,000.	\$0.	\$160,000.
National Science Foundation Position-Dependent Properties of Novel Electronic Materials: Tunneling, Infrared, and Electromechanical Measurements				
<b>Crawford, Christopher B.</b>	3048105131	\$5,000.	\$0.	\$5,000.
Oak Ridge Associated Universities Development of a Parity-Violating Neutron-Capture Experiment (NDT) for the Spallation Neutron Source (SNS): Measurement of Neutron Depolarization in D20				
<b>Das, Sumit Ranjan</b>	3046999400	\$0.	\$12,000.	\$12,000.
National Science Foundation Research on Gauge Theories, Gravity and Strings				
<b>Elitzur, Moshe</b>	3048105097	\$358,261.	\$0.	\$358,261.
National Science Foundation Radiative signatures of dust and lines: From protostellar disks to active galactic nuclei				
<b>Elitzur, Moshe</b>	3048105333	\$15,000.	\$0.	\$15,000.
Jet Propulsion Laboratory Is the Structure of the Dusty Torus Related to the Physics of Accretion Disk?				
<b>Gardner, Susan V</b>	3046921600	\$0.	\$100,000.	\$100,000.
Department of Energy Tests of Fundamental Symmetries				

**Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Arts &amp; Sciences</u></b>				
<b><u>Physics and Astronomy</u></b>				
<b>Levenson, Nancy A</b>		\$22,845.	\$0.	\$22,845.
Jet Propulsion Laboratory Disentangling the Starburst-AGN Connection				
<b>Liu, Kehfei</b>	3046169100	\$0.	\$180,000.	\$180,000.
Energy Research Research in Theoretical Nuclear Physics				
<b>Martin, Nicholas L</b>	3048005800	\$0.	\$126,089.	\$126,089.
National Science Foundation E2E and Laser Assisted Electron Impact Studies of Helium Ionization				
<b>Murthy, Ganpathy</b>	3048104379	\$0.	\$100,000.	\$100,000.
National Science Foundation Mesoscopic Quantum Critical Regimes and Disorder-Driven Deconfinement				
<b>Plaster, Bradley R.</b>	3048105057	\$105,000.	\$0.	\$105,000.
Department of Energy Fundamental Electroweak and Hadronic Physics Studies of the Neutron				
<b>Shlosman, Isaac</b>		\$78,971.	\$0.	\$78,971.
National Science Foundation Evolution of Inner Halos: Disk Growth and First Generation of Galactic Bars				
<b>Troland, Thomas H</b>	3048104809	\$18,000.	\$0.	\$18,000.
Western KY University Fellowship for Mathew Lykins: The Orgins of Stars and Planets-A Continuing Study of the Role of Magnetic Fields in the W3 Star Formation Region of the Galaxy				
<b>Physics and Astronomy</b>	<b>Totals:</b>	<b>\$763,077.</b>	<b>\$518,089.</b>	<b>\$1,281,166.</b>
<b><u>Psychology</u></b>				
<b>Bardo, Michael T</b>	3048104928	\$0.	\$164,641.	\$164,641.
National Institute on Drug Abuse CDART - Center for Drug Abuse Research Translation				
<b>Bardo, Michael T</b>	3048104928	\$1,303,218.	\$0.	\$1,303,218.
National Institute on Drug Abuse CDART - Center for Drug Abuse Research Translation				
<b>Carlson, Charles R</b>	3048105063	\$56,000.	\$0.	\$56,000.
Eastern State Hospital Clinical Training Agreement with Eastern State Hospital				
<b>Fillmore, Mark</b>	3048052100	\$0.	\$236,388.	\$236,388.
National Institute on Alcohol Abuse and Alcoholism Mechanisms Of Alcohol Tolerance And Priming In Humans				
<b>Giancola, Peter</b>	3046840800	\$0.	\$272,382.	\$272,382.
National Institute on Alcohol Abuse and Alcoholism Individual Differences in Alcohol-Related Aggression				

**Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Arts &amp; Sciences</u></b>				
<b><u>Psychology</u></b>				
<b>Prendergast, Mark A</b>	3048105299	\$333,594.	\$0.	\$333,594.
National Institute on Alcohol Abuse and Alcoholism Hippocappal neurotoxicity induced by ethanol withdraw				
<b>Smith, Gregory T</b>	3048105064	\$30,239.	\$0.	\$30,239.
National Institute on Alcohol Abuse and Alcoholism Fellowship for Melissa Cyders: Longitudinal & Experimental Analysis of Positive Urgency				
<b>Zentall, Thomas R</b>	3046628100	\$0.	\$20.	\$20.
National Institute of Mental Health Effect of Prior Effort on Reward Value				
<b>Psychology</b>	<b>Totals:</b>	<b>\$1,723,051.</b>	<b>\$673,431.</b>	<b>\$2,396,482.</b>
<b><u>Statistics</u></b>				
<b>YOSHIDA, RURIKO</b>	3048105141	\$280,000.	\$0.	\$280,000.
National Institute of General Medical Sciences Geometry of Gene Cophylogenies as Relates to Genome Evolution and Speciation				
<b>Statistics</b>	<b>Totals:</b>	<b>\$280,000.</b>	<b>\$0.</b>	<b>\$280,000.</b>
<b><u>Sociology</u></b>				
<b>Oser, Carrie</b>	3048103624	\$0.	\$143,583.	\$143,583.
National Institute on Drug Abuse Rural Drug Abuse Treatment: Organizations, Counselors, and Client Outcomes				
<b>Oser, Carrie</b>	3048104523	\$0.	\$515,844.	\$515,844.
National Institute on Drug Abuse African American Female Drug Users: HIV, Health Disparities, & Criminality				
<b>Som Castellano, Rebecca Lorraine</b>	3048105096	\$3,125.	\$0.	\$3,125.
Rural Sociological Society School Lunch Programs and the American Diet: Exploring a Contested Food Terrain				
<b>Sociology</b>	<b>Totals:</b>	<b>\$3,125.</b>	<b>\$659,427.</b>	<b>\$662,552.</b>
<b><u>Biological Sciences</u></b>				
<b>Cassone, Vincent</b>	3048105121	\$203,054.	\$0.	\$203,054.
Texas A&M Research Foundation Coordination of Circadian Physiology in Diverse Organism: Project 4: Pacemaker Properties of the Avian Pineal				
<b>Jones, Grace M</b>	3046941900	\$0.	\$284,764.	\$284,764.
National Institute of General Medical Sciences Role of USP Ligand Binding Pocket During Development				
<b>Osborn, Jeffrey</b>	3046858000	\$0.	\$21,500.	\$21,500.
KY Science and Technology Co Inc Noyce Loan/Scholarship Program				
<b>Peterson, Martha L</b>	3048104756	\$0.	\$412,506.	\$412,506.
University of Louisville Subcontract, Kentucky Biomedical Research Infastructure Network				

**Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Arts &amp; Sciences</u></b>				
<b><u>Biological Sciences</u></b>				
<b>Voss, Stephen Randal</b>	3048093100	\$0.	\$52,740.	\$52,740.
National Center for Research Resources Genome Resources for Model Amphibians				
<b>Westneat, David F</b>	3048105078	\$1,000.	\$0.	\$1,000.
Animal Behavior Society Animal Behavior-The Effects of Grassland Restoration on Avian Mating Patterns				
<b>Wigginton, Andrew J</b>	3048105114	\$0.	\$7,041.	\$7,041.
KY Department of Environmental Protection Assessment of Ecological Conditions Compared to Environmental Sampling at the Paducah Gaseous Diffusion Plant With a Reassessment of Previous Analysis				
<b>Wigginton, Andrew J</b>	3048105114	\$205,959.	\$0.	\$205,959.
KY Department of Environmental Protection Assessment of Ecological Conditions Compared to Environmental Sampling at the Paducah Gaseous Diffusion Plant With a Reassessment of Previous Analysis				
<b>Biological Sciences</b>	<b>Totals:</b>	<b>\$410,013.</b>	<b>\$778,551.</b>	<b>\$1,188,564.</b>
<b><u>Modern &amp; Classical Languages</u></b>				
<b>Desormeaux, Daniel</b>	3048105134	\$50,400.	\$0.	\$50,400.
National Endowment for the Humanities A Scholarly Edition of Toussaint Louverture's Memoirs				
<b>Jiang, Wei</b>	3048105062	\$40,738.	\$0.	\$40,738.
KY Department of Education UK/Chinese Online Course Development				
<b>Slaymaker, Douglas N</b>		\$6,000.	\$0.	\$6,000.
Japan Foundation Building a Japan Studies Concentration at the University of Kentucky				
<b>Modern &amp; Classical Languages</b>	<b>Totals:</b>	<b>\$97,138.</b>	<b>\$0.</b>	<b>\$97,138.</b>
<b><u>Russian and Eastern Studies</u></b>				
<b>Fiedler, Theodore</b>	3046345400	\$0.	\$60,028.	\$60,028.
Omar Ibn Al Khattab Foundation Lectureship in Islamic Studies				
<b>Russian and Eastern Studies</b>	<b>Totals:</b>	<b>\$0.</b>	<b>\$60,028.</b>	<b>\$60,028.</b>
	<b>Arts &amp; Sciences Totals:</b>	<b>\$5,212,691.</b>	<b>\$3,817,833.</b>	<b>\$9,030,524.</b>
<b><u>Business &amp; Economics</u></b>				
<b><u>Management</u></b>				
<b>Holbein, Gordon F</b>		\$38,770.	\$0.	\$38,770.
KY Economic Development Cab Business Plan Competition				
<b>Muralidhar, Krishnamurty</b>		\$19,872.	\$0.	\$19,872.
KY Department of Education UK/FERPA Confidentiality Study				
<b>Management</b>	<b>Totals:</b>	<b>\$58,642.</b>	<b>\$0.</b>	<b>\$58,642.</b>

**Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Business &amp; Economics</u></b>				
<b><u>Center for Business &amp; Econ Res</u></b>				
<b>Jepsen, Christopher</b>	3048104796	\$171,000.	\$0.	\$171,000.
Spencer Foundation Women's Economic Returns from Obtainig a GED				
<b>Troske, Kenneth R</b>	3048104935	\$49,959.	\$0.	\$49,959.
Kentucky Workforce Development Cabinet Update and Maintenance of the Mercer Computerized Model				
<b>Troske, Kenneth R</b>	3048105368	\$55,529.	\$0.	\$55,529.
KY Community & Technical College System/University of Economic Returns from Obtaining KCTCS Certificates and Diplomas				
<b>Center for Business &amp; Econ Res</b>	<b>Totals:</b>	<b>\$276,488.</b>	<b>\$0.</b>	<b>\$276,488.</b>
<b><u>B&amp;E Poverty Center</u></b>				
<b>Ziliak, James P</b>	3048105303	\$107,804.	\$0.	\$107,804.
Meals on Wheels Association of American Foundation Update on Senior Hunger in America				
<b>B&amp;E Poverty Center</b>	<b>Totals:</b>	<b>\$107,804.</b>	<b>\$0.</b>	<b>\$107,804.</b>
<b>Business &amp; Economics Totals:</b>		<b>\$442,934.</b>	<b>\$0.</b>	<b>\$442,934.</b>
<b><u>Education</u></b>				
<b><u>Educational Leadership Studies</u></b>				
<b>Hausman, Charles</b>	3048104721	\$61,506.	\$0.	\$61,506.
KY Department of Education CEO Superintendent Network				
<b>Educational Leadership Studies</b>	<b>Totals:</b>	<b>\$61,506.</b>	<b>\$0.</b>	<b>\$61,506.</b>
<b><u>Curriculum &amp; Instruction</u></b>				
<b>Burns, Leslie David</b>	3046791200	\$0.	\$250.	\$250.
University of California Berkeley Bluegrass Writing Project - Program Income				
<b>Burns, Leslie David</b>	3046791200	\$0.	\$100.	\$100.
University of California Berkeley Bluegrass Writing Project - Program Income				
<b>Burns, Leslie David</b>	3046791200	\$0.	\$250.	\$250.
University of California Berkeley Bluegrass Writing Project - Program Income				
<b>Burns, Leslie David</b>	3046791200	\$0.	\$800.	\$800.
University of California Berkeley Bluegrass Writing Project - Program Income				
<b>Burns, Leslie David</b>	3046791200	\$0.	\$800.	\$800.
University of California Berkeley Bluegrass Writing Project - Program Income				
<b>Burns, Leslie David</b>	3046791200	\$0.	\$810.	\$810.
University of California Berkeley Bluegrass Writing Project - Program Income				

**Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Education</u></b>				
<b><u>Curriculum &amp; Instruction</u></b>				
<b>Smith, Douglas C</b>	3048105274	\$4,000.	\$0.	\$4,000.
KY Department for Technical Education UK Perkins Leadership Funding to Improve CTE- Professional Development Education				
<b>Smith, Felicia C</b>		\$130,282.	\$0.	\$130,282.
KY Department of Education Carry Forward: Early Childhood Teacher Academy-Undergraduate Project UK Collaborative Center for Literacy Development				
<b>Smith, Felicia C</b>	3048105157	\$0.	-\$130,282.	-\$130,282.
KY Department of Education Carry Forward: Early Childhood Teacher Academy-Undergraduate Project UK Collaborative Center for Literacy Development				
<b>Curriculum &amp; Instruction</b>	<b>Totals:</b>	<b>\$134,282.</b>	<b>-\$127,272.</b>	<b>\$7,010.</b>
<b><u>Educational &amp; Counseling Psych</u></b>				
<b>Love, Keisha</b>	3048105219	\$2,500.	\$0.	\$2,500.
Kuder Inc Promoting Enhanced Career Opportunities for Underprivileged Teens (PECOT)				
<b>Educational &amp; Counseling Psych</b>	<b>Totals:</b>	<b>\$2,500.</b>	<b>\$0.</b>	<b>\$2,500.</b>
<b><u>Kinesiology and Health Promoti</u></b>				
<b>Shapiro, Robert</b>	3046974000	\$0.	\$2,500.	\$2,500.
Drayer Physical Therapy Institute Research Assistantship to Study Biomechanical and Gender Issues in Sport				
<b>Shapiro, Robert</b>	3048105275	\$97,264.	\$0.	\$97,264.
KY Science and Technology Co Inc KSEF R&D Excellence: A novel Biomechanical Approach for Preventing Spinal Disorders				
<b>Kinesiology and Health Promoti</b>	<b>Totals:</b>	<b>\$97,264.</b>	<b>\$2,500.</b>	<b>\$99,764.</b>
<b><u>Educational Policy Studies &amp; Evaluation</u></b>				
<b>Carey, K W</b>	3048104814	\$61,843.	\$0.	\$61,843.
KY Council on Postsecondary Education Development and Implementation of the Statewide Assessment of College Level Learning				
<b>Educational Policy Studies &amp; Evaluation</b>	<b>Totals:</b>	<b>\$61,843.</b>	<b>\$0.</b>	<b>\$61,843.</b>
<b><u>Special Ed &amp; Rehab Counseling</u></b>				
<b>Bausch, Margaret</b>	3046935500	\$0.	\$99,996.	\$99,996.
Department of Education Kentucky Assistive and Rehabilitation Technology Training (KARTT)				
<b>Collins, Belva J</b>	3046941400	\$0.	\$199,810.	\$199,810.
Special Education and Rehabilitative Services Special Education Leadership Program in Distance Education Teacher Preparation				
<b>Grisham-Brown, Jennifer L</b>	3046971800	\$0.	\$75,050.	\$75,050.
Kent State University Preparing Tomorrow's Early Childhood Intervention Leaders				

**Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009**

		New Accounts	Adjustments to Existing Accounts	Total
<b>Education</b>				
<b>Special Ed &amp; Rehab Counseling</b>				
<b>Grisham-Brown, Jennifer L</b>	3048104727	\$235,000.	\$0.	\$235,000.
KY Department of Education Deaf/Blind Project Supplemental Grant				
<b>Grisham-Brown, Jennifer L</b>	3048104802	\$250,000.	\$0.	\$250,000.
KY Department of Education KIDS NOW Evaluation Project 08-09				
<b>Grisham-Brown, Jennifer L</b>	3048105255	\$165,145.	\$0.	\$165,145.
KY Department of Education Kentucky Deaf Blind Project (Main Grant)				
<b>Jung, Lee Ann</b>	3046963700	\$0.	\$199,987.	\$199,987.
Department of Education Project Increasing the Number, Competence, and Resources of Early Interventions in Areas of Shortage (INCREAS) - (Alternate Name = "Combined Priority for Personnel Preparation")				
<b>Jung, Lee Ann</b>	3048104858	\$96,000.	\$0.	\$96,000.
KY Health Services Cabinet UK First Steps Part C Coordinator 08-09				
<b>McCormick, Katherine</b>	3048104813	\$235,514.	\$0.	\$235,514.
KY Health Services Cabinet University of Kentucky First Step Technical Assistance Team				
<b>McCormick, Katherine</b>	3048105284	\$62,738.	\$0.	\$62,738.
Jumpstart For Young Children Inc Higher Education Affiliate Partnership				
<b>Sampers, Jackie L</b>	3048105049	\$104,760.	\$0.	\$104,760.
KY Health Services Cabinet UK First Steps Evaluation Coordinator				
<b>Schuster, John W</b>	3046831600	\$0.	\$249,996.	\$249,996.
Department of Education Reaching Educators with an Alternate Certification for Teachers (REACT)				
<b>Schuster, John W</b>	3048104791	\$200,000.	\$0.	\$200,000.
Special Education and Rehabilitative Services Special Education Leadership Program in Applied Behavior Analysis (SELABA) in Distance Teacher Preparation				
<b>Slaton, Deborah B</b>	3048104816	\$127,181.	\$0.	\$127,181.
KY Department of Education Reading First Coach 2008-2009				
<b>Stenhoff, Donald M</b>	3048104726	\$29,144.	\$0.	\$29,144.
KY Department of Education Behavior Web Home Page				
<b>Special Ed &amp; Rehab Counseling</b>	<b>Totals:</b>	<b>\$1,505,482.</b>	<b>\$824,839.</b>	<b>\$2,330,321.</b>

**Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Education</u></b>				
<b><u>Collaborative Center for Literacy Develo</u></b>				
<b>Cantrell, Susan Chambers</b>	3048104820	\$99,998.	\$0.	\$99,998.
KY Department of Education Kentucky Reading First Evaluation Project				
<b>Smith, Felicia C</b>	3048104811	\$469,854.	\$0.	\$469,854.
KY Department of Education Adolescent Literacy Project 0809				
<b>Smith, Felicia C</b>	3048104917	\$150,000.	\$0.	\$150,000.
KY Department of Education Early Childhood Teacher Academy-Undergraduate Project UK Collaborative Center for Literacy Development				
<b>Smith, Felicia C</b>	3048104947	\$345,390.	\$0.	\$345,390.
KY Council on Postsecondary Education Kentucky Adult Education Literacy Institute-KAELI 08-09				
<b>Smith, Felicia C</b>	3048105329	\$200,000.	\$0.	\$200,000.
KY Department of Education Early Childhood Teacher Academy: Three-Five at the Undergraduate and Graduate Level				
<b>Collaborative Center for Literacy Develo</b>	<b>Totals:</b>	<b>\$1,265,242.</b>	<b>\$0.</b>	<b>\$1,265,242.</b>
	<b>Education Totals:</b>	<b>\$3,128,119.</b>	<b>\$700,067.</b>	<b>\$3,828,186.</b>
<b><u>Engineering</u></b>				
<b><u>Visualization Center</u></b>				
<b>Bailey, Stephen P</b>	3048105214	\$3,000.	\$0.	\$3,000.
Research Channel Smoking and Tobacco Policy Research				
<b>Donohue, Kevin D</b>	3048105037	\$80,000.	\$0.	\$80,000.
Federal Bureau of Investigation Statistical Array Geometries for Real-Time Covert Surveillance with Parallel Computer Implementations				
<b>Firey, Abigail</b>	3048105171	\$49,133.	\$0.	\$49,133.
National Endowment for the Humanities Carolingian Canon Law Project: A Collaborative Initiative				
<b>Hassebrook, Laurence G</b>	3048104933	\$40,000.	\$0.	\$40,000.
National Institute for Hometown Security Supplement to Real-Time 3D Finger and Palm-Print Scanner for Entry and Access Portal Security				
<b>Hassebrook, Laurence G</b>	3048105312	\$199,721.	\$0.	\$199,721.
Flashscan 3D Miniature, Non-Contact Rolled Equivalent Fingerprint Collection Device				
<b>Hassebrook, Laurence G</b>	3048105370	\$988,511.	\$0.	\$988,511.
National Institute for Hometown Security Rolled Equivalent, 3-D Fingerprint and Palm Print Scanner				
<b>Lau, Daniel L</b>	3048104954	\$46,562.	\$0.	\$46,562.
KY Science and Technology Co Inc KSEF R&D Excellence: Integral Lens Array Imaging as an Anti-Counterfeit Marker				

**Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Engineering</u></b>				
<b><u>Visualization Center</u></b>				
<b>Walcott, Bruce L</b>	3048043800	\$0.	\$910,332.	\$910,332.
US Army Large Rapidly Deployable Immersive Visualization for Training and Simulation in Urban Terrains				
<b>Yang, Ruigang</b>	3046875100	\$0.	\$100,000.	\$100,000.
National Science Foundation CAREER: The Light Portal: 3D Reconstruction and Visualization over Space and Time				
<b>Yang, Ruigang</b>	3048104957	\$324,993.	\$0.	\$324,993.
National Science Foundation CPA-G&V: Self-Completion of 4D (Space+Time)Models				
<b>Yang, Ruigang</b>	3048105109	\$60,000.	\$0.	\$60,000.
VSee Lab Inc STTR Phase I: Rapidly Deployable Display with Continuous Self-Correction				
<b>Yang, Ruigang</b>	3048105174	\$65,189.	\$0.	\$65,189.
Direct i2i Technologies Inc STTR Phase 1: Eye-Gaze Correction for more Effective Telepresence				
<b>Visualization Center</b>	<b>Totals:</b>	<b>\$1,857,109.</b>	<b>\$1,010,332.</b>	<b>\$2,867,441.</b>
<b><u>Computer Science</u></b>				
<b>Calvert, Kenneth L</b>	3048051100	\$0.	\$65,564.	\$65,564.
National Science Foundation NeTS-NBD: Collaborative Research: Human-Centered Networking for the Home				
<b>Cheng, Fuhua</b>	3048103223	\$0.	\$75,000.	\$75,000.
KY Science and Technology Co Inc Kentucky Commercialization Fund: Portable Digital Mouth & Occlusion Reproducer				
<b>Griffioen, James N</b>	3048105220	\$132,973.	\$0.	\$132,973.
BBN Technologies Instrumentation Tools for a GENI Prototype				
<b>Hayes, Jane E</b>	3048104958	\$250,000.	\$0.	\$250,000.
National Science Foundation CPA-SEL-T:Collaborative Research:Traceability+:a Service Oriented Framework to Support Value-added software Traceability				
<b>Marek, Victor W</b>	3048105296	\$214,773.	\$0.	\$214,773.
Department of Defense IPA Agreement for Victor Marek				
<b>Seales, William B</b>	3048047200	\$0.	\$300,000.	\$300,000.
National Science Foundation EDUCE: Enhanced Digital Unwrapping for Conservation and Exploration				
<b>Computer Science</b>	<b>Totals:</b>	<b>\$597,746.</b>	<b>\$440,564.</b>	<b>\$1,038,310.</b>
<b><u>Kentucky Transportation Center</u></b>				
<b>Anderson, Patsy P</b>	3048104345	\$0.	-\$47,500.	-\$47,500.
KY Transportation Cabinet LTAP Safety Circuit Rider Program				

**Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Engineering</u></b>				
<b><u>Kentucky Transportation Center</u></b>				
<b>Chen, Mei</b>	3048105282	\$19,405.	\$0.	\$19,405.
KY Transportation Cabinet Kentucky ADMS Update for 2006-2007 - Planning Study No 17				
<b>Crabtree, Joseph D</b>	3048043200	\$0.	\$50,000.	\$50,000.
KY Transportation Cabinet Support of Kentucky s PRISM and CVISN Programs, Research Study-Federal no. 20				
<b>Crabtree, Joseph D</b>	3048103539	\$0.	\$83,819.	\$83,819.
KY Transportation Cabinet Southeast Regional Research Initiative (SERRI) Integrated Threat Tracking and Information System, Research Study-Federal no. 22				
<b>Crabtree, Joseph D</b>	3048104950	\$340,000.	\$0.	\$340,000.
KY Transportation Cabinet Deployment and Evaluation of a Next Generation Virtual Weigh Station, Research Study Federal No. 26				
<b>Crabtree, Joseph D</b>	3048104951	\$300,000.	\$0.	\$300,000.
KY Transportation Cabinet Electronic License Plate and Screening System, Research Study-Federal No. 25				
<b>Graves, Ronnie C</b>	3048105384	\$15,000.	\$0.	\$15,000.
KY Transportation Cabinet Warm Mix Asphalt Performance Warren County IM NH 65-1 (90) Federal Aid Research Task No. 176				
<b>Graves, Ronnie C</b>	3048105385	\$15,000.	\$0.	\$15,000.
KY Transportation Cabinet Warm Mix Asphalt Performance - Simpson County IM NH 65-1 (83) 5, Federal Aid Research Task No. 175				
<b>Graves, Ronnie C</b>	3048105386	\$15,000.	\$0.	\$15,000.
KY Transportation Cabinet Warm Mix Asphalt Performance - Grant County IM NH 75-6 (96), Federal Aid Research Task No. 174				
<b>Graves, Ronnie C</b>	3048105387	\$15,000.	\$0.	\$15,000.
KY Transportation Cabinet Warm Mix Asphalt Performance - Grant County IM NH 75-6 (95) 146, Federal Aid Research Task No. 173				
<b>Graves, Ronnie C</b>	3048105388	\$15,000.	\$0.	\$15,000.
KY Transportation Cabinet Warm Mix Asphalt Performance - Warren - Simpson County IM NH 65-1 (81) Federal Aid Research Task No. 172				
<b>Green, Eric R</b>	3048105292	\$177,687.	\$0.	\$177,687.
KY Justice Cabinet Evaluation Plan for the Ticketing Aggressive Cars and Trucks (TACT) Program in Kentucky Year 2				
<b>Grossardt, Theodore H</b>	3046337100	\$0.	\$150,000.	\$150,000.
KY Transportation Cabinet Information Technology Technical Assistance Project -- Federal Aid Research Task No. 88				
<b>Grossardt, Theodore H</b>	3048104480	\$0.	\$25,515.	\$25,515.
University of Tennessee Southeastern Transportation Center Transportation Systems Management Program				

**Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Engineering</u></b>				
<b><u>Kentucky Transportation Center</u></b>				
<b>Grossardt, Theodore H</b>	3048104979	\$141,073.	\$0.	\$141,073.
Wilbur Smith Associates Milton-Madison Bridges Structured Public Involvement Support Project - Phase 1 tasks 4, 5 and 21				
<b>Hopwood, Theodore</b>	3048103723	\$0.	\$93,770.	\$93,770.
KY Transportation Cabinet Investigation of Voids/Cracking on the I-25 Twin Bridges over the Ohio River in Kenton County, KY--Kentucky Highway Investigative Task No. 60				
<b>Hopwood, Theodore</b>	3048104617	\$0.	\$120,113.	\$120,113.
Northwestern University Continuation of the Midwest Bridge Working Group - Phase XIII				
<b>Hopwood, Theodore</b>	3048104617	\$0.	\$6,000.	\$6,000.
Northwestern University Continuation of the Midwest Bridge Working Group - Phase XIII				
<b>Hunsucker, David Q</b>	3046815100	\$0.	\$99,500.	\$99,500.
KY Transportation Cabinet Advantage CVO Operations and Maintenance, Research Study-State No. 10.				
<b>Toussaint, Paul</b>	3048104705	\$0.	\$38,000.	\$38,000.
KY Transportation Cabinet Kentucky Cooperative Transportation Research Program KCTRP 09-29 (Part III)				
<b>Toussaint, Paul</b>	3048104705	\$220,000.	\$0.	\$220,000.
KY Transportation Cabinet Kentucky Cooperative Transportation Research Program KCTRP 09-29 (Part III)				
<b>Toussaint, Paul</b>	3048104707	\$0.	\$25,000.	\$25,000.
KY Transportation Cabinet Kentucky Cooperative Transportation Research Program Part II KCTRP 09-29				
<b>Toussaint, Paul</b>	3048104707	\$3,849,606.	\$0.	\$3,849,606.
KY Transportation Cabinet Kentucky Cooperative Transportation Research Program Part II KCTRP 09-29				
<b>Toussaint, Paul</b>	3048105033	\$54,500.	\$0.	\$54,500.
KY Transportation Cabinet Construction Co-op Tech Program - Federal Aid Research Task no. 171				
<b>Kentucky Transportation Center</b>	<b>Totals:</b>	<b>\$5,177,271.</b>	<b>\$644,217.</b>	<b>\$5,821,488.</b>
<b><u>Chemical and Materials Engin.</u></b>				
<b>Anderson, Kimberly Ward</b>	3048103842	\$0.	\$599,955.	\$599,955.
National Science Foundation IGERT: Building Leadership Through a Program on Engineered Bioactive Interfaces and Devices				
<b>Anderson, Kimberly Ward</b>	3048103842	\$0.	\$599,907.	\$599,907.
National Science Foundation IGERT: Building Leadership Through a Program on Engineered Bioactive Interfaces and Devices				

## Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009

		New Accounts	Adjustments to Existing Accounts	Total
<b>Engineering</b>				
<b><u>Chemical and Materials Engin.</u></b>				
<b>Balk, Thomas John</b>	3048060700	\$0.	\$5,000.	\$5,000.
American Iron and Steel Institute Developing Ferrous Matallurgy Course Material For An Updated Materials Engineering Curriculum at the University Of Kentucky				
<b>Balk, Thomas John</b>	3048104919	\$99,930.	\$0.	\$99,930.
KY Science and Technology Co Inc R&D Excellence: Nanoporous Nickel as an Alternative to Raney Nickel				
<b>Balk, Thomas John</b>	3048105263	\$80,000.	\$0.	\$80,000.
National Science Foundation CAREER: Understanding Nanoscale Deformation by Characterizing the Mechanical Behavior of Nanoporus Noble Metals				
<b>Bhattacharyya, Dibakar</b>	3048104774	\$87,900.	\$0.	\$87,900.
Compact Membrane Systems Inc SBIR: Novel Pharmaceutical Solvent-Water Separation System				
<b>Bhattacharyya, Dibakar</b>	3048105158	\$25,000.	\$0.	\$25,000.
NEI Corporation SBIR: A New Class of Nanocomposite Treatment Media for Efficient Mercury Remediation				
<b>Cheng, Yang-Tse</b>	3048105346	\$36,361.	\$0.	\$36,361.
General Motors Research Strategies for Mitigating Stress-Induced Damages to Lithium Ion Battery Electrodes				
<b>Gulke, Eric A</b>	3048103782	\$0.	\$149,995.	\$149,995.
Ashland Inc Nanofluids for Advanced Military Mobility Systems - Coolants, Fuels and Lubricants				
<b>Gulke, Eric A</b>	3048103803	\$0.	\$250,000.	\$250,000.
KY Council on Postsecondary Education State DOE EPSCoR Match: Nanoscale Materials and Architecture for Energy Conversion				
<b>Gulke, Eric A</b>	3048104376	\$0.	\$28,618.	\$28,618.
Optical Dynamics Co Len-forming Nanocomposite for High-strength, Clear Ophthalmic Lenses				
<b>Gulke, Eric A</b>	3048105030	\$23,102.	\$0.	\$23,102.
Environmental Protection Agency EPA polymer nanocomposite applications				
<b>Hilt, James Z</b>	3048105021	\$99,656.	\$0.	\$99,656.
KY Science and Technology Co Inc KSEF R&D Excellence: FTIR Imaging for Microscale Analysis of Hydrogel Patterning Reactions				
<b>Hinds, Bruce J</b>	3048057100	\$0.	\$289,703.	\$289,703.
National Institute on Drug Abuse Gated Carbon Nanotube Membrane Transdermal Drug Delivery				
<b>Hinds, Bruce J</b>	3048105302	\$220,000.	\$0.	\$220,000.
Statkraft Development AS Aligned Carbon Nanotube Membranes for Forward Osmosis Power Generation				

**Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009**

		New Accounts	Adjustments to Existing Accounts	Total
<b>Engineering</b>				
<b><u>Chemical and Materials Engin.</u></b>				
<b>Knutson, Barbara</b>	3048104976	\$81,236.	\$0.	\$81,236.
KY Office of Energy Policy Separation and Recovery of High-value Pentose Derivatives from Cellulosic Biomass using Mol+				
<b>Yang, Fuqian</b>		\$64,861.	\$0.	\$64,861.
Lexmark International Inc Mechanical Property Analysis of Ink Jet Heater Thin Film Materials				
<b>Yang, Fuqian</b>		\$7,000.	\$0.	\$7,000.
University of Tennessee Characterization of Localized Residual Stresses in Bulk Metallic Glass				
<b>Yang, Fuqian</b>		\$7,000.	\$0.	\$7,000.
University of Tennessee Electromechanical Effort on the Formation and Growth of Tin Whiskers				
<b>Yang, Fuqian</b>	3048104717	\$222,600.	\$0.	\$222,600.
National Science Foundation Collaborative Research: Making nanostructured ceramics from micrometer-sized starting powders				
<b>Zhai, Tongguang</b>	3048103774	\$0.	\$-6,000.	\$-6,000.
National Science Foundation CAREER: Quantitative Understanding of the Effects of Micro and Macro-Texture on Fatigue Crack Initiation and Early Growth in High Performance Alloys				
<b>Zhai, Tongguang</b>	3048103774	\$0.	\$6,000.	\$6,000.
National Science Foundation CAREER: Quantitative Understanding of the Effects of Micro and Macro-Texture on Fatigue Crack Initiation and Early Growth in High Performance Alloys				
<b>Chemical and Materials Engin.</b>	<b>Totals:</b>	<b>\$1,054,646.</b>	<b>\$1,923,178.</b>	<b>\$2,977,824.</b>
<b><u>CFFLS</u></b>				
<b>Huffman, Gerald P</b>	3046900100	\$0.	\$87,605.	\$87,605.
Department of Energy Development of Novel Technologies for the Production and Storage of Hydrogen from Coal Using C1 Chemistry				
<b>Huffman, Gerald P</b>	3046900100	\$0.	\$350,000.	\$350,000.
Department of Energy Development of Novel Technologies for the Production and Storage of Hydrogen from Coal Using C1 Chemistry				
<b>Huffman, Gerald P</b>	3048103876	\$0.	\$1,312,000.	\$1,312,000.
US Army Production of Military Fuels by C1 Chemistry				
<b>CFFLS</b>	<b>Totals:</b>	<b>\$0.</b>	<b>\$1,749,605.</b>	<b>\$1,749,605.</b>
<b><u>Civil Engineering</u></b>				
<b>Fox, James F</b>	3048105120	\$246,294.	\$0.	\$246,294.
National Science Foundation Collaborative Research: REU SITE: Coal Mining Impacts on Soil Carbon Storage and Impacts in Appalachian Headwater Streams: A Research Experience for Undergraduates				

**Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Engineering</u></b>				
<b><u>Civil Engineering</u></b>				
<b>Maloney, William F</b>	3048105348	\$20,000.	\$0.	\$20,000.
Virginia Polytechnic Institute and State University Analysis of NIOSH FACE Reports				
<b>Civil Engineering</b>	<b>Totals:</b>	<b>\$266,294.</b>	<b>\$0.</b>	<b>\$266,294.</b>
<b><u>Mining Engineering</u></b>				
<b>LUSK, BRADEN</b>	3048105371	\$874,750.	\$0.	\$874,750.
National Institute for Hometown Security Response of Curtain Wall Architectural Envelopes to Negative Phase Blast Effects				
<b>LUSK, BRADEN</b>	3048105372	\$824,738.	\$0.	\$824,738.
National Institute for Hometown Security Blast Protection for Power Transformers				
<b>Tao, Dongping</b>	3048104234	\$0.	\$105,424.	\$105,424.
Virginia Polytechnic Institute and State University Improving Coal Flotation Recovery Using Cavitation Concepts				
<b>Mining Engineering</b>	<b>Totals:</b>	<b>\$1,699,488.</b>	<b>\$105,424.</b>	<b>\$1,804,912.</b>
<b><u>Electrical and Computer Engineering</u></b>				
<b>Adams, Robert J</b>	3046777800	\$0.	\$226,775.	\$226,775.
US Office of Naval Research Efficient Iterative and Direct Solvers for Electromagnetic Simulations				
<b>Adams, Robert J</b>	3048105324	\$0.	\$30,000.	\$30,000.
US Office of Naval Research Modular Fast Direct Solvers for Electromagnetic Modeling				
<b>Adams, Robert J</b>	3048105324	\$60,000.	\$0.	\$60,000.
US Office of Naval Research Modular Fast Direct Solvers for Electromagnetic Modeling				
<b>Gedney, Stephen D</b>	3048105132	\$0.	\$101,375.	\$101,375.
ERC Inc DGFETD/MSCAT Enhancement				
<b>Gedney, Stephen D</b>	3048105132	\$9,215.	\$0.	\$9,215.
ERC Inc DGFETD/MSCAT Enhancement				
<b>Hastings, Jeffrey T</b>	3048105023	\$100,000.	\$0.	\$100,000.
KY Science and Technology Co Inc KSEF: Liquid Phase Electron-Beam Induced Processing				
<b>Heath, J R</b>	3046947100	\$0.	\$14,444.	\$14,444.
Lexmark International Inc Systemic Approach to SOC Evaluation and Verification				
<b>Heath, J R</b>	3046947100	\$0.	\$16,439.	\$16,439.
Lexmark International Inc Systemic Approach to SOC Evaluation and Verification				

**Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Engineering</u></b>				
<b><u>Electrical and Computer Engineering</u></b>				
<b>Lau, Daniel L</b>	3048082200	\$0.	\$45,865.	\$45,865.
M2 Technologies Inc Anti-Sniper Infrared Targeting Systems (ASITS) Phase IIIa				
<b>Liao, Yuan</b>	3048104853	\$248,002.	\$0.	\$248,002.
National Science Foundation Transmission line fault location utilizing sparse measurements				
<b>Liao, Yuan</b>	3048104938	\$10,000.	\$0.	\$10,000.
KY Science and Technology Co Inc KY EPSCoR: Exploring new operating and control algorithms for the composite electric power system				
<b>Liao, Yuan</b>	3048105040	\$20,000.	\$0.	\$20,000.
EON US Development of a New Power Course Focusing on Advanced Power Software				
<b>Liao, Yuan</b>	3048105041	\$70,000.	\$0.	\$70,000.
EON US Power Flow and Stability Analysis and Development of Tools Facilitating Simulations Studies				
<b>Lumpp, James E</b>	3048104695	\$0.	\$7,000.	\$7,000.
KY Science and Technology Co Inc Site Preparation for Space Systems Laboratory Spacecraft Assembly & Test Facility				
<b>Lumpp, Janet K</b>	3048105269	\$18,000.	\$0.	\$18,000.
Western KY University KSGC Fellowship: Integrated Structural-Electrical Composite Spacecraft Graduate Fellowship				
<b>Lumpp, Janet K</b>	3048105374	\$26,761.	\$0.	\$26,761.
Western KY University Integrated Structural-Electrical Composite Spacecraft (InSECS)				
<b>Todd, Lee T</b>	3048032200	\$0.	\$489,771.	\$489,771.
National Science Foundation LSAMP: Kentucky-West Virginia Alliance for Minority Participation				
<b>Electrical and Computer Engineering</b>	<b>Totals:</b>	<b>\$561,978.</b>	<b>\$931,669.</b>	<b>\$1,493,647.</b>
<b><u>UK Center for Manufacturing</u></b>				
<b>Holloway, Lawrence E</b>	3048105273	\$900,000.	\$0.	\$900,000.
Small Business Administration Innovation Extension Centers to Assist Small and Rural Manufacturers with Innovation				
<b>Zhang, Yuming</b>	3048105042	\$364,269.	\$0.	\$364,269.
National Science Foundation Control of Metal Transfer at Given Arc Variables				
<b>UK Center for Manufacturing</b>	<b>Totals:</b>	<b>\$1,264,269.</b>	<b>\$0.</b>	<b>\$1,264,269.</b>
<b><u>Mechanical Engineering</u></b>				
<b>Karaca, Haluk E.</b>	3048105071	\$0.	\$40,000.	\$40,000.
Western KY University Development of High-Temperature Shape Memory Alloys for Aerospace Applications				

**Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009**

		New Accounts	Adjustments to Existing Accounts	Total
<b>Engineering</b>				
<b>Mechanical Engineering</b>				
<b>Karaca, Haluk E.</b>	3048105071	\$5,000.	\$0.	\$5,000.
Western KY University Development of High-Temperature Shape Memory Alloys for Aerospace Applications				
<b>Lebeau, Raymond P</b>	3048105319	\$72,012.	\$0.	\$72,012.
National Aeronautics and Space Administration Development and Application of Computational Simulations for Observed Persistent and Time-Varying Phenomena in the Atmospheres of the Ice Giants				
<b>McDonough, James M</b>	3048104978	\$18,000.	\$0.	\$18,000.
Western KY University Fellowship for Joshua Strodtbeck: Mathematical and Numerical Studies of Large-Eddy Simulation of Compressive Flow				
<b>Menguc, M P</b>	3048105022	\$100,000.	\$0.	\$100,000.
KY Science and Technology Co Inc KSEF R&D Excellence: Experimental Investigation of Near-Field Radioactive Transfer for High-Efficiency Thermophotovoltaic Power Generators				
<b>Sheng, Jian</b>	3048104689	\$0.	-\$400,002.	-\$400,002.
National Science Foundation CAREER: Simultaneous Measurement of Wall Deformation and 3-D Flow Structures for Flow-Structure Interaction Investigations				
<b>Sheng, Jian</b>	3048104689	\$400,002.	\$0.	\$400,002.
National Science Foundation CAREER: Simultaneous Measurement of Wall Deformation and 3-D Flow Structures for Flow-Structure Interaction Investigations				
<b>Smith, Suzanne W</b>		\$2,400.	\$0.	\$2,400.
National Academy of Sciences Student Leadership Workshop for Women in Engineering				
<b>Smith, Suzanne W</b>	3048104340	\$0.	\$10,000.	\$10,000.
Mevicon Inc Deployment Measurement of Stowed Thin Film Shells				
<b>Smith, Suzanne W</b>	3048104988	\$0.	\$71,486.	\$71,486.
L3 Communications Corp Inflatable Wing Structural Design and Analysis				
<b>Smith, Suzanne W</b>	3048104988	\$5,000.	\$0.	\$5,000.
L3 Communications Corp Inflatable Wing Structural Design and Analysis				
<b>Smith, Suzanne W</b>	3048105241	\$76,486.	\$0.	\$76,486.
L3 Communications Corp Inflatable Wing Structural Design and Analysis				
<b>Mechanical Engineering</b>	<b>Totals:</b>	<b>\$678,900.</b>	<b>-\$278,516.</b>	<b>\$400,384.</b>
<b>IR4TD</b>				
<b>Saito, Koza</b>	3048104800	\$0.	\$9.	\$9.
Toyota Motor Co IRSIS Phase 2 Line Trial				

**Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Engineering</u></b>				
<b><u>IR4TD</u></b>				
<b>Saito, Kozo</b>	3048104800	\$49,956.	\$0.	\$49,956.
Toyota Motor Co IRSIS Phase 2 Line Trial				
<b>Saito, Kozo</b>	3048105315	\$30,000.	\$0.	\$30,000.
KY Science and Technology Co Inc Production and Characterization of Bio-fuel from Vegetable Oil Residue				
<b>Saito, Kozo</b>	3048105318	\$25,075.	\$0.	\$25,075.
Toyota Motor Co Wax Detection				
<b>IR4TD</b>	<b>Totals:</b>	<b>\$105,031.</b>	<b>\$9.</b>	<b>\$105,040.</b>
	<b>Engineering Totals:</b>	<b>\$13,262,732.</b>	<b>\$6,526,482.</b>	<b>\$19,789,214.</b>
<b><u>Law</u></b>				
<b><u>Law</u></b>				
<b>Davis, Mary J</b>		\$18,000.	\$0.	\$18,000.
Bureau of Prisons Legal Assistance to Inmates				
<b>Davis, Mary J</b>	3048105178	\$357,738.	\$0.	\$357,738.
Department of Justice University of Kentucky Legal Education Access Program (LEAP)				
<b>Law</b>	<b>Totals:</b>	<b>\$375,738.</b>	<b>\$0.</b>	<b>\$375,738.</b>
	<b>Law Totals:</b>	<b>\$375,738.</b>	<b>\$0.</b>	<b>\$375,738.</b>
<b><u>Communication &amp; Information Stu</u></b>				
<b><u>School of Journalism</u></b>				
<b>Barnes, Beth</b>	3048105222	\$26,008.	\$0.	\$26,008.
American International Health Alliance Partnering with ZAMCOM to train Zambian Journalists in coverage of HIV/AIDS.				
<b>School of Journalism</b>	<b>Totals:</b>	<b>\$26,008.</b>	<b>\$0.</b>	<b>\$26,008.</b>
<b><u>Communication</u></b>				
<b>Sellnow, Timothy L</b>	3048104430	\$0.	\$285,842.	\$285,842.
University of Minnesota National Center for Food Protection and Defense: Robust Case Study Analysis of Media				
<b>Zimmerman, Rick S</b>	3046965300	\$0.	\$458,003.	\$458,003.
National Institute of Mental Health Targeting Mass Media Campaigns for HIV, STD and Pregnancy Prevention				
<b>Communication</b>	<b>Totals:</b>	<b>\$0.</b>	<b>\$743,845.</b>	<b>\$743,845.</b>
<b><u>School of Library &amp; Information Science</u></b>				
<b>Huber, Jeffrey Todd</b>	3048105350	\$7,300.	\$0.	\$7,300.
KY Department for Libraries and Archives KDLA LSTA Kentucky Guide Program				

**Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Communication &amp; Information Stu</u></b>				
<b><u>School of Library &amp; Information Science</u></b>				
<b>Kim, Sujin</b>	3048104876	\$339,420.	\$0.	\$339,420.
Institute of Museum and Library Services Librarians for the 21st Century: A Study of Metadata Framework for Digitized Pathologic Images				
<b>School of Library &amp; Information Science</b>	<b>Totals:</b>	<b>\$346,720.</b>	<b>\$0.</b>	<b>\$346,720.</b>
<b>Communication &amp; Information Studies Totals:</b>		<b>\$372,728.</b>	<b>\$743,845.</b>	<b>\$1,116,573.</b>
<b><u>Design</u></b>				
<b><u>Design</u></b>				
<b>Carpenter, Clyde R</b>	3046816600	\$0.	\$23,190.	\$23,190.
KY Transportation Cabinet Interns for Cultural Historic Assessment of Highway Projects				
<b>Carpenter, Clyde R</b>	3048105060	\$10,000.	\$0.	\$10,000.
City of Elkton City of Elkton Comprehensive Plan				
<b>Carpenter, Clyde R</b>	3048105118	\$12,000.	\$0.	\$12,000.
Todd County County of Todd Comprehensive Plan				
<b>Speaks, Michael Angelo</b>	3048105029	\$50,000.	\$0.	\$50,000.
Louisville Metro Government Urban Design Studio 2008-2009				
<b>Design</b>	<b>Totals:</b>	<b>\$72,000.</b>	<b>\$23,190.</b>	<b>\$95,190.</b>
<b>Design Totals:</b>		<b>\$72,000.</b>	<b>\$23,190.</b>	<b>\$95,190.</b>
<b><u>Social Work</u></b>				
<b><u>Social Work</u></b>				
<b>Badger, Karen</b>	3048105335	\$14,000.	\$0.	\$14,000.
Phoenix Society for Burn Survivors Station Night Club Fire Needs Assessment				
<b>Cerel, Julie A</b>	3048105257	\$99,996.	\$0.	\$99,996.
Substance Abuse & Mental Health Services Administr University of Kentucky KEEP: Increasing Networks for Campus Awareness to Suicide and Emergencies (UK-IN-CASE)				
<b>Cerel, Julie A</b>	3048105272	\$58,578.	\$0.	\$58,578.
Department for Mental Health Mental Retardation Service Suicide Prevention for Youth - SPYCE Project Evaluation				
<b>Cook-Craig, Patricia G</b>	3048105136	\$37,000.	\$0.	\$37,000.
KY Association of Sexual Assault Programs EMPOWER Project				
<b>Gillen, Martie L</b>	3048104918	\$235,681.	\$0.	\$235,681.
KY Health Services Cabinet Post Secondary - Successful Transitions Program & Comprehensive Family Services				
<b>Godlaski, Theodore M</b>	3048105320	\$64,410.	\$0.	\$64,410.
KY River Community Care Inc Assertive Community Living for Appalachian Dually Diagnosed Adults Grant (ACLADDA)-Project Evaluation				

**Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Social Work</u></b>				
<b><u>Social Work</u></b>				
<b>Hall, Jennifer G</b>	3048105066	\$900,000.	\$0.	\$900,000.
Administration for Children and Families National Quality Improvement Center on the Privatization of Child Welfare Services				
<b>Rompf, Elizabeth L</b>	3048104932	\$8,199.	\$0.	\$8,199.
Eastern KY University Public Child Welfare Certification Program				
<b>Segress, Melissa Jh</b>	3048104916	\$83,401.	\$0.	\$83,401.
KY Health Services Cabinet Citizens Review Panel				
<b>Segress, Melissa Jh</b>	3048104923	\$31,134.	\$0.	\$31,134.
Eastern KY University Training Resource Center: Consulting Services				
<b>Segress, Melissa Jh</b>	3048104930	\$114,402.	\$0.	\$114,402.
Eastern KY University Training Resource Center: Medically Fragile				
<b>Segress, Melissa Jh</b>	3048104931	\$5,093.	\$0.	\$5,093.
Eastern KY University Training Resource Center: Cultural Diversity				
<b>Segress, Melissa Jh</b>	3048104934	\$0.	-\$351,869.	-\$351,869.
Eastern KY University Training Resource Center: Resource Parent Mentor Program/Retention				
<b>Segress, Melissa Jh</b>	3048104934	\$351,869.	\$0.	\$351,869.
Eastern KY University Training Resource Center: Resource Parent Mentor Program/Retention				
<b>Segress, Melissa Jh</b>	3048105100	\$299,149.	\$0.	\$299,149.
Eastern KY University Training Resource Center: Office of Technology & Outcome Support				
<b>Segress, Melissa Jh</b>	3048105101	\$405,731.	\$0.	\$405,731.
Eastern KY University Training Resource Center: Adoption Support Programs				
<b>Sprang, Mary</b>		\$400,000.	\$0.	\$400,000.
Substance Abuse & Mental Health Services Administr Child and Adolescent Trauma Treatment Institute				
<b>Tindall, Michele Staton</b>	3048105313	\$0.	-\$800.	-\$800.
HOPE Center of Lexington Evaluation for the Center on Substance Abuse Treatment Men (CSAT-Men)				
<b>Tindall, Michele Staton</b>	3048105313	\$45,000.	\$0.	\$45,000.
HOPE Center of Lexington Evaluation for the Center on Substance Abuse Treatment Men (CSAT-Men)				

**Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Social Work</u></b>				
<b><u>Social Work</u></b>				
<b>Tindall, Michele Staton</b>	3048105363	\$91,800.	\$0.	\$91,800.
Chrysalis Inc Chrysalis House PPW-2 Evaluation				
<b>Tindall, Michele Staton</b>	3048105392	\$60,000.	\$0.	\$60,000.
KY Administrative Office of the Courts AOC Drug Court Evaluation - Christian County				
<b>Weeks, Pamela L</b>	3048105227	\$429,594.	\$0.	\$429,594.
Eastern KY University Training Resource Center: Credit for Learning Program				
<b>Social Work</b>	<b>Totals:</b>	<b>\$3,735,037.</b>	<b>-\$352,669.</b>	<b>\$3,382,368.</b>
<b><u>Cntr for Stdy of Violence Against Childr</u></b>				
<b>Clark, James J</b>	3048105133	\$200,000.	\$0.	\$200,000.
KY Cabinet for Health and Family Services Comprehensive Assessment and Training Services Project - Title IV-B				
<b>Sprang, Mary</b>	3048105146	\$658,000.	\$0.	\$658,000.
KY Cabinet for Health and Family Services Comprehensive Assessment and Training Services Project- Title V				
<b>Cntr for Stdy of Violence Against Childr</b>	<b>Totals:</b>	<b>\$858,000.</b>	<b>\$0.</b>	<b>\$858,000.</b>
	<b>Social Work Totals:</b>	<b>\$4,593,037.</b>	<b>-\$352,669.</b>	<b>\$4,240,368.</b>
<b><u>Graduate School</u></b>				
<b><u>Martin School of Public Policy</u></b>				
<b>Berger, Philip K</b>	3048105340	\$0.	\$-10.	\$-10.
University of Cincinnati Worker Health and Safety Cooperative Agreement				
<b>Berger, Philip K</b>	3048105340	\$145,530.	\$0.	\$145,530.
University of Cincinnati Worker Health and Safety Cooperative Agreement				
<b>Jennings, Edward T</b>	3048104847	\$210,975.	\$0.	\$210,975.
KY Department of Military Affairs Hazard Mitigation Grants Program FY 2009 and 2010				
<b>Jennings, Edward T</b>	3048105230	\$105,430.	\$0.	\$105,430.
KY Council on Developmental Disabilities Policy Analysis for the Kentucky Council on Developmental Disabilities				
<b>Toma, E F</b>		\$2,500.	\$0.	\$2,500.
KY Council on Postsecondary Education Martin School Graduate Student				
<b>Martin School of Public Policy</b>	<b>Totals:</b>	<b>\$464,435.</b>	<b>-\$10.</b>	<b>\$464,425.</b>

**Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 1/31/2009**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Graduate School</u></b>				
<b><u>Graduate School Dean</u></b>				
<b>Blackwell, J L</b>	3048104269	\$0.	\$40,500.	\$40,500.
National Science Foundation National Science Foundation Graduate Fellowship Program				
<b>Graduate School Dean</b>	<b>Totals:</b>	<b>\$0.</b>	<b>\$40,500.</b>	<b>\$40,500.</b>
<b><u>Center for Biomedical Engineering</u></b>				
<b>Evans, Joyce M</b>	3048104848	\$4,985.	\$0.	\$4,985.
Western KY University Internship for Rachel Moore: Efficacy of Countermeasures to Cardiovascular Deconditioning in Men and Women During Simulated Moon Explorations				
<b>Knapp, Charles F</b>	3048104489	\$0.	\$166,666.	\$166,666.
Western KY University NASA EPSCoR: Efficacy of Countermeasures to Cardiovascular Deconditioning in Men and Women During Simulated Moon Explorations				
<b>Knapp, Charles F</b>	3048104834	\$125,000.	\$0.	\$125,000.
Western KY University NASA EPSCoR 2007, State Match to NNX07AT58A: Efficacy of Countermeasures to Cardiovascular Deconditioning in Men and Women During Simulated Moon Explorations				
<b>Patwardhan, Abhijit</b>	3048104817	\$60,500.	\$0.	\$60,500.
American Heart Association Great Rivers Affiliate Restitution of Repolarization Duration: Hysteresis, Alternans and Spatial Heterogeneity				
<b>Puleo, David A</b>	3048072600	\$0.	\$28,700.	\$28,700.
Shriners Hospital for Crippled Children Recapitulation of a Growth Plate in a Rabbit Model				
<b>Center for Biomedical Engineering</b>	<b>Totals:</b>	<b>\$190,485.</b>	<b>\$195,366.</b>	<b>\$385,851.</b>
	<b>Graduate School Totals:</b>	<b>\$654,920.</b>	<b>\$235,856.</b>	<b>\$890,776.</b>
<b><u>Fine Arts</u></b>				
<b><u>Music</u></b>				
<b>Pen, Ronald A</b>	3048105281	\$2,500.	\$0.	\$2,500.
Lexarts Bluegrass IN the Blugrass				
<b>Music</b>	<b>Totals:</b>	<b>\$2,500.</b>	<b>\$0.</b>	<b>\$2,500.</b>
	<b>Fine Arts Totals:</b>	<b>\$2,500.</b>	<b>\$0.</b>	<b>\$2,500.</b>
	<b>University Totals:</b>	<b>\$130,707,071.</b>	<b>\$52,674,582.</b>	<b>\$183,381,653.</b>